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Abstract 
This thesis addresses the development of topical formulations designed to treat atopic 
dermatitis (AD) using nicotinamide (NA). A rational approach to the development of topical 
formulations based on the physical and chemical properties of the drug and vehicle 
components is studied. This approach is an alternative to the model of formulation 
development where the drug is added into an existing vehicle without optimisation of the 
formulation in terms of the active delivery to its site of action. 
The work encompasses preliminary pre-formulation studies, in vitro uptake and permeation 
studies using a model silicone membrane and pig ear skin. Moreover, the influence of topical 
formulations containing the model drug on the parameters indicative of skin health is tested in 
the in vivo studies. 
The primary objective is to optimise the skin delivery of NA with the use of appropriate 
excipients. The solvents are chosen on the basis of their physicochemical parameters, namely 
solubility parameter (δ), mutual miscibility and ability to dissolve the model drug.  
The performance of rationally developed simple formulations is tested in vitro and compared 
with prototype formulations containing more complex vehicles. In vitro uptake and 
permeation studies using silicone are performed to determine the influence of chosen solvents 
on NA permeation in a membrane which is less complex than skin. In addition NA skin delivery 
is evaluated with in vitro and in vivo techniques and the relationship between the 
physicochemical parameters of the solvents used and the drug percutaneous absorption is 
examined.  
Finally, the efficacy of prototype NA formulations in improving the skin state in vivo is 
investigated. The performance of prototype formulations in terms of NA percutaneous 
absorption is determined with reference to their influence on the skin condition. 
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List of Abbreviations 
AD Atopic dermatitis 
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1 Introduction 
1.1 Skin anatomy and function 
The skin is the largest organ of human body. It accounts for 15% of total body weight and has 
an average surface area of approximately 2m2. It allows for an effective communication 
between the endo- and exogenous environments and enables the maintenance of internal 
homeostasis of the human body [1-3].  
Human skin is organized into three distinct layers: 
 hypodermis – an insulator and protector, which consists of adipocytes specialised in 
fat storage, 
 dermis – which nourishes skin appendages and connects all skin layers via capillary 
blood vessels and nerve endings; it is also responsible for mechanical resistance and 
elasticity of the skin thanks to the presence of collagen and elastin (noncellular 
connective tissue which accounts for about 70% of the dermis [4]), 
 epidermis – the main barrier for exogenous substances permeation and endogenous 
water loss. The epidermis is described in detail in a later section.  
The skin structure is represented in Figure 1.1. 
 
Figure 1.1 Schematic representation of the skin [adapted from 1] 
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1.1.1 Epidermis 
The epidermis is the outermost, avascularised layer of the skin [5, 6]. The average thickness of 
the epidermis is about 0.1mm [7, 8]. However, depending on the site of the body, it varies 
from 0.06mm on the eyelids to 0.6mm on palms of the hands and soles of the feet [9, 10]. The 
epidermis can be divided into two layers: the stratum corneum (SC) and the viable epidermis 
(VE). 
Epidermal cells, also called keratinocytes, are at various stages of differentiation progressing 
from the most inward layer of the epidermis (stratum germinativum) upwards to the stratum 
corneum [1]. A schematic representation of the stratified epidermal structure is shown in 
Figure 1.2. 
 
Figure 1.2 Structure of the epidermis 
The adherence between the epidermis and the dermis is provided by the basement membrane 
connected to the stratum germinativum cells by proteinaceous hemi-desmosomes [11-13]. 
Adjacent cells in the VE are connected by desmosomes formed by transmembrane 
glycoproteins (desmoglein and desmocollin) associated with several cytoplasmic proteins [14]. 
Cells in the stratum geminativum are subject to mitotic division enabling renewal of the 
epidermis. It is estimated that in healthy skin total epidermal turnover time is approximately 
40 days: 13 days of proliferation in the stratum germinativum, 10-14 days of differentiation 
and 14 days of desquamation from the stratum corneum [15-17]. 
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1.1.1.1 Stratum corneum 
Most of the skin barrier properties are localised in the stratum corneum (SC), the final product 
of epidermal cell differentiation [18]. Keratinocytes on their way to the SC lose their nuclei, 
become more flattened and transform into corneocytes. At the same time, keratin molecules 
are cross-linked and aligned in parallel inside the cell [19, 20]. The profilaggrin protein, 
processed into filaggrin (filament aggregating protein) is involved in the process of keratin 
aggregation [12, 21]. Further filaggrin digestion provides compounds responsible for skin 
moisturisation [12, 22, 23]. This mixture of free amino acids, their derivatives and salts is called 
natural moisturising factor (NMF) [22]. 
At the outermost surface of corneocytes, a 10-20nm thick cornified envelope (CE) is formed by 
protein and lipid components [24]. The main protein-bound lipids in the healthy skin (~50%) 
are ceramides connected to the extracellular proteins by ω-hydroxyester bonds [25]. Loricrin 
and involucrin are the main proteins involved in the formation of CE [12, 26]. The protein 
molecules are interconnected by γ-glutamyl links [27, 28]. The degree of cross-linking of the 
envelope proteins by the transglutaminases (TGases) increases during the SC maturation 
process. Thus, CEs can be divided into two types: fragile (CEf) and rigid (CEr). The latter type is 
characteristic for more mature corneocytes closer to the skin surface [28, 29]. The proteins, 
incorporated into the CE, are responsible for cohesion between the cells and the SC integrity 
[30, 31]. Also, a relationship between covalently bound ceramides and transepidermal water 
loss (TEWL) was found, implicating the importance of CE lipids in the skin barrier function [32]. 
In the process of epidermal maturation, lamellar bodies located in the stratum granulosum 
deliver key components for the permeability and antimicrobial barriers. These components 
include: lipid precursors, catabolic enzymes and antimicrobial peptides [33-35]. Lamellar 
bodies contribute to the formation of the lipid matrix by supplying enzymes involved in the 
synthesis of cholesterol, free fatty acids and ceramides [36]. They also secrete catabolic 
proteases which guarantee correct digestion of corneodesmosomes and epidermal 
desquamation [30, 37-39]. Two serine proteases from the kallikrein (KLK) family: trypsin-like 
KLK5 and chymotrypsin-like KLK7 are the main SC desquamatory enzymes [38]. 
The SC is perceived as a two-compartment structure. It consists of ten to fifteen layers of cells 
surrounded by a lipid matrix [40, 41]. This ‘brick and mortar’ model of the SC, proposed by 
Michaels et al. [42], is shown in Figure 1.3. 
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Figure 1.3 Idealised model of the stratum corneum [based on 42] 
Each corneocyte is 0.5 to 1.5μm thick and has a diameter of approximately 35μm [43]. The 
thickness of the SC depends on the anatomic site, but usually it is about 10-20μm [1, 7, 44-46]. 
It is thickest on the palms and soles and thinnest on the lips [47, 48]. The SC mainly consists of 
protein (approximately 75% w/w) [49] while extracellular lipids account for 5-15% w/w of the 
SC dry mass [50, 51]. The unique composition of the SC extracellular lipid bilayers is reflected 
in the fact that many different ceramide types and no phospholipids can be found in this 
phase. The intercellular lipid matrix is composed of approximately 40% ceramides, 25% 
cholesterol, 18% cholesterol esters and 10% fatty acids [12, 52]. The lipid composition varies 
depending on the anatomic site and it influences epidermal barrier function [53-56]. 
1.2 Percutaneous absorption 
Several steps are involved in the process of percutaneous absorption. The drug, after 
dissolution and diffusion in the vehicle, is subject to partitioning into the SC. The crucial role in 
this step is attributed to the relative solubility of the drug in the vehicle and the SC [57-59]. 
What follows is the diffusion across the SC and partition into the VE [60]. Further drug 
movement includes diffusion through the VE and the dermis, clearance through the blood and 
lymphatic circulation and partitioning into the subcutaneous fat and muscles [2, 61, 62]. On 
the way across the skin, the drug can interact with a receptor, be metabolised or form a 
reservoir [63, 64]. 
Although the SC is very thin (approximately 10μm) [46] compared with the viable epidermis 
and papillary dermis (both approximately 100μm), the highest diffusional resistance lies in the 
stratified structure of the SC. The role of other layers in impeding the diffusion process of a 
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drug is in most cases negligible [7]. The SC with its ‘brick and mortar’ organisation of 
corneocytes and intercellular lipids ensures skin function as a permeability barrier to topically 
applied penetrants [9, 65]. Skin impermeability can be particularly attributed to the high 
degree of molecular order in the extracellular lipids [9]. For example, water flux through SC 
was shown to increase with an increasing disorder of the lipids in the membrane [66]. 
The routes of percutaneous penetration were proposed in the 1960’s. Tregear [67] postulated 
that the penetration of molecules through skin occurs ‘through or around the horny plates’ 
and that the appendageal route is most probably not significant in this process. 
The molecule can penetrate the SC either intercellularly (by going around the corneocytes 
through the lipid matrix), intracellularly (or transcellularly, i.e. by taking the route across the 
cells and the lipids) or through the appendages (sweat glands or hair follicles) [9]. The three 
routes of penetration are shown schematically in Figure 1.4. 
 
Figure 1.4 Possible routes of percutaneous penetration 
The intercellular route of penetration is considered the most important for the majority of 
molecules [68]. First of all, the diffusional path length derived from Fick’s laws of diffusion for 
model substances was found to be much higher than the actual thickness of the skin. The SC is 
approximately 10-20μm thick, but the estimated diffusional path length can be as long as 
880μm [69]. Moreover, it was also possible to visualise molecular diffusion through this 
tortuous pathway [70, 71]. The intercellular route is rich in lipids which constitute ~10% of the 
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dry SC volume [51]. This volume may seem small, but it is the only continuous phase in the SC, 
thus it forms a preferential route for penetration of many substances [9]. 
The intracellular (transcellular) route requires the molecule to repeatedly partition and diffuse 
through the hydrophilic and very dense environment of corneocytes and the lipophilic 
intercellular spaces. Thus, this route, even though it is shorter, may not be the easiest and is 
not preferred by the majority of molecules [1]. 
Skin appendages cover only ~0.1% of the skin surface area. Thus, the appendageal pathway for 
skin penetration in most cases is considered insignificant. This route may be of importance for 
large polar molecules, ions or other slowly penetrating substances which would be able to 
diffuse faster through shunts, before steady state diffusion through and around the SC cells is 
established [1]. The hair follicles may be targeted by sub-micron sized particles as a result of 
massaging them into the lipids that surround the hair shaft. 
Molecules penetrating through the superficial layers of the skin are removed from the dermis 
by the circulatory system. An abundant blood supply allows for the maintenance of ‘sink’ 
conditions for the penetrating compounds. Highly lipophilic materials may be transported 
away by the lymphatic system or protein bound within the blood plasma. This means that the 
concentration of the penetrating substance in the dermis remains close to zero allowing for 
maximal thermodynamic activity gradient across the skin. This gradient provides a driving force 
for diffusion and aids percutaneous absorption [1, 60, 72].  
1.2.1 Interactions between drug, skin and vehicle 
Drugs are rarely applied to the skin as pure compounds. Usually, the active substance is 
incorporated into a suitable vehicle which facilitates application and may also influence the 
skin barrier function [1]. The selective permeability of the skin depends not only on its 
physiological state but also on the properties of the vehicle and the drug [73, 74]. 
Percutaneous absorption depends on various physicochemical parameters of the permeant. 
The permeability of a drug can be estimated from such parameters as the octanol/water 
partition coefficient (Koct) and molecular weight (MW) [75]. For systemic delivery, the drug 
needs to have a balanced water and lipid solubility allowing for the optimum partitioning 
behaviour into the lipophilic SC and the VE which is more hydrophilic [76]. Molecules with log 
Koct between 1 and 3 are considered to be good candidates for transdermal drug delivery [76, 
77]. On the other hand, the diffusion coefficient across the skin is related to MW [78]. Small 
molecules (i.e. the ones with lower MW) permeate faster across the skin [79]. Another 
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important factor is the drug melting point, which is inversely proportional to its transdermal 
permeability [80, 81]. In the case of weak acids or weak bases, permeation depends on the 
degree of ionisation. Ionised molecules have lower permeability coefficients than their 
unionised forms, which are the predominant diffusing species [82, 83].  
Skin-drug interactions can include various forces: from weak Van der Waals attractions to 
strong chemical bonding, which may cause drug reservoir formation in the skin [1]. The skin is 
a hydrogen bond donor, thus a decrease in drug diffusion is expected with an increase in the 
number of hydrogen bonding groups [84, 85]. For some topical preparations, reservoir 
formation or adherence and binding of drug molecules to the skin components may be crucial 
for the achievement of the desirable effect [61, 86]. The metabolism of the permeant by the 
skin enzymes may also be important in determining the extent of percutaneous absorption 
[87-89]. 
Drug-vehicle interactions are equally important in the percutaneous absorption process [90]. 
The thermodynamic activity of the drug in the vehicle is crucial for the diffusion process and is 
related to the solubility of the drug in this vehicle [91]. Also, the release of the drug from the 
vehicle may be rate-limiting, and in this case, skin barrier is not the major factor which 
influences the diffusion of the drug [1].  
The vehicle can also have an effect on skin hydration and temperature [92-94]. At the same 
time, body temperature and water present in the skin can influence vehicle components. 
Solvents present in the vehicle may reversibly or irreversibly alter barrier properties of the skin 
or damage it. These substances can enhance or retard penetration and their properties are 
exploited to achieve required skin delivery of the compound of interest [1]. 
1.2.2 Chemical penetration enhancers 
Various techniques can be used to deliver the drug from the formulation to the skin (topical 
drug delivery) or across the skin to the systemic circulation (transdermal drug delivery) [95]. 
The use of chemical penetration enhancers (CPEs) is a widely investigated and commonly 
applied approach to increase percutaneous absorption [see the following patent literature 
reviews: 96, 97].  
CPEs are the components of topically applied formulations that reversibly decrease the 
resistance and enable drug access into the deeper layers of the skin or to the systemic 
circulation [52]. 
Introduction 
28 
 
The ideal penetration enhancer should: 
 be non-toxic, non-irritant or non-allergenic (i.e. safe to use), 
 not be pharmacologically active, 
 have immediate onset of action, 
 have immediate and full reversibility in terms of changes in the SC properties upon 
removal of the enhancer, 
 be chemically and physically compatible with other formulation components, 
 be cosmetically acceptable with good spreading and feel on the skin surface, 
 be a good solvent for the drug, 
 be inexpensive, odourless, tasteless and colourless [1, 98, 99]. 
Probably no enhancer, which combines all these properties, exists. Water is considered one of 
the most ideal compounds since an increase in the skin hydration leads to a decrease in the 
diffusional resistance of the skin [100]. In some cases occlusion can also enhance penetration 
by increasing the water content of the SC, but occlusive vehicles are not considered to be 
penetration enhancers, since they do not interact with the structures inside the SC [99]. 
The main mechanisms of action of penetration enhancers include:  
 an increase of skin hydration [100],  
 an extraction of intracellular lipids (e.g. ethanol) [101],  
 an increase of drug partitioning into the skin (e.g. isopropyl myristate (IPM) and 
ethanol) [102, 103], 
 an increase of drug diffusion through the skin (e.g. oleic acid and IPM) [104, 105] 
 prevention of crystallisation of the drug on and in the skin (e.g. IPM and ethanol). 
CPEs can act on different components of the skin interacting with SC lipids in their polar or 
lipophilic regions or influencing SC proteins [52]. A disruption in the packaging of the lipids 
fluidises the lipid domain and increases the water volume between the bilayers. Thus, the 
penetration of both lipophilic and hydrophilic molecules is enhanced [59]. Solvents such as 
propylene glycol are believed to increase drug solubility in the aqueous domain of lipid 
bilayers, by altering the solubility parameter of the membrane [106]. 
The solubility parameter (δ) is one of the values taken into account when choosing the 
penetration enhancer. This parameter was defined by Hildebrand and Scott [107] as the sum 
of the cohesive forces in the molecule. Hansen further developed this approach proposing a 
three-dimensional δ value where dispersion, polar and associative (hydrogen bonding) 
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attractions are the components of the total cohesive energy of a liquid [108]. When a solvent 
with an appropriate δ value is chosen, it can increase the drug solubility in the membrane, by 
shifting the δ value of the skin [109] towards the δ value of the drug. Increased solubility in the 
skin means increased affinity of the drug for the membrane and thus, the transport of the drug 
is increased [108, 110, 111].  It may also help in the identification of solvents, which prevent 
crystallisation of the drug on and in the skin. 
1.3 Investigation of percutaneous absorption in vitro 
There are several advantages of the use of in vitro techniques in the assessment of 
percutaneous absorption. One is the simplicity of experimental conditions which enables 
greater insight into the role of excipients in the transport of compounds through the skin. 
There is no need for extensive sample preparation, as opposed to the quantification of the 
drug in blood or excreta samples obtained during in vivo studies. In vitro techniques also 
enable the optimal use of human or animal tissue minimising the need for laboratory animals 
and human volunteers [112]. It is especially important when formulations exhibit toxic or 
irritant properties [113]. In comparison with in vivo investigations, in vitro methods require 
less space, have smaller variability and allow for correlation between human and animal tissue 
when the same experimental conditions are maintained [114]. 
A number of in vitro methods are used to study percutaneous absorption. The most common 
are diffusion methods, where a drug is applied to the donor compartment of a diffusion cell 
and permeation is evaluated by measuring the concentration of the drug in the receptor. 
According to the US Food and Drug Administration (FDA), the recommended in vitro method 
for evaluation of topical formulations is based on an open chamber diffusion system (e.g. 
Franz-type diffusion cell) [115]. Diffusion experiments without a barrier membrane give 
information on drug-vehicle interactions and release mechanisms. Permeation experiments 
using human, animal or artificial membranes may give more insight into the drug-vehicle-
membrane interactions [1]. A Franz-type diffusion cell is shown in Figure 1.5. 
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Figure 1.5 Franz-type diffusion cell 
In permeation studies, the membrane is chosen based on its resemblance to the in vivo 
situation. However, human skin can often be difficult to obtain. Instead, polymeric membranes 
or animal skin have been used as mechanistic models of the skin.  
The most popular and extensively studied artificial membranes are lipophilic silicone 
membranes [58, 116-125]. Dimethylpolysiloxane (silicone) membrane is a homogenous 
barrier, which can be used as a model for human skin because of its hydrophobicity [123]. The 
evaluation of silicone membrane as a relevant model for prediction of percutaneous 
absorption was attempted by several authors. A comparison of ibuprofen diffusion studies 
from supersaturated systems showed a linear correlation between skin and silicone data [126]. 
On the other hand, no correlation between silicone membrane and skin was found for caffeine 
permeation from saturated solvent systems and cosmetic formulations [127]. However, the 
authors concluded that diffusion studies across synthetic membranes can give valuable 
information in terms of quality and batch-to-batch variability of topical products. They also 
provide information about the thermodynamic activity of the active in the formulation. 
Animal models for percutaneous absorption include several species such as rat, rabbit, monkey 
and guinea pig [128-130]. In vivo studies showed that skin permeability for a series of 
radioactive compounds is highest for rabbit, followed by rat, pig and human skin [128]. This 
and many other studies suggest that pig skin has a better predictive value for human skin 
permeation than the skin of rodents. Porcine skin is preferred to other animal membranes 
because of its similarity to human epidermis in terms of morphology and permeability [51, 
131-133]. Although human skin is more robust to freezing and usually is less permeable many 
authors support the use of porcine skin, especially from the outer region of the ear [113, 134-
138]. 
Comparisons between human and animal skin listed above showed that there are major 
differences in the skin permeability between species. Thus, human skin is postulated to have 
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the best predictive value for the in vitro assessment of percutaneous absorption [139, 140]. 
Human skin may be obtained from cadavers, biopsies or surgery and it usually maintains its 
integrity upon long-term storage (up to one year at -20°C) [141-143]. The permeability of 
human skin varies between individuals and within individuals depending on the anatomic site. 
Southwell et al. [144] reported the inter-individual and intra-individual variation in in vitro 
studies to be as high as 66±25% (n=45) and 43±25% (n=32), respectively. 
1.4 Physicochemical models of percutaneous absorption 
The level of molecular transport and absorption through the skin depends on numerous 
factors, such as the dose, vehicle, length of time of application, anatomic site and skin state 
[145]. Nevertheless, there have been attempts to analyse and understand the process, taking 
into account idealised conditions. Mathematical modelling of percutaneous absorption 
includes physicochemical and pharmacokinetic models. This section will focus on the 
physicochemical diffusion models of percutaneous absorption. 
1.4.1 Fick’s laws of diffusion 
Diffusion is the transport caused by random molecular motion [146]. Since percutaneous 
absorption is the process of passive diffusion, it is possible to analyse permeation data and to 
predict permeation parameters using Fick’s laws of diffusion [1, 147]. 
The driving force for passive diffusion is the chemical potential gradient across the membrane 
(
𝜕𝜇
𝜕𝑥
). The chemical potential gradient is often simplified to the concentration gradient (
𝜕𝐶
𝜕𝑥
), 
but strictly speaking, it is the difference in thermodynamic activity of the drug across the 
diffusional pathway that enables diffusion [91]. 
Fick’s first law of diffusion [148] relates the concentration gradient to the diffusion coefficient 
(𝐷) in the following manner [78]: 
𝐽 = −𝐴𝐷
𝜕𝐶
𝜕𝑥
 
Equation 1.1 
where: 
𝐽 - steady state flux [μg/cm2/h], 
𝐴 - diffusion area [cm2], 
𝐷 - diffusion coefficient [cm2/h], 
𝜕𝐶
𝜕𝑥
 - concentration gradient across the membrane. 
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To describe the steady state diffusion Fick’s first law is simplified to: 
𝐽 = −𝐴𝐷𝐾𝑚/𝑣
∆𝐶
ℎ
 
Equation 1.2 
where: 
𝐾𝑚/𝑣 - partition coefficient of the compound between the membrane and the vehicle, 
∆𝐶 - concentration difference across the membrane [µg/cm3], 
ℎ - membrane thickness or diffusional pathlength [cm]. 
Usually the concentration of the drug in the vehicle, i.e. the concentration applied to the 
surface of the membrane is significantly higher than the concentration under the skin surface 
and ∆𝐶 ≈ 𝐶𝑣, where 𝐶𝑣 is the concentration of the drug in the vehicle. Thus:  
𝐽 = 𝐴𝐷𝐾𝑚/𝑣
𝐶𝑣
ℎ
 
Equation 1.3 
The diffusion coefficient reflects the rate of penetration of a specific molecule under specific 
conditions. The partition coefficient describes the affinity of the drug for the vehicle and the 
SC. However, the diffusion coefficient (𝐷) and the partition coefficient (𝐾) may be difficult to 
deconvolute. What is more, flux calculated with these two parameters depends on the 
diffusion pathlength which in the case of the skin diffusion process through the tortuous route 
is difficult to determine. The permeability coefficient (𝑘𝑝) [cm/h] is related to these three 
parameters according to the following equation: 
𝑘𝑝 =
𝐾𝐷
ℎ
 
Equation 1.4 
Hence, the flux calculation can be simplified to: 
𝐽 = 𝑘𝑝𝐶𝑣 
Equation 1.5 
According to Fick’s laws of diffusion, for simple solutions, the flux shows a linear increase with 
𝐶𝑣 until it reaches the solubility limit in the vehicle. For suspensions (saturated solutions), 
which have enough undissolved drug particles to replace the diffusing molecules, flux is 
constant. This is because the thermodynamic activity (or chemical potential) of the drug in 
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these systems stays the same during the permeation process (as long as there is enough of 
undissolved drug to prevent its depletion from the solution). Drug that is diffusing through the 
membrane must be in solution. Hence, the concentration available for the process is equal to 
the solubility of the drug in the vehicle [149]. 
After about 3 times the lag time, a straight line of the cumulative amount of the drug 
permeated against time should be obtained, meaning that steady state conditions are 
achieved. Experiments with skin or artificial membranes can lead to achievement of pseudo 
steady state conditions from which flux values can be calculated. However, taking into account 
only the steady state part of the data can be erroneous and may be a serious limitation. 
Factors such as maintenance of sink condition and prevention of drug and solvent depletion 
have to be taken into account when designing an experiment. Thus, modelling of the non-
steady and steady state data is attempted. The second Fick’s law is used in this case [78]: 
𝜕𝐶
𝜕𝑡
= 𝐷 (
𝜕2𝐶
𝜕𝑥2
) 
Equation 1.6 
Fick’s second law relates the change in concentration of the drug in the membrane to the rate 
of change in the concentration gradient relative to any point within the membrane, depending 
on time (𝑡) and position (𝑥). This equation is a second order partial differential equation, 
difficult to solve in a real time domain. In this case, full curve analysis by fitting all the 
experimental data to Fick’s laws by an iterative least squares computer program can be used, 
utilizing for example the Laplace transform approach. 
It should be noted that, the following assumptions hold to apply Fick’s laws for studying 
percutaneous absorption [78, 150]: 
 skin permeation is a simple passive diffusion process, 
 the SC is the major, rate limiting step in the percutaneous absorption process, 
 the diffusion coefficient is constant during permeation, 
 the diffusion occurs in one direction across a homogenous and inert membrane of a 
defined thickness and cross sectional area. 
1.4.2 Laplace transform 
The Laplace transform is an integral transform method which enables solution of the ordinary 
and partial differential equations [78]. The Laplace transform ?̅?(𝑠) of a function 𝑓(𝑡) is defined 
as: 
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?̅?(𝑠) = ∫ 𝑒−𝑠𝑡𝑓(𝑡)𝑑𝑡
∞
0
 
Equation 1.7 
where 𝑠 is a Laplace variable and the bar over the function symbol indicates that the function 
is written in the Laplace transform. 
When the Laplace transform method is applied to the Equation 1.6, the time variable (𝑡) is 
replaced with the Laplace variable (𝑠) according to: 
𝐿 [
𝜕𝑓(𝑥, 𝑡)
𝜕𝑡
] = 𝑠?̅?[𝑓(𝑥, 𝑡)] − 𝑓(𝑥, 0) 
Equation 1.8 
where  𝐶(𝑥, 0) = 𝐶0 in the region of 0 ≤ 𝑥 ≤ ℎ of the membrane thickness. 
Thus, the Laplace transform reduces the partial differential equation to the following ordinal 
differential equation: 
𝑑2𝐶̅
𝑑𝑥2
−
𝑠
𝐷
𝐶̅ = −
𝐶0
𝐷
 
Equation 1.9 
A general solution of Fick’s law of diffusion is thus described by: 
𝐶̅(𝑥) = 𝑎𝑠𝑖𝑛ℎ(𝜆𝑥) + 𝑏𝑐𝑜𝑠ℎ(𝜆𝑥) +  
𝐶0
𝑠
 
Equation 1.10 
where 𝜆 = √
𝑠
𝐷
 and 𝑎, 𝑏 are constants determined from the boundary conditions. 
The use of Laplace transforms for predicting percutaneous absorption began in the late 1970s 
[151]. However, it became more popular with the development of mathematical software, 
such as Scientist® (MicroMath Scientific, USA) [152]. The software inverts data from the time 
domain into the Laplace domain where it fits the experimental data to Fick’s equations with 
appropriate boundary conditions. Modelling of the permeation data using Laplace transform 
and Scientist® software has been described by previous authors [119, 121]. 
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1.4.3 Analysis of the permeation data 
The analysis of the permeation data depends on the boundary conditions associated with the 
design of the experiment [150]. In general, two types of Franz cell diffusion experiments can 
be conducted: infinite and finite dose studies. The typical permeation profiles obtained for 
finite and infinite dose studies are shown in Figure 1.6. 
 
Figure 1.6 Typical permeation profiles for finite and infinite dose studies 
 
1.4.3.1 Infinite dose studies 
Infinite dose studies are commonly used to study the influence of CPEs on the skin permeation 
of a model compound. In this technique, a saturated suspension of a drug in a vehicle is 
applied to the donor compartment of a diffusion cell. The drug permeating from the vehicle is 
replaced by the drug dissolved from the crystals, allowing for the maintenance of a constant 
donor concentration. In the ideal situation, application of a saturated suspension of the drug in 
a range of vehicles should result in the same flux, provided that the vehicle components have 
no influence on the membrane [123]. 
The permeation data are often presented as the cumulative amount of the compound 
permeated per unit surface area of the membrane [μg/cm2] against the collection time in 
hours [h]: 
𝑄𝐴 =
𝑉𝑅𝐶𝑛 + 𝑉𝑠 ∑(𝐶1 + ⋯ + 𝐶𝑛−1)
𝐴
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Equation 1.11 
where: 
𝑄𝐴 - cumulative amount of the compound permeated per unit area [μg/cm
2], 
𝑉𝑅 - total volume of the receptor phase in the cell [cm
3], 
𝐶𝑛 - concentration of the sample at the n
th time point, 
𝑉𝑠 - volume or the receptor phase sampled at each time point [cm
3], 
𝐴 - diffusional area of the Franz cell [cm2]. 
Permeation profiles are plotted as a 𝑄𝐴(𝑡) curve. For infinite dose studies, the steady state flux 
can be derived from the slope of the linear part of this curve using linear regression, while 𝑡𝑙𝑎𝑔 
can be expressed as the x-intercept of the steady state line. This is a simplified approach to 
permeation data analysis, where no iterative least squares calculations are necessary and 
simple straight line equations are used [153]. However, difficulties in visual determination of 
the steady-state data can be encountered. Also, the duration of the experiment might be 
insufficient to achieve steady state flux for slowly diffusing compounds and can lead to 
underestimation of the 𝐽𝑠𝑠 and lag time period (𝑡𝑙𝑎𝑔)  [154]. The 𝑡𝑙𝑎𝑔 and the time needed to 
achieve the steady state (𝑡𝑠𝑠) can be described as [153]: 
𝑡𝑙𝑎𝑔 =
ℎ2
6𝐷
 
Equation 1.12 
𝑡𝑠𝑠 = 3 𝑡𝑙𝑎𝑔 
Equation 1.13 
The following boundary conditions are used to simplify the solution of Fick’s second law and to 
describe the infinite dose study [155]: 
 No drug in the membrane (0 ≤ 𝑥 ≤ ℎ) at the beginning of the experiment (𝑡 = 0) 
𝐶𝑚 (𝑥, 0) = 0 
Equation 1.14 
 There is an equilibrium of the drug concentration between the donor and the 
membrane defined by the drug partitioning: 
𝐾𝑚/𝑣 =
𝐶𝑚
𝐶𝑣
 (0, 𝑡) 
Equation 1.15 
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where: 
𝐾𝑚/𝑣 - partition coefficient between the membrane and the vehicle, 
𝐶𝑚 - the drug concentration in the membrane, 
𝐶𝑣 - the drug concentration in the donor. 
 The receptor phase acts as a ‘sink’ 
𝐶𝑅(ℎ, 𝑡) = 0 
Equation 1.16 
The boundary conditions for an infinite dose diffusion study across a homogenous membrane 
of a finite thickness (ℎ) are shown in Figure 1.7. The donor phase has a constant concentration 
of the drug (𝐶𝑣) and the receptor phase acts as a perfect ‘sink’. 
 
Figure 1.7 Schematic representation of an infinite dose study (the profile shown is for a partition 
coefficient of 1) 
Applying the above summarised boundary conditions to the general solution of Fick’s law 
(Equation 1.10) gives: 
𝐶̅(0) =
𝐾𝐶𝑣
𝑠
 
Equation 1.17 
𝐶̅(ℎ) =
𝐶𝑅
𝑠
= 0 
Equation 1.18 
and allows calculation of the constants 𝑎 and 𝑏 in Equation 1.10: 
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𝑎 = −
𝐶𝑣𝐾 𝑐𝑜𝑠ℎ(𝜆ℎ)
𝑠 𝑠𝑖𝑛ℎ(𝜆ℎ)
 
Equation 1.19 
𝑏 = −
𝐶𝑣𝐾
𝑠
 
Equation 1.20 
After substitution of the constants into Equation 1.10 and appropriate mathematical 
transformations the equation which represents the concentration change at any point in the 
membrane is derived: 
𝐶̅(𝑥) =
𝐾𝐶𝑣𝑠𝑖𝑛ℎ[𝜆(𝑥 − ℎ)]
𝑠 sinh (𝜆ℎ)
 
Equation 1.21 
Thus, the transform for the flux (described in Equation 1.1) is: 
𝐽(̅𝑥) =
𝐴𝐾𝐶𝑣𝑐𝑜𝑠ℎ[𝜆(𝑥 − ℎ)]
𝜆 sinh (𝜆ℎ)
 
Equation 1.22 
The cumulative amount of the drug permeated over the time into the receptor solution can be 
derived as: 
𝑄𝐴̅̅̅̅ =  
𝐽(̅𝑠)̅̅ ̅̅ ̅
𝑠
=  
𝐴𝐾𝐶𝑣
𝑠√
𝑠
𝐷  sinh (
√𝑠ℎ
2
𝐷 )
 
Equation 1.23 
After fitting the steady and non-steady state permeation data to Equation 4.6 it is possible to 
determine 𝐷 and 𝐾 parameters for the best fit automatically inverting from Laplace to the real 
time domain. This equation is used to model the permeation data obtained from the silicone 
membrane studies, where the diffusion path length (ℎ) is known. 
Alternatively, parameters of 𝑃1 [cm] and 𝑃2 [hour
-1] can be obtained which are related to the 
diffusion (𝐷) and partition (𝐾) coefficients and ℎ in the following manner [156]: 
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𝑃1 = 𝐾ℎ 
Equation 1.24 
𝑃2 =
𝐷
ℎ2
 
Equation 1.25 
From these parameters, the permeability coefficient can be obtained: 
𝑘𝑝 = 𝑃1𝑃2 
Equation 1.26 
𝑃1 (partition parameter) and 𝑃2 (diffusion parameter) are used when the exact ℎ is not known 
i.e. for the skin permeation studies [157]. In this case the equation for modelling of the 
permeation data is: 
𝑄𝐴̅̅̅̅ =  
𝐴𝑃1𝐶𝑣
𝑠√
𝑠
𝑃2
 sinh (√
𝑠
𝑃2
)
 
Equation 1.27 
1.4.3.2 Finite dose studies 
Finite dose permeation studies imply different boundary conditions to those encountered in 
the infinite dose studies. The three basic boundary conditions, listed for the infinite dose 
study, remain true also for the finite experiment. However, a finite dose of the drug is applied 
to the donor compartment and depletion of the drug from the vehicle occurs in the course of 
the study. Figure 1.8 shows a schematic representation of the boundary conditions for the 
finite dose study. 
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Figure 1.8 Schematic representation of a finite dose study 
Mathematical models for finite dose studies take into account the depletion of the drug, thus 
the flux is not constant and changes with the changing concentration of the drug in the vehicle 
according to: 
𝑉
𝜕𝐶𝑣
𝜕𝑡
= −𝐴𝐷𝑚
𝜕𝐶
𝜕𝑥
(0, 𝑡) 
Equation 1.28 
where 𝑉 is the volume of the vehicle applied to the membrane. 
The Laplace transform of Equation 1.28 after appropriate mathematical transformations 
results in the following equation for the modelling of the finite dose studies: 
 
𝜕𝐶̅
𝜕𝑥
= 𝑎𝑐𝑜𝑠ℎ(𝜆𝑥) + 𝑏𝑠𝑖𝑛ℎ(𝜆𝑥) 
Equation 1.29 
Combining this equation with the general solution of Fick’s law for the diffusion studies 
(Equation 1.10) and applying appropriate mathematical transformations the following 
equations are obtained for model membranes: 
𝑄𝐴̅̅̅̅ =  
𝐾𝐶𝑣𝑉√
𝐷
𝑠
𝑠2 (𝐴𝐾𝑐𝑜𝑠ℎ√
𝑠ℎ2
𝐷 + 𝑉𝑠𝑖𝑛ℎ
√𝑠ℎ
2
𝐷 )
 
Equation 1.30 
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and for the skin: 
𝑄𝐴̅̅̅̅ =  
𝐴𝑃1𝑄0
𝑠 (𝑉√
𝑠
𝑃2
𝑠𝑖𝑛ℎ√
𝑠
𝑃2
+ 𝑃1𝐴𝑐𝑜𝑠ℎ√
𝑠
𝑃2
)
 
Equation 1.31 
where 𝑄0 is the amount of the drug applied to the donor compartment. 
Modeling of both steady and non-steady state data according to these equations results in 
obtaining the permeation parameters: 𝐷 and 𝐾 or 𝑃1 and 𝑃2, for silicone membrane and skin 
finite dose permeation studies respectively.  
1.5 Skin assessment in vivo – minimally invasive techniques  
In vivo methods for prediction of percutaneous absorption and investigation of skin properties 
are considered to be more reliable than in vitro methods. However, whether humans or 
laboratory animals are involved, special care must be taken to perform the research ethically. 
The Declaration of Helsinki is considered to be the primary document listing the ethical 
principles for medical research involving human subjects [158].  
When in vivo methods are further considered, the studies involving humans have the best 
predictive value for the performance of formulations tested. Animal skin is usually more 
permeable and thus, it is often not possible to predict percutaneous absorption in humans 
from animal studies [159]. 
In vivo penetration of the drug can be assessed by a variety of assays: from the quantification 
of the molecule in the blood, urine and faeces, to pharmacological response monitoring [160]. 
Depth concentration profiles of the drug can be obtained with skin stripping procedures [161]. 
Appropriate mathematical modelling of the data can give diffusion and partition coefficient 
values, enabling estimation of drug bioavailability [162, 163]. Combining tape stripping with 
spectroscopic methods enables drug assay in the skin [164]. Also skin state assessment can 
give an indirect measurement of bioavailability of the active, which has an influence on the 
skin properties. The skin state can be assessed with a whole array of non-invasive or minimally 
invasive techniques such as tape stripping combined with measurement of transepidermal 
water loss [165] or spectroscopic techniques such as ATR-FTIR [166, 167]. One of the non-
invasive techniques to investigate skin conditions in vivo is Confocal Raman Spectroscopy [168, 
169]. Evaluation of drug penetration can be done by observation of the pharmacological 
response such as vasodilatation or vasoconstriction [62, 70, 72, 170, 171]. These techniques 
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can also provide information on how excipients present in the formulation influence the 
permeation process of the drug and the state of the skin [172]. 
1.5.1 Tape stripping 
Tape stripping is a method widely used in skin physiology, morphology and SC barrier research 
[172-178]. In this method adhesive tapes are pressed to the skin surface and thereafter the 
superficial layers of the SC are removed together with the tape [179, 180]. The tapes together 
with the removed tissue can be subject to further investigations such as assessment of the 
morphological and physiological properties of the stripped tissue [179, 181] or percutaneous 
penetration and retention of the drug applied topically [64, 103, 165]. Combining tape 
stripping with TEWL measurements can give information on skin resistance to damage [182, 
183] and the depth of SC that is reached with the stripping procedure [184]. Various factors, 
such as the method of pressing the tape to the skin surface, pressure degree and duration, 
together with the type of tape used, can influence the outcome of tape stripping [173, 185]. 
Thus, it is crucial to establish all the experimental conditions involved in the stripping 
technique. This will enable the maintenance of the same conditions throughout the 
experiment and will allow for comparison between different studies [172].  
1.5.2 Protein content 
The analysis of the SC can involve quantification of the active component or the drug in the 
subsequent layers of the tissue which would result in the creation of a drug distribution depth 
profile [103, 163, 165]. The amount of SC removed with consecutive tapes from the skin 
surface can also be a good indicator of the tissue cohesion and thus gives information on the 
state of the skin [180, 186]. 
SC protein quantification on tape strips can be performed by a variety of analytical procedures, 
such as the gravimetric method [103, 187], or protein extraction and colorimetric 
quantification [174, 188]. These methods are usually difficult to perform, time consuming and 
often prevent the analysis of any other analyte on the same tape. Spectroscopic methods, 
which correlate the amount of protein with optical absorbance allow for quantification of the 
amount of the SC removed without damaging the sample [178, 189-191]. The results obtained 
with absorbance measurements are in agreement with traditional colorimetric measurements 
[174, 192]. 
Voegeli et al. [178] validated a method for SC protein quantification by infrared densitometry. 
Those workers derived calibration curves, which can be used for protein evaluation on tape 
strips by infrared absorbance measurement. This indirect method enables further analysis of 
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the tapes, because it does not destroy the SC samples. The optical absorption of SC tape strips 
proved to be linearly proportional to the protein content. The method is based on the 
determination of the absorption of the tapes after removing the SC layer at the infrared 
wavelength (850nm) according to: 
𝐴 = 𝐼 − (
𝐼0
𝐼
) 
Equation 1.32 
where: 
𝐴 - absorption [%], 
𝐼 - intensity of the transmitted light, 
𝐼0 - intensity of the incident light. 
Data on the drug position in the SC (i.e. amount of drug quantified in the consecutive tapes at 
a given skin depth) can be normalized to the amount of the SC removed with the tape (i.e. the 
amount of protein on the tape). In this dermatopharmacokinetic approach, parameters 
describing drug transport in the SC (such as partition and diffusion coefficient) can be obtained 
[160, 165]. 
1.5.3 Transepidermal water loss 
Transepidermal water loss (TEWL) measurements provide information on the SC barrier 
function against water loss [193]. TEWL indicates the extent of barrier improvement or 
disruption caused by various factors, such as experimental procedures [183, 194], 
dermatological products [195, 196] or diseases [197]. TEWL measures the quantity of water 
that passes from the inside to the outside of epidermal barrier by diffusion or evaporation 
(usually in [g/m2/h]) [198, 199].  
TEWL is used as an endogenous standard for in vitro permeation studies [200, 201] and as a 
skin water holding capacity indicator in the in vivo studies [199, 202, 203]. It has been shown 
that reduction in SC hydration correlates with increased values of TEWL, which indicated the 
barrier impairment [204]. Hence, TEWL can be considered as a valuable source of information 
in dry skin condition investigations [205]. 
TEWL reflects the hydration of the SC as described in terms of Fick’s first law of diffusion in the 
following equation [148]: 
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𝑇𝐸𝑊𝐿 =
𝐾𝐷∆𝐶
ℎ
= 𝑘𝑝∆𝐶 
Equation 1.33 
where: 
𝐾 - partition coefficient of water between the SC and the viable epidermis, 
𝐷 - average apparent diffusion coefficient of water in the SC, 
ℎ - thickness of the SC, 
∆𝐶 - water concentration difference across the SC, 
𝑘𝑝 - permeability coefficient of water across the SC. 
It is worth noting that TEWL may be affected by environmental factors such as temperature, 
relative humidity and the season of the year [206, 207]. TEWL may also vary depending on the 
anatomic site [208, 209] and demographic parameters [209, 210]. Thus, it is crucial to control 
and take note of the experimental conditions during the TEWL measurement procedure [211]. 
The relationship between TEWL and skin hydration or dryness may not always be 
straightforward. Higher than normal levels of TEWL can be encountered not only in dry skin 
conditions, such as atopic dermatitis [186], but also in hyper hydrated skin [183, 194]. Usually 
the lowest values of TEWL are expected for healthy skin, but this may be also the case for skin, 
which appears to be dry in its outer layers and has the permeability barrier situated in the 
lower parts of the SC [212]. TEWL measurements are correlated with the thickness of the SC 
removed with tape stripping, i.e. the deeper stripped the tissue the higher the values of TEWL 
[165]. This is in agreement with the statement that SC cells and intercellular lipids are the main 
permeability barrier of the skin [172]. Thus, TEWL measurements after sequential removal of 
the SC with tape stripping procedure may provide information on skin integrity [192]. 
1.5.4 Stratum corneum protease activity 
Several serine proteases are present in the epidermis and take part in various processes such 
as skin desquamation and maintenance of skin barrier function [30, 37-39]. Changes in their 
activity in the SC can give important information on the influence of the formulation on skin 
state, especially on the desquamation and inflammatory processes [213]. 
The key desquamatory enzymes are human tissue kallikreins (KLKs), which are a family of 
trypsin-like (SCTE) and chymotrypsin-like (SCCE) stratum corneum enzymes [30, 214, 215]. The 
skin KLKs function as an enzymatic cascade, i.e. a sequence of activation reactions where the 
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product of one reaction catalyses the next one [39, 216]. Cathepsins [217] and heparanase 1 
[218] are also believed to be involved in epidermal desquamation. 
50% of total serine protease activity in the SC comes from KLK5 (trypsin-like serine protease) 
and the major part of remaining activity is associated with KLK14 (which has a dual trypsin- and 
chymotrypsin-like activity, with significant predominance of the former). KLK7 constitutes 
almost all of the chymotrypsin-like KLK activity in SC [213]. The activity of SCTE and SCCE is 
higher in the outermost layers of the SC, where the desquamation occurs [39]. 
The SC protease activity was reported to vary depending on the anatomic site and the depth 
into the SC [214, 219, 220]. The protease activity is also influenced by external factors such as 
the season of the year  [204], environmental conditions [221] and topically applied compounds 
[195, 222]. Reduced activity of KLK5 and KLK7 enzymes was found in dry skin [223-225]. On the 
other hand, elevated KLK7 expression was associated with inflammatory skin diseases such as 
atopic dermatitis [215, 226]. No differences in the SC protease activities were found between 
genders [177, 227]. Also KLK5 and KLK7 activity was found to be similar in Black and Caucasian 
ethnicities [177]. However, an effect of skin pigmentation on the SC protease activity was 
postulated by Gunathilake et al. [228]. 
Other SC enzymes important for the SC barrier function include: plasmin-, furin- and tryptase-
like enzymes. These protease activities were found to be elevated in atopic skin suggesting 
their role in inflammatory skin diseases [213, 226]. Urokinase-type plasminogen activation was 
reported after SC barrier disruption [229].  
1.5.5 Corneocyte size 
The investigation of corneocyte size and maturity gives information on the skin cell 
proliferation and maturation process [230]. Also the permeation process of topically applied 
products depends on the size of the cells, especially when the intercellular route is considered 
as the major route of penetration [70, 231]. 
The surface area of corneocytes differs depending on the anatomic site [231-233], age and 
gender [234] ranging from approximately 0.5 to 1.2 mm2. Hunter et al. [43] measured the area 
of corneocytes obtained by the skin stripping method from forearm, shoulder and thigh in 
different age and gender groups. An average value of 0.7-0.9 mm2 was obtained, which was in 
agreement with theoretical calculations and more recent studies [235]. It was established that 
the size of corneocytes changes in the following order: axilla > thigh > upper arm > abdomen > 
scalp > lower arm > heel > hand > forehead [232]. Remarkably, larger corneocytes were found 
Introduction 
46 
 
on the eyelids, when compared with small corneocytes on cheek and nose [233]. Plewig [234] 
reported gender differences in corneocyte size, i.e. larger cells were obtained for female 
subjects. However, no statistical difference between men and women was found in other 
studies [177, 231, 236]. Also no differences in terms of corneocyte size were found between 
ethnicities [177, 235, 236]. 
1.5.6 Corneocyte maturity 
As described in section 1.1.1.1, corneocytes in the SC have characteristic proteinaceous 
insoluble structures, called cell envelopes or cornified envelopes (CEs), which are formed 
through the crosslinking of several precursor proteins. Two main types of CE can be 
distinguished on the basis of their maturity and shape [29]. The more mature, polygonal, rigid 
cornified envelopes (CEr) can be found in the outermost layers of the SC, whereas irregular, 
less mature and less hydrophobic fragile cornified envelopes (CEf) are characteristic for the 
deeper layers of the SC and can be found in the outer layers of the SC of psoriatic and 
eczematous patients [237, 238] .  
Since the CE is an insoluble structure, it can be separated from the other SC components by 
boiling of the SC samples (e.g. obtained by the tape stripping technique) in reducing agents 
and detergents. Then the CEr and CEf can be distinguished by the double staining method, 
described by Hirao et al., which uses Nile red and fluorescent anti-involucrin immunostaining 
[238]. Nile red is a fluorescent agent which is extensively used for detection of lipids [239]. 
Involucrin is one of the cornified envelope precursor proteins, which in the process of 
maturation are cross-linked by transglutaminases. These precursor proteins are present to 
some extent in the immature CEf, but not in CEr, which in addition acquire hydrophobicity by 
the attachment of lipids to its proteins. Because of their hydrophobicity CErs are Nile red-
positive and stain little with anti-involucrin antibody. On the other hand CEfs are Nile red-
negative and can be strongly stained with anti-involucrin allowing for the differentiation of CEs 
with the use of fluorescent microscopy [238]. 
1.6 Atopic dermatitis 
Atopic dermatitis (AD) is a chronic skin condition, which is characterised by skin dryness, 
xerosis (cracking) and pruritus (itching), with excessive desquamation of the SC. It is inherently 
connected to the malfunction of the epidermal barrier and alterations in the barrier function 
are observed in both lesional and lesion-free skin of atopic patients [240-242]. 
The prevalence of AD is thought to have increased significantly over the past years, probably 
because of modern world lifestyle changes. The worldwide prevalence of AD in children ranges 
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from 1 to 20% and the United Kingdom is one of the countries with the highest prevalence 
rates [243]. The epidemiology of AD was reviewed by Daveiga [244]. 
1.6.1 Atopic dermatitis pathophysiology 
In general, dermatitis is caused by disturbance of three basic skin responses: 
 functional - impairment of function without morphologic changes, 
 inflammatory - degenerative changes following cellular injury,  
 proliferative - increase in number of different types of skin cells [1]. 
Atopy is a tendency to become sensitised and produce immunoglobulin E (IgE) antibodies in 
response to ordinary exposures to allergens [245]. However, 15 to 30% of AD patients do not 
show IgE-mediated sensitisation, manifesting intrinsic, non-IgE mediated AD [246, 247]. For 
many years AD was thought to be a consequence of internal inherent abnormal sensitisation 
(‘inside-to-outside’ hypothesis of AD pathophysiology). However, in the 1990s a new ‘outside-
inside’ hypothesis became prominent [248]. Recently, some authors proposed an even more 
complex form of this view (‘outside-inside-outside’) on AD pathogenesis [249-252]. According 
to this hypothesis, a primary structural abnormality of SC (i.e. inherited defects in the SC 
structure and function such as gene mutation) can be activated by external agents. These 
abnormalities can further aggravate permeability barrier dysfunction. In other words, initial 
changes in barrier function might drive the disease activity. 
One of the intrinsic factors responsible for AD may be mutation in the filaggrin encoding gene 
FLG. Filaggrin (FLG) is a protein of major importance for skin barrier function. A significant 
reduction in FLG expression was found in AD when compared with normal skin [253]. Studies 
in mice showed that FLG mutations can cause the primary structural abnormality of the SC 
encountered in AD [254, 255]. In humans, FLG mutations were associated with dry skin and 
higher TEWL values at 3 months of age [256]. Also, there are several variants of FLG associated 
with AD [257, 258]. Irvine [259] reviewed the prevalence of FLG mutations in the European 
population and their association with AD. 
Impairment of the SC function in AD includes changes in: 
 the permeability barrier [242, 260, 261],  
 the antimicrobial barrier [262],  
 the SC integrity (leading to excess scaling/abnormal desquamation) [213], 
 the SC hydration [263]. 
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The breakdown of epidermal barrier function in AD results from changes in such skin 
characteristics as: corneocyte size and maturation [230], desquamation [264], lipid profiles 
[265, 266] and some protease activities [213, 226]. A modulation in sensory nerves (dendritic 
cell signalling) is responsible for the itch-scratch vicious cycle [267]. 
1.6.1.1 Biophysical changes 
Barrier abnormalities in AD can be reflected in the changes in biophysical properties of the 
skin: increase in TEWL and decrease in skin capacitance (i.e. skin ability to conduct electrical 
current, which reflects skin hydration) [194, 212, 242, 256, 268-270]. 
Higher TEWL and decreased capacitance values were observed for the eczematous skin of AD 
patients when compared with lesion-free skin sites and to the skin of healthy volunteers. What 
is more, these parameters differed significantly between uninvolved atopic skin and the skin of 
healthy subjects [242, 271]. Also increased TEWL and decreased capacitance values were 
observed after treatment of atopic skin with detergent and non-detergent cleansers [269]. 
Lee at al. [268] correlated the increase in TEWL with high IgE and beta-endorphin serum levels 
in AD patients. The authors concluded that TEWL may be a good biomarker for the assessment 
of itch intensity. TEWL was also correlated with the severity of the disease described by the 
SCORAD index [272, 273]. A correlation between capacitance measurements and severity of 
skin dryness [274] or disease activity [270] was also established. Voegeli at al. [226] reported 
elevated basal TEWL, reduced skin hydration and increased irritation in lesional skin of AD 
patients, which indicated barrier dysfunction. The effects of topical treatment of AD with 
glycerol were also evaluated with TEWL and capacitance instrumental measurements [212]. 
The authors found a significant (r=0.33, p=0.0004) correlation between the TEWL values and 
the skin dryness assessed by a dermatologist postulating that TEWL measurements may be a 
helpful tool to determine AD severity. 
1.6.1.2 Serine proteases 
Symptoms of AD are similar to one of the symptoms of Netherton syndrome, which is 
associated with loss-of-function mutations in the SPINK5 gene. SPINK5 encodes the serine 
protease inhibitor LEKTI 5 - lympho-epithelial Kazal-type inhibitor 5 [275]. This similarity leads 
to an assumption that one of the probable pathomechanisms of AD lies in an increased activity 
of serine proteases (SPs) [276]. This increase may explain the global decrease in extracellular 
lipids, decrease in ceramide levels, immunologic abnormalities and disrupted cell proliferation 
and desquamation encountered in AD [266, 276-279]. 
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The increase of KLK5 activity alone induces abnormalities similar to the characteristics of AD 
[277]. Also mutations in the KLK7 encoding genes (KLK7) were found to be associated with AD 
[280]. KLK7 deregulation was detected in AD patients who showed no IgE level elevation. Thus, 
SP expression could be an independent AD factor from atopy or IgE-mediated sensitization. 
KLKs may also be contributing to the regional inflammatory reaction in AD, by triggering the 
protease-activated receptor 2 (PAR2) signalling, which modulates inflammatory responses 
[213, 281, 282]. 
Voegeli et al. [226] reported increased SP activities in acute eczematous AD, especially in 
deeper layers of the SC. This increase was associated with impaired barrier function, irritation, 
reduced skin capacitance, elevated TEWL and increased skin cohesion. 
Not all SP activities are elevated in AD. Abnormally high proteolytic activity of plasmin was 
observed by Komatsu and co-workers in AD and psoriasis. In this study, elevation of KLK7 
activity was predominant, compared with trypsin-like KLKs, implying that an increase in KLK7 
may be crucial in AD pathogenesis or manifestations. The alterations of KLKs levels in the SC 
were more evident than in serum, suggesting that KLKs could be involved in a regional 
inflammatory reaction [213, 283]. It was shown that in lesional AD skin SC tryptase-like 
enzyme, plasmin, urokinase, trypsin-like KLKs and chymotrypsin-like KLK activity values are 
significantly increased compared with healthy or non-lesional skin. The enzymatic activity 
increased towards the surface of the SC in healthy and non-lesional skin. On the contrary, their 
elevated activity was maintained across lesional SC, indicating KLKs function in manifestation 
of AD symptoms [226]. 
1.6.1.3 Epidermal differentiation 
A shorter epidermal turnover time was observed in AD when compared with healthy skin 
[284]. Also smaller corneocytes with less water-soluble amino acids were found in the skin of 
atopic patients [284, 285]. Uninvolved atopic skin was characterised by thinner SC when 
compared with healthy skin. However, the overall thickness of the epidermis was increased 
[285]. Corneocytes in AD were shed as aggregates rather than individual cells [284, 285]. 
At the final stage of differentiation, keratinocytes form a cornified envelope (CE) consisting of 
lipid and protein components [50, 286]. This structure is responsible for the SC cohesion [287] 
thanks to covalent bonds between the extracellular lipids and proteins (mainly involucrin) 
[288]. Ceramides are the main protein-bound lipids in healthy skin (~50%). However, a 
decrease in this percentage was observed in atopic patients, both in lesion-free and affected 
skin [25]. 
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1.6.2 Treatment of atopic dermatitis 
In accordance with the inflammatory theory of AD pathogenesis, treatment of this condition is 
mainly focused on diminishing immunological response. Nevertheless, there is increasing 
evidence of barrier impairment, rather than improvement, caused by topical 
glucocorticosteroids [289] and calcineurin inhibitors [290] used in AD therapy. Among other 
side effects, the treatment with topical corticosteroids caused skin thinning and disruption in 
the intercellular lipids, reflected in elevated TEWL [291]. Thus, other AD therapy options 
should be considered. 
According to the ‘outside-inside-outside’ theory, which states that inflammation is a result of 
inherited and acquired barrier impairment, restoring barrier function of the epidermis should 
be an effective treatment of AD [251]. Because AD is inherently bound to dry and scaly skin, 
topical moisturisers are widely used to alleviate these symptoms [212] and decrease the use of 
steroids [292]. However, care must be taken in terms of the composition of moisturisers. 
Depending on the vehicle and actives present in the formulation, the topical preparations may 
improve or deteriorate skin barrier properties and symptoms of AD [212, 293-298]. 
The use of lipids and lipophilic substances in the treatment of AD is popular. Petrolatum 
accelerated barrier recovery after acetone-induced disruption. It was found in the intercellular 
space in the SC, suggesting that its effect is because of skin lipid replacement, rather than an 
occlusive effect [299]. Specific lipid-replacement therapy of AD gave comparable effects to 
mid-strength steroid treatment [300]. Also ceramide treatment of AD proved effective in 
alleviating the disease symptoms [297]. 
Based on the elevated levels of SP activities in the SC of AD patients, it is postulated that the 
use of SP inhibitors might be a potential treatment of AD [226]. Use of topical nicotinamide has 
been shown to accelerate barrier recovery in experimentally damaged skin barrier models 
[301] and in patients with dry skin disorders [302]. However, its influence on the SP activity in 
the SC has not yet been fully documented. 
1.7 Nicotinamide 
Nicotinamide (NA) is a component of the vitamin B complex. Together with nicotinic acid, NA is 
a constituent of vitamin B3. NA is involved in over 200 enzymatic reactions as NAD 
(Nicotinamide Adenine Dinucleotide) and NADP (Nicotinamide Adenine Dinucleotide 
Phosphate) - enzyme cofactors, which serve as electron transporters in cell metabolism. 
Humans are able to synthesise nicotinic acid from tryptophan. Also intestinal bacterial flora is a 
source of nicotinic acid. Nevertheless, it is necessary to deliver vitamin B3 in products such as 
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grains, meat and milk. The deficiency of this vitamin initially induces non-specific symptoms: 
fatigue, anorexia and irritability. Subsequently, shortage of vitamin B3 can lead to more severe 
condition called pellagra, which is associated with dermatitis, diarrhoea and dementia [303]. 
Oral NA is used in vitamin B3 deficiency. It can be found in tablets or capsules of multivitamin 
preparations used as dietary supplements [304]. Also bread, flour and other grain-derived 
products are in some countries enriched in NA [303]. NA is an ingredient of numerous 
cosmetics, where it serves as a hair and skin conditioning agent [305]. Currently in the UK, 
there are two topical pharmaceutical formulations of NA (4%) registered for the treatment of 
acne vulgaris [304, 306] 
1.7.1 Physicochemical properties 
The physicochemical properties of NA are listed in Table 1.1 and the structural formula is 
shown in Figure 1.9. 
Table 1.1 Physicochemical properties of nicotinamide 
Chemical name 3-pyridinecarboxamide; pyridine-3-carboxamide [307] 
Molecular formula C6H6N2O [307] 
Molecular weight 122.13g/mol [307] 
Appearance White crystalline powder or colourless crystals [307] 
Water solution stability Stable in pH 3.5 - 7 [303] 
Dissociation Constant pKa 3,35 (20˚C) [307] 
Partition coefficient logKo/w -0,38 at 22˚C [307] 
Melting point 128-131˚C [307] 
Water solubility Freely soluble 1:1 [307] 
Ethanol solubility Freely soluble 1:1.5 [307] 
Glycerol solubility Freely soluble (1:10) [307] 
Maximum UV absorption 255nm; 262.5nm [303, 307] 
UV detection wavelength 260-264nm [303, 307] 
 
Figure 1.9 Structural formula of nicotinamide 
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1.7.2 Absorption, distribution and excretion 
NA is readily absorbed from the intestinal tract and from parenteral sites of administration 
(e.g. skin). It is widely distributed in all tissues throughout the body [308]. Of the constituents 
of vitamin B3, it is NA that is transported between different tissues as a precursor of NAD [303]. 
NA is a hydrophilic compound and thus it is not assumed that it penetrates through lipid 
lamellar structures between corneocytes easily. However, in vitro studies using human cadaver 
skin confirmed that NA penetrates the skin after topical application of various products 
containing this compound [305]. NA permeation across pig and rabbit skin was also 
investigated in vitro [309-311]. 
1.7.3 Nicotinamide in the therapy of inflammatory and dry skin disorders 
The symptoms of vitamin B3 deficiency, pellagra, include skin xerosis and pruritus. Hence, NA 
has found use in alleviating dry and itchy skin conditions. However, it is only recently that the 
probable mechanisms of NA action in dry skin have been hypothesised [312].  
NA is a precursor of endogenous enzyme cofactors: NAD, its phosphorylated form (NADP), and 
their reduced forms NADH and NADPH. These cofactors may influence skin properties by 
participating in various skin enzymatic reactions [301]. Namazi [313] suggested that because of 
its anti-inflammatory and antioxidant properties, together with the ability to inhibit and 
suppress various enzymes and reactions in the skin (such as nitric oxide synthase and antigen-
induced lymphocyte transformation), NA might be useful in the topical treatment of AD. 
NA is in general regarded as safe at pharmacologic doses and thus can be used in long-term 
topical therapy [93, 302, 314-316]. 
1.7.3.1 Nicotinamide influence on stratum corneum lipids 
Tanno et al. [316] postulated that NA increases the levels of SC ceramides. In vitro studies with 
cultured normal human keratinocytes incubated for 6 days with 1-30µmol/L NA showed that it 
increases intercellular lipid synthesis: glucosylceramides, sphingomyelin, cholesterol and fatty 
acids. The mechanism of NA action is the augmentation of serine palmitoyltransferase (SPT) 
activity, by increasing the levels of human LCB1 and LCB2 mRNA, which both encode subunits 
of SPT – the rate-limiting enzyme in sphingolipid synthesis [317]. 
In vivo studies on volunteers with dry skin conducted for 4 weeks confirmed that NA influences 
skin lipid composition. Topical application of 2% NA increased ceramide, cholesterol and free 
fatty acids levels in SC (via an increase in acetyl coenzyme A activity) and decreased TEWL 
[316]. 
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1.7.3.2 Nicotinamide influence on epidermal differentiation 
An increase in the SC thickness and the total skin water content was observed in a study 
conducted by Crowther et al. in 2008 [93]. After 2 weeks of treatment with a formulation 
containing NA and 1-week regression, compared with 2 formulations without NA, NA was 
found to improve the SC barrier function and decrease desquamation. The formulation 
containing NA induced a statistically significant (p<0.05) increase in the SC thickness after 2 
weeks (mean 2µm, i.e. 10% increase). It also increased the SC water content and improved the 
SC water profile. The proposed mechanism of these changes was an improvement in 
keratinocyte differentiation and an increase in ceramide synthesis. 
Kitamura et al. [318] investigated the influence of NA on the cornified envelope formation and 
the presence of differentiated keratin K1. Both of these markers of keratinocyte maturation 
were highly expressed in NA treated cells. Also TGase, the enzyme crucial for CE formation, 
showed high activity. The authors concluded that NA promotes differentiation of human 
keratinocytes. 
1.7.3.3 Anti-inflammatory activity of nicotinamide 
NA is an inhibitor of Poly-ADP-ribose polymerase 1 (PARP-1), an enzyme which plays an 
important role in the expression of adhesion molecules and inflammatory mediators [319]. It 
also inhibits cAMP phosphodiesterase and stabilises mast cells and leukocytes, thus decreasing 
the release of histamine and IgE [320, 321]. 
The potent anti-inflammatory activity of NA has been used in the treatment of acne vulgaris. A 
4% NA gel reduced acne lesions (papules and pustules) and acne severity at a rate of 60% and 
52% respectively. In in vivo studies, comparable results to the effects of 1% clindamycin were 
obtained after NA formulations were applied [315]. Fiveson [314] proposed a variety of 
potential mechanisms of action of the combination of NA and zinc used in the treatment of 
acne, mainly related to the anti-inflammatory potential of this combination. NA was also found 
to inhibit production of IL-8 induced by Propionibacterium acnes [322]. 
A topical moisturiser containing 2% NA was shown to be beneficial in patients with rosacea. 
Following a 4 weeks twice-daily application period, the skin of 50 patients participating in the 
study exhibited higher resistance to damage (DMSO test) and better hydration, together with 
lower TEWL values and erythema scores [323]. 
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1.7.3.4 Nicotinamide influence on barrier enhancement and hydration 
NA significantly improved SC barrier function in a vehicle-controlled study with a sodium lauryl 
sulphate (SLS) and a dimethylsulfoxide (DMSO) challenge model [301]. Significantly lower 
TEWL values (p<0.01), together with improved redness (p<0.0005) and wheal (p<0.05) scores 
were observed in the challenge tests after 24 days treatment with 2% NA applied twice daily. 
Baseline TEWL values were also significantly (p<0.02) lower for the NA treated group when 
compared with control. 
In a study by Crowther et al. [93], an increase in skin thickness brought about by formulations 
containing NA was accompanied by changes in epidermal water gradients and increased skin 
hydration. 
In conclusion, because of its anti-inflammatory and skin barrier enhancing properties, NA has 
potential as an active substance to be used in the topical treatment of AD. 
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2 Aims and objectives 
Chapter 1 provided general information about the skin, percutaneous absorption and methods 
used in skin research. It also summarised the pathophysiology and the treatment of atopic 
dermatitis and highlighted the properties of nicotinamide as a potential active compound for 
the treatment of inflammatory skin diseases.  
Taking into account the information provided in the introductory chapter, the following aims 
and objectives of this work were identified: 
 to optimise the skin delivery of nicotinamide with the use of appropriate excipients, 
 to evaluate nicotinamide skin delivery with in vitro and in vivo techniques, 
 to investigate the efficacy of nicotinamide formulations in improving the skin state in 
vivo. 
In Chapter 3, pre-formulation studies, i.e. solubility parameter calculation, miscibility, solubility 
and NA stability studies, are described. Based on these studies, the optimal excipients for 
prototype nicotinamide formulations were chosen and further studied in the following 
chapters. Chapter 4 encompasses in vitro uptake and permeation studies in silicone membrane 
and pig skin. Evaluation of prototype nicotinamide formulations in vivo was described in 
Chapter 5. The performance of formulations in terms of nicotinamide percutaneous absorption 
was compared with their influence on the skin condition. 
Conclusions regarding the in vitro and in vivo studies performed within the boundaries of this 
thesis are given in Chapter 6 and possible future developments discussed in Chapter 7. 
Additional information regarding the methodology used in this research can be found in the 
appendices.  
This work looks at nicotinamide from a new perspective of its potential use in atopic dermatitis 
treatment. Also, a practical approach to topical formulation development is attempted, i.e. 
theoretical calculations of solubility parameter are used to choose the optimal vehicle 
components for a successful topical delivery of the model drug.  
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3 Pre-formulation studies 
Pre-formulation studies are the preliminary experiments performed during the development 
of any formulation. In the case of topical formulations, it is crucial to determine the solubility 
and stability of the drug in the chosen excipients and the mutual miscibility of the formulation 
components. These parameters influence the performance of the formulation in terms of 
delivery of the drug and the achievement of the required pharmacological effect.  
Investigation of the drug solubility in the chosen solvents gives information on the drug 
thermodynamic activity, which is important in the diffusion process [1, 2].  
Knowledge of the mutual miscibility of the formulation components is essential, because not 
only simple solvents but also their combinations must be taken into account in the choice of 
the final formulation. Synergistic effects of solvents on percutaneous absorption have been 
reported in the literature [3-8] and are explored in other sections of the present work.  
The physicochemical properties of the drug, the vehicle and the skin are of major importance 
for percutaneous absorption. The structural complexity of the skin further complicates this 
process. Thus, theoretical calculations of solubility parameter could be helpful in the 
determination of solubility and miscibility, providing guidelines for choosing the best 
excipients in the formulation development process. Predicting the interactions between the 
drug, the vehicle and the model membrane from theoretical solubility parameter values has 
been attempted previously [9-13] and was investigated further in the present work. 
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3.1 Materials 
Table 3.1 Materials used in the pre-formulation studies  
Material Supplier 
Nicotinamide (NA) Dermal Laboratories Ltd., UK 
Glycerol (GLY) Dermal Laboratories Ltd., UK 
Mineral oil (MO) Dermal Laboratories Ltd., UK 
Isopropyl myristate (IPM) Dermal Laboratories Ltd., UK 
Propylene glycol monolaurate type II (PGML) Gattefossé, France 
Propylene glycol monocaprylate type II (PGMC) Gattefossé, France 
Propylene glycol dipelargonate (DPPG) Gattefossé, France 
Propylene glycol (PG) Sigma Aldrich, UK 
Laboratory water purifier (OPTION 3, 75 litre volume) USF Elga, UK 
Phosphate Buffered Saline (PBS) tablets (DulbeccoA, pH 7.3±0.2) Oxoid, UK 
Nuova II stirrer Thermolyne, UK 
Dow Corning 7-4107 Silicone Elastomer Membrane Seneffe, Belgium 
High Vacuum Silicone Grease Dow Corning, UK 
Water bath type JB5 Grant Instruments Ltd., UK 
Variomag® HP16 Stirring Drive Unit H+P Labortechnik GmbH, Germany 
Teflon coated magnetic stirrers (7, 12, 25 and 35mm length) Fisher Scientific, UK 
HPLC grade solvents: Acetonitrile, Methanol and Water Fisher Scientific, UK 
HPLC vials with flat bottom inserts and caps with rubber seal Fisher Scientific, UK 
Sudan III Sigma Aldrich, UK 
Polyoxyethylene (20) oleyl ether Sigma Aldrich, UK 
AnalaR Normapur Perchloric acid 70% WVR International, UK 
Digitron
TM
-22 Differential Digital Thermometer with probe RS Components, UK 
Eppendorf Research® pipettes Eppendorf AG, Germany 
Analytical balances (accuracy 0.0001g and 0.0001mg) Sartorius GmbH, Germany 
HPLC Column Primesep A 250x4.6mm, Particle 5µm, 100Å SIELC Technologies Inc., USA 
SecurityGuard Cartridge with C18 4mmLx3mm filter Phenomenex, USA 
Stuart® Rotator SB3 Bibby Scientific Ltd., UK 
Laboratory glassware and containers UCL School of Pharmacy 
Metallic membrane cutter UCL School of Pharmacy 
Parafilm®M Bemis Flexible Packaging, USA 
Orbital incubator S150 Stuart Scientific, UK 
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Traceable® Extra - Extra Loud Timer Fisher Scientific, UK 
Molecular Modelling PRO software Version 6.3.3. Norgwyn Montgomery Software Inc., USA 
IBM SPSS Statistics software Version 19  SPSS Inc., an IBM Company 
3.2 Methods 
3.2.1 Theoretical calculations of solubility parameter 
Van Krevelen and Hoftyzer three-dimensional solubility parameter (δ) [cal1/2/cm3/2] values 
were determined for the chosen molecules with Molecular Modelling PRO software Version 
6.3.3. (Norgwyn Montgomery Software Inc., USA). 
The δ values for the mixtures of solvents were calculated according to the following equation 
[14, 15]: 
𝛿𝑚𝑖𝑥𝑡𝑢𝑟𝑒 = ∑(𝜑1 × 𝛿1) + ⋯ + (𝜑𝑛 × 𝛿𝑛) 
Equation 3.1 
where: 
𝛿𝑚𝑖𝑥𝑡𝑢𝑟𝑒 - solubility parameter of the solvent mixture, 
𝜑𝑛 - volume fraction of the n
th solvent, 
𝛿𝑛 - solubility parameter of the n
th solvent. 
3.2.2 Miscibility studies 
Miscibility studies were performed at room temperature for the binary mixtures of the chosen 
solvents within a range of proportions in 10% steps. Miscibility was determined by observation 
of the point (ratio of the solvents) where the mixtures stopped being clear or phase separation 
could be seen. Sudan III (Sigma Aldrich, UK) was used to dye the lipophilic phase in cases 
where it was difficult to determine whether the separation occurred. After mixing, the samples 
were left at 32°C overnight to check if any changes in miscibility might occur in contact with 
the skin surface which temperature is believed to be 32°C [16-19]. 
3.2.3 Solubility studies 
Excess drug was added to each solvent system and mixed. Throughout the study the samples 
were maintained at 32 ± 1°C and stirred continuously at 40rpm. Solubility was determined 
after 48 hours. This equilibration time was validated in the preliminary studies where solubility 
was measured after 24, 48 and 72h equilibration. No statistically significant differences (one-
way ANOVA, p>0.05) were found between the results obtained at each time point. In the 
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literature, a 48h equilibration period was used for NA solubility determination [20, 21]. Thus, a 
48h equilibration time was chosen for further experiments. 
At the end of the equilibration period, suspensions of the drug in the solvents were 
centrifuged for 10min at 12000rpm and the temperature of the centrifuge (Eppendorf, UK) 
was maintained at 32 ± 1°C throughout the process. The samples of supernatant were 
analysed with high performance liquid chromatography (HPLC) after appropriate dilutions. The 
experiment was performed in triplicate for each solvent. 
3.2.4 Nicotinamide stability in chosen solvents 
NA stability in various solvents was tested at 32 ± 1°C for 48h (taking into account the 
permeation study temperature and the length of the testing period). Solutions of a known 
concentration of NA in the solvent were prepared and mixed with magnetic stirrer bars. At 
designated time points, aliquots of NA solutions were collected and, after appropriate 
dilutions, analysed for NA concentration with HPLC. The experiment was performed in 
triplicate. 
3.2.5 Sample analysis 
HPLC with UV detection was used for NA quantification in the permeation samples. The 
method was validated according to the guidelines and met the required criteria (coefficient of 
variance≤10-15%; r2≥0.999) [22, 23]. The parameters of the HPLC method used for NA 
quantification are listed in Table 3.2. 
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Table 3.2 Parameters of the HPLC method for nicotinamide quantification 
Column Primesep A 250x4.6mm, Particle 5µm, 100Å  
(SIELC Technologies, USA) 
Guard column SecurityGuard Cartridge System with C18 (ODS, Octadecyl) 
4mmLx3mm filter (Phenomenex, USA) 
HPLC System Agilent Technologies 1100 Series HPLC system 
Software ChemStation for LC Systems software 
Copyright
© 
Agilent Technologies 
Mobile phase Mobile phase A (80%): 0.07% Perchloric Acid in Purified Water 
(1mL of 70% Perchloric Acid in 1L), pH 2 
Mobile phase B (20%): Acetonitrile (HPLC grade) 
Injection volume 10μL 
Flow rate 2 mL/min 
Temperature control 40°C 
UV detection wavelength 263nm 
Retention time of nicotinamide ~9min 
Analysis time ~11min 
Calibration curve range 2-200μg/mL (standard concentrations: 2; 10; 20; 50; 100; 
200μg/mL prepared from a 1000μg/mL stock solution by dilution 
with PBS) 
3.2.6 Data analysis 
Statistical significance was determined using one-way ANOVA with the Tukey post-hoc test or 
the independent samples 2-tailed t-test performed with IBM SPSS Statistics Version 19 
software (SPSS Inc., an IBM Company). A probability of p<0.05 was considered statistically 
significant. All results are presented as mean ± SD (n=3) unless otherwise stated. 
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3.3 Results 
3.3.1 Solubility parameter 
Table 3.3 summarises the δ values of the chosen solvents calculated with Molecular Modeling 
PRO software (Norgwyn Montgomery Software Inc., USA) and the literature values for skin [12] 
and silicone membrane [24]. The δ values summarised in the table are the van Krevelen and 
Hoftyzer type 3-D solubility parameters. 
Table 3.3 Solubility parameters of chosen solvents 
Compound/membrane Solubility parameter [cal
1/2
/cm
3/
]
2
 
Silicone 7.50 
MO 7.74 
IPM 8.21 
DPPG 8.66 
PGML 9.44 
PGMC 9.85 
Skin 10.00 
NA 13.85 
PG 14.07 
GLY 17.14 
Water 22.97 
 
3.3.2 Miscibility studies 
Table 3.4 shows the results of binary solvent system miscibility studies over the whole range of 
proportions tested. After mixing, the samples were left at 32°C overnight and changes in 
miscibility were noted. In general, no changes in miscibility were observed the following day. 
Solvents with δ values close to each other proved to be miscible, which is in line with the 
approach to use this parameter to predict miscibility [14]. 
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Table 3.4 Miscibility of binary solvent systems (M-miscible, IM-immiscible) 
 MO IPM DPPG PGMC PGML PG GLY Water 
MO  M M M M IM IM IM 
IPM M  M M M IM IM IM 
DPPG M M  M M IM IM IM 
PGMC M M M  M M IM IM 
PGML M M M M  M IM IM 
PG IM IM IM M M  M M 
GLY IM IM IM IM IM M  M 
Water IM IM IM IM IM M M  
 
3.3.3 Solubility studies 
The saturated solubility of NA in single solvents and in binary solvent systems was determined 
and the results are summarised in Table 3.5 and Table 3.6.  
Table 3.5 Solubility of NA in chosen single solvents at 32 ± 1°C (mean ± SD, n=3) 
Solvent Solubility 48h ± SD [mg/mL] Solubility parameter [cal
1/2
/cm
3/2
] 
MO 0.006 ± 0.001 7.74 
IPM 0.68 ± 0.04 8.22 
DPPG 1.63 ± 0.01 8.66 
PGML 22.15 ± 0.35 9.44 
PGMC 38.17 ± 1.25 9.85 
PG 243.37 ± 8.76 14.07 
Water 552.70 ± 11.49 22.97 
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Table 3.6 Solubility of NA in binary (1:1) solvent systems at 32 ± 1°C (mean ± SD, n=3) 
Solvent Solubility 48h ± SD [mg/mL] Solubility parameter [cal
1/2
/cm
3/2
] 
IPM:DPPG 1.12 ± 0.02 8.44 
IPM:PGML 8.29 ± 0.09 8.83 
DPPG:PGML 9.93 ± 0.23 9.05 
IPM:PGMC 12.70 ± 0.37 9.03 
DPPG :PGMC 15.74 ± 0.24 9.25 
PGML:PGMC 31.35 ± 1.38 9.64 
PG:PGML 128.54 ± 4.24 11.75 
PG:PGMC 143.75 ± 3.12 11.96 
PG:Water 471.96 ± 6.67 18.52 
 
The solubility of NA in the chosen solvents ranged from very low values for the most lipophilic 
solvents, MO and IPM, to extremely high solubility obtained in water. The solubility of NA 
increased with increasing δ value of the solvent system. The more hydrophilic the solvent, the 
higher its potential to dissolve NA. A good linear correlation was established between NA 
solubility and the δ value for the solvent systems tested (r2=0.98) and is illustrated in Figure 
3.1. 
 
Figure 3.1 Correlation between solubility parameter and experimental solubility of NA in chosen 
solvent systems (mean ± SD, n=3) 
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3.3.4 Nicotinamide stability in chosen solvents 
Table 3.7 summarises the results of the stability test. 
Table 3.7 Stability of NA in chosen solvents after 48h equilibration at 32 ± 1°C (results shown as mean 
± SD, n=3) 
Solvent Recovery [%] 
IPM 105.04 ± 2.71 
DPPG 100.87 ± 3.32 
PGML 106.58 ± 5.54 
PGMC 112.29 ± 8.67 
PG 97.93 ± 1.62 
PBS 101.98 ± 1.76 
 
3.4 Identification of optimal solvents and formulations 
Investigated solvents encompass a wide range of solubility parameters: from 7.74 cal1/2/cm3/2 
for MO to 22.97 cal1/2/cm3/2 for water. PGMC, PGML, DPPG and IPM have a δ value close to 
that of skin (approximately 10 cal1/2/cm3/2). Moreover, close values of δ for NA and PG 
implicate their strong interaction and possible positive effect of this solvent on NA 
percutaneous absorption. These solvents were further investigated in the rational 
development process of topical NA formulations. The application of δ calculation in prediction 
of topical delivery was tested and will be described in other chapters in this thesis.  
Based on the results of miscibility studies, simple miscible solvent systems were chosen to be 
investigated further. NA permeation from the miscible solvent systems was investigated in 
vitro. Miscible solvent systems were used to simplify the experimental conditions and the 
analysis of the data. In the case of miscible solvent systems, NA partitioning occurs between 
the solvent system and the skin, as opposed to a more complex formulation where, for 
example, the drug will distribute between the immiscible phases of the vehicle e.g. a cream.  
Knowledge of the saturated solubility allows determination of the maximal concentration of 
the drug which can be incorporated into the vehicle. Also, application of the saturated solution 
on the skin will result in the maximal thermodynamic activity of the drug in the vehicle, and 
thus the maximal flux across the skin can be achieved [2]. Further in vitro permeation studies 
were performed with saturated solutions of NA, to ensure the maximal thermodynamic 
activity of the drug in the vehicle. 
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The stability of the drug is crucial for the development of a safe formulation. NA hydrolysis to 
nicotinic acid, which can induce skin reddening [25], should be avoided. In general, NA proved 
to be stable for 48h at 32 ± 1°C in the range of solvents tested. This means that a stable NA 
formulation can be developed with the chosen solvents. 
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4 In vitro studies in silicone membrane and pig skin 
The rate and the extent of drug diffusion and absorption from a topical product depends on 
the physicochemical properties of the drug, the amount of the formulation applied and the 
thermodynamic activity of the drug in the vehicle [1]. It is also known that excipients influence 
permeation of the drug, although the mechanisms of their action are not yet fully elucidated. 
Thus, optimisation of the formulation composition is an important step in the development of 
a topical preparation and investigating the role of excipients in the drug permeation process is 
crucial for appropriate execution of this task [2]. 
Two prototype formulations containing 4% NA were prepared by Dermal Laboratories Ltd., UK. 
The strategy was to investigate NA performance in terms of improving skin state separately 
from other excipients present in the formulation. Thus, one of the formulations (DENI) 
contained several components, including IPM, MO and GLY, while the other (NIAD) contained 
approximately 93% of water.  
Before the formulation reaches the stage of in vivo investigations, in vitro studies should be 
performed to obtain information about the interactions between the drug, skin and the 
vehicle. Understanding these interactions is important for achievement of an optimal topical 
delivery as it provides the basis for the choice of an appropriate vehicle for the given drug. 
Uptake studies, using silicone as a model membrane, have shown that high solvent sorption 
into the membrane enhances drug permeation [3]. The authors suggested that increased drug 
flux was because of higher drug solubility in the membrane caused by the presence of solvent. 
This would indicate that drug partitioning into the membrane was increased when an 
appropriate solvent was used. The drug diffusivity was considered to be also influenced by the 
vehicle, although to a lesser extent. 
In vitro permeation studies with human skin as a barrier membrane are the closest 
representation of the conditions in vivo. However, the complexity and variability of human 
skin, together with its limited availability causes the need for alternative membranes. Animal 
skin and artificial model membranes can be used instead, as they are readily available and less 
variable than human skin. Silicone membrane has been used by many authors to study drug 
permeation and to help to elucidate more complex skin-drug-vehicle interactions [4-14]. Also, 
pig skin is considered to be one of the best substitutes of human skin [15-18]. Although human 
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skin usually is less permeable many authors support the use of pig skin, especially from the 
outer region of the ear, for in vitro permeation studies [19-24]. 
Since the vehicle components can influence the permeation of an active, knowing the solvent 
fate in the permeation process is equally as important as monitoring the transport of the drug. 
To investigate how solvents with different physicochemical properties influence nicotinamide 
(NA) transport in model membranes, solvent uptake, NA partitioning and in vitro permeation 
studies were performed. Permeation of both NA and specific solvents were investigated, to 
see if any relationship between these two could be established. For a better understanding of 
NA permeation and retention in the membrane after application of prototype NA formulations 
and simple solvent systems containing NA, both infinite (for prototype formulations) and finite 
dose studies across silicone membrane were performed. Silicone membrane was chosen for 
these preliminary studies to simplify experimental conditions, particularly to reduce the impact 
of biological variability. Permeation was further studied using pig ear skin, bringing the 
conditions closer to the real life situation when a finite amount of formulation is applied to the 
skin. Washing and extraction of the skin and the silicone membrane was included in the finite 
dose studies to enable assessment of the retention of NA in these model membranes. 
4.1 Materials 
Table 4.1 Materials used in the in vitro studies in silicone membrane and pig skin 
Material Supplier 
Nicotinamide (NA) Dermal Laboratories Ltd., UK 
Glycerol (GLY) Dermal Laboratories Ltd., UK 
Mineral oil (MO) Dermal Laboratories Ltd., UK 
Isopropyl myristate (IPM) Dermal Laboratories Ltd., UK 
Propylene glycol monolaurate type II (PGML) Gattefossé, France 
Propylene glycol monocaprylate type II (PGMC) Gattefossé, France 
Propylene glycol dipelargonate (DPPG) Gattefossé, France 
Propylene glycol (PG) Sigma Aldrich, UK 
Laboratory water purifier (OPTION 3, 75 litre volume) USF Elga, UK 
Phosphate Buffered Saline (PBS) tablets (DulbeccoA, pH 7.3±0.2) Oxoid, UK 
Nuova II stirrer Thermolyne, UK 
Dow Corning 7-4107 Silicone Elastomer Membrane Seneffe, Belgium 
Franz-type diffusion cells UCL School of Pharmacy 
Metallic clamps UCL School of Pharmacy 
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Electronic Outside Micrometer, 0-25mm, min 0.001mm RS Components, UK 
High Vacuum Silicone Grease Dow Corning, UK 
Water bath type JB5 Grant Instruments Ltd., UK 
Variomag® HP16 Stirring Drive Unit H+P Labortechnik GmbH, Germany 
Impedance meter UCL School of Pharmacy 
Stainless steel hardened electronic callipers  Fisher Scientific, UK 
Teflon coated magnetic stirrers (7, 12, 25 and 35mm length) Fisher Scientific, UK 
Silicone tubing Nalge Nunc Corp., USA 
HPLC grade solvents: Acetonitrile, methanol and water Fisher Scientific, UK 
HPLC vials with flat bottom inserts and caps with rubber seal Fisher Scientific, UK 
Plastic syringes (1, 2 and 5mL) and needles Fisher Scientific, UK 
Microscope cover glasses Fisher Scientific, UK 
Surgical scalpels, scissors and tweezers Fisher Scientific, UK 
Polyoxyethylene (20) oleyl ether Sigma Aldrich, UK 
AnalaR Normapur Perchloric acid 70% WVR International, UK 
Essential Waitrose cotton buds  Waitrose, UK 
Digitron
TM
-22 Differential Digital Thermometer with probe RS Components, UK 
Eppendorf Research® pipettes Eppendorf AG, Germany 
Analytical balances (accuracy 0.0001g and 0.0001mg) Sartorius GmbH, Germany 
HPLC Column Primesep A 250x4.6mm, Particle 5µm, 100Å SIELC Technologies Inc., USA 
SecurityGuard Cartridge with C18 4mmLx3mm filter Phenomenex, USA 
Stuart® Rotator SB3 Bibby Scientific Ltd., UK 
Laboratory glassware and containers UCL School of Pharmacy 
Metallic membrane cutter UCL School of Pharmacy 
Parafilm®M Bemis Flexible Packaging, USA 
Orbital incubator S150 Stuart Scientific, UK 
Traceable® Extra - Extra Loud Timer Fisher Scientific, UK 
Prototype formulations (DENI and NIAD) Dermal Laboratories Ltd., UK 
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Table 4.2 Composition of DENI formulation 
Material % w/w 
Nicotinamide EP 4.0 
Isopropyl Myristate EP  
Paraffin Liquid EP  
Glycerol EP  
Modified acrylic polymer (Pemulen
TM
 HSE TR1)  
Sorbitan Laurate EP  
Triethanolamine BP 2000  
Phenoxyethanol EP  
Water Purified EP  
 
Table 4.3 Composition of NIAD formulation 
Material % w/w 
Nicotinamide EP 4.0 
Modified acrylic polymer (Pemulen
TM
 HSE TR1)  
Sorbitan Laurate EP  
Citric Acid Anhydrous EP  
Phenoxyethanol EP  
Triethanolamine BP 2000  
Water Purified EP  
 
4.2 Methods 
4.2.1 Solvent uptake into the silicone membrane 
The silicone membrane was cut to size with a metallic membrane cutter and weighed on an 
analytical balance (Sartorius GmbH, Germany, accuracy 0.0001mg). The membranes were 
immersed in single solvents (water, GLY, PG, PGML, MO, PGMC, DPPG and IPM) and allowed to 
equilibrate for 48h at 32 ± 1°C. Following the equilibration period, the membranes were taken 
out of the solvent, patted dry with a tissue paper and weighed again. The % increase in the 
mass of the membrane was determined. The experiment was performed in triplicate for each 
solvent. 
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4.2.2 Solvent uptake into the stratum corneum 
The stratum corneum (SC) was isolated from full thickness pig ear skin using the heat 
separation method followed by trypsinisation [25]. The full thickness skin was immersed in 
distilled water heated to 60°C for 45 seconds and the epidermis was gently removed. Isolated 
epidermal membranes were stored at -20°C until used. SC was obtained by 12 hours 
incubation with 0.1% trypsin solution in phosphate buffered saline (PBS) at 37°C. The isolated 
SC was washed with distilled water and dried over silica gel for at least 2 days. Dry SC was cut 
into pieces of similar size, weighed on an analytical balance (Sartorius GmbH, Germany, 
accuracy 0.0001mg) and hydrated over a saturated solution of sodium chloride (relative 
humidity 75%) at 25°C to approximately 5% hydration. Hydration was calculated according to 
Equation 4.1. 
% ℎ𝑦𝑑𝑟𝑎𝑡𝑖𝑜𝑛 =
ℎ𝑦𝑑𝑟𝑎𝑡𝑒𝑑 𝑆𝐶 𝑚𝑎𝑠𝑠 − 𝑑𝑟𝑦 𝑆𝐶 𝑚𝑎𝑠𝑠
𝑑𝑟𝑦 𝑆𝐶 𝑚𝑎𝑠𝑠
× 100% 
Equation 4.1 
The SC was placed into glass sample vials, immersed in a single solvent (PG, PGML, PGMC, 
DPPG and IPM) and allowed to equilibrate for 24h at 32 ± 1°C. Following the equilibration 
period, the SC was taken out of the solvent, patted dry with a tissue paper and weighed again. 
The per cent increase in the dry mass of the membrane was determined. The experiment was 
performed in triplicate for each solvent. 
4.2.3 Nicotinamide partitioning into model membranes 
The silicone membrane was cut to size with a metallic membrane cutter, weighed and placed 
into glass sample vials. Saturated solutions of NA in the single solvents were prepared by 48h 
equilibration at 32 ± 1°C. The suspensions of the drug in the solvents were centrifuged (10min, 
12000rpm, 32 ± 1°C). The concentration of NA in the solvents was determined before uptake 
with HPLC, after appropriate dilutions. The membrane was immersed in the supernatant and 
allowed to equilibrate for 24h at 32 ± 1°C. Following the equilibration period, membranes were 
taken out of the solvent, patted dry with a tissue paper and weighed again. The percentage 
increase in the mass of the membrane was determined. The membranes were extracted with 
1mL of methanol for 1h at 45°C and the amount of NA extracted and present in the solvent 
was quantified, after appropriate dilutions, with HPLC. The extraction method was validated 
prior to the experiment, as described in appendices. The experiment was performed in 
triplicate for each solvent. The partition coefficient (𝐾) of NA was calculated according to 
Equation 4.2. 
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𝐾 =
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑁𝐴 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑁𝐴 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑜𝑙𝑣𝑒𝑛𝑡
 
Equation 4.2 
4.2.4 Equipment preparation for in vitro permeation studies 
PBS was prepared by dissolving 10 tablets (Dulbecco A, pH 7.3±0.2 at 25°C, Oxoid, UK) in 1 litre 
of purified water and was used as a receptor solution in the nicotinamide permeation studies. 
For the solvent permeation studies 6% polyoxyethylene (20) oleyl ether (PE(20)OE) in PBS was 
used as a receptor solution. The receptor solution was degassed by high speed stirring under 
vacuum (Nuova II stirrer, Thermolyne, UK) for at least 25 minutes to prevent the formation of 
air bubbles below the membrane.  
The diameter of each Franz cell receptor compartment was accurately measured with 
electronic callipers (Fisher Scientific, UK). The permeation data were corrected for the exact 
diffusion area of each cell. The diffusional area of the Franz cells used in the experiments was 
approximately 1cm2.  
Donor and receptor compartments of Franz cells were smeared at the adjoining surfaces with 
silicone grease (Dow Corning, UK). The model membrane was aligned on the receptor 
compartment of the Franz cell. The donor compartment was then fitted on top of the 
membrane and the compartments were secured together with a metallic clamp.  
The receptor compartments were filled with a known amount of degassed receptor solution, 
which was determined gravimetrically by weight difference between the Franz cell before and 
after adding the receptor solution. The volume of the receptor solution varied between 3 to 4 
cm3 depending on the size of the cell.  
The micro magnetic stirrer bars (7mm) were placed inside the receptor compartments and the 
receptor phase was continuously stirred throughout the experiment to ensure sink conditions. 
The sampling ports of the receptor compartments were sealed with Parafilm®M (Bemis 
Flexible Packaging, USA) to prevent receptor phase evaporation. The assembled Franz cells 
were placed in a temperature controlled water bath (Grant Instruments Ltd., UK) and the 
temperature was allowed to equilibrate for 30 minutes. The temperature of the water bath 
was maintained at a level sufficient to achieve 32 ± 0.5°C at the membrane surface. The 
temperature of the membrane in each cell was measured with a DigitronTM-22 digital 
thermometer (RS Components, UK) prior to the experiment. The temperature of the water 
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bath was 34.0±0.5°C and 37.0±0.5°C throughout the study, for silicone and pig skin studies 
respectively. 
Before application of the formulations, the t0 sample was taken from the receptor 
compartment and replaced with fresh PBS solution, which was maintained at the experimental 
temperature throughout the study. The time of the application of a formulation to the 
membrane was considered as the beginning of the experiment. At designated time points 200 
μL of the receptor solution was sampled from each cell and replaced by the fresh PBS solution 
to maintain a constant volume of the receptor phase. 
4.2.5 Silicone membrane preparation for in vitro permeation studies 
The silicone membrane was cut to size with a metallic membrane cutter and soaked overnight 
in the PBS solution at the experimental temperature. The pre-treated membranes were taken 
out of the PBS solution and carefully blotted with an absorbent tissue paper to remove the 
excess moisture before alignment on the receptor compartments of Franz cells. The thickness 
of the membrane was measured at the end of the experiment (Electronic Outside Micrometer, 
RS Components, UK) and averaged (n=5 for each formulation). 
4.2.6 Pig skin preparation for in vitro permeation studies 
Pig ear skin preparation was based on the literature [21, 24, 26-34]. Pig ears obtained from a 
local abattoir were kept at -20°C before the membrane preparation. The ears were defrosted 
prior to preparation and cleaned under cold running tap water. Full thickness skin was 
removed from the underlying cartilage with a scalpel. The skin was further cleaned by floating 
in purified water in a metal basin. Circles of a similar size, large enough to cover the opening of 
a Franz cell receptor, were marked with a metallic membrane cutter and cut to size with 
surgical scissors. Hair was trimmed with surgical scissors. Isolated skin samples were cleaned 
with purified water and stored on aluminium foil at -20°C until use. The integrity of skin 
samples was tested prior to the experiment by impedance measurements. In general, for pig 
ear skin experiments, impedance values were above 4kΩ, which is in line with 
recommendations [19]. The donor compartments of the cells were dried with an absorbent 
paper tissue prior to the application of formulations. 
4.2.7 Infinite dose permeation studies 
In the case of infinite dose permeation studies, the donor compartment of each Franz cell was 
loaded with approximately 1g of a prototype formulation (1.08±0.08g/cm2, n=5 for each 
formulation). Because of the high viscosity of the prototype formulations, 2mL disposable 
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plastic syringes (Fisher Scientific, UK) were used to apply the formulations. The dosing, i.e. the 
amount of formulation added to each cell, was determined gravimetrically.  
For the simple solvent systems, 1mL of saturated NA solution in the solvent system was 
applied to the model membrane with an Eppendorf Research® pipette (Eppendorf AG, 
Germany). To avoid drug depletion, the solvent system applied into the donor compartment 
contained excess crystals of the drug.  
The permeation study was conducted for 6 to 10 hours, which allowed for observation of the 
expected permeation profile. The collection time points were: 0, 1, 2, 4, 6, 8 and 10 hours. 
Each formulation was tested in five Franz cells. The donor compartment was sealed with 
Parafilm®M (Bemis Flexible Packaging, USA) to prevent evaporation of formulation 
components. 
4.2.8 Finite dose silicone permeation studies 
In the case of finite dose silicone permeation studies, the donor compartment of each Franz 
cell was loaded with approximately 10mg of a prototype formulation (11.01±1.78mg/cm2, n=5 
for each formulation). Formulations were applied to, and spread uniformly on the membrane 
using a glass rod. The dosing was determined by gravimetric measurements of the rod before 
and after application.  
For the simple solvent systems, 10µL of saturated NA solution in the solvent system was 
applied to the model membrane with an Eppendorf Research® pipette (Eppendorf AG, 
Germany).  
To mimic in vivo conditions, the donor compartment was not sealed, to allow for formulation 
evaporation. The permeation study was conducted for 24 hours to enable observation of the 
plateau phase. The collection time points were: 0, 2, 5, 8, 18, 21 and 24 hours. Each 
formulation was tested in five Franz cells. At the end of the study the membrane was washed 
and extracted according to the protocol described below. 
4.2.8.1 Mass balance protocol for finite dose silicone permeation study 
Prior to cell disassembly, the membrane was washed with 1mL of 6% polyoxyethylene (20) 
oleyl ether (PE(20)OE) and rubbed thoroughly with a cotton bud dipped in the washing 
solution. The cotton bud was then added into the washing fraction and extracted for 1h at 
45°C. Thereafter, the cells were disassembled. The membrane was placed in the Eppendorf vial 
and extracted with 1mL of purified water or methanol (for solvent analysis) for 1h at 45°C in an 
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orbital incubator (Stuart Scientific, UK). Appropriate aliquots of the washing and extraction 
samples were taken for dilution and further HPLC analysis. 
4.2.9 Finite dose permeation studies in pig ear skin 
In the case of finite dose pig ear permeation studies,  the donor compartment of each Franz 
cell was loaded with approximately 10mg (11.17±1.80mg/cm2, n=10, i.e. 5 cells for each 
formulation) of a prototype formulation.  
For the simple solvent systems, excess drug was added to each solvent system and 
equilibrated for 48h at 32 ± 1°C. The suspensions of the drug in the solvents were centrifuged 
(10min, 12000rpm, 32 ± 1°C). The donor compartment of each Franz cell (n=5 per solvent 
system) was loaded with 10µL of supernatant (i.e. saturated solution of NA in a solvent 
system).  
The donor compartment was not sealed to mimic in vivo conditions. The permeation study was 
conducted for 8 hours, which allowed for observation of an expected permeation profile. The 
collection time points were: 0, 1, 2, 4, 6 and 8 hours. Each of the formulations was tested in 
five Franz cells. 
4.2.9.1 Mass balance protocol for finite dose pig ear permeation study 
The membrane washing and extraction procedures were performed using a protocol similar to 
the mass balance study described in section 4.2.8.1. The membrane was washed with 1mL of 
6% PE(20)OE and wiped thoroughly with a cotton bud dipped in the washing solution. The 
cotton bud was added to the washing solution and extracted for 1h at 45°C. Cells were 
disassembled and the full thickness pig ear skin was separated into epidermis and dermis prior 
to the extraction procedure. This enabled assessment of NA retention in different skin layers. 
The epidermis was separated from the dermis using a dry heat separation method described 
by previous authors [31, 33, 35]. Skin samples were subject to the hot air treatment at a 
temperature of 50°C for 30 seconds followed by the removal of the epidermis with a surgical 
scalpel. The temperature and the time of the hot air treatment were controlled (DigitronTM-22 
Thermometer, RS Components, UK and Traceable® Extra - Extra Loud Timer, Fisher Scientific, 
UK). The epidermis and the dermis were placed in pre-weighed Eppendorf vials and the mass 
of the membrane was determined. This was followed by the epidermis and the dermis 
extraction with 1mL of purified water or methanol for 1h at 45°C. Appropriate aliquots of the 
washing and extraction samples were taken for dilution and further HPLC analysis. 
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4.2.10 Sample analysis 
HPLC with UV detection was used for NA quantification as described in section 3.2.5. 
4.2.11 Data analysis 
The permeation was evaluated by plotting the cumulative amount (𝑄𝐴) of the compound 
permeated per unit surface area of the membrane against the collection time for each 
diffusion cell. 
For the infinite dose studies with silicone as a model membrane, 𝐽𝑠𝑠 was calculated by linear 
regression using Microsoft Excel software within the interval of 2 to 6 hours. The lag time 
(𝑡𝑙𝑎𝑔) was determined by the visual inspection of the permeation profiles. Knowing the 
thickness (ℎ) of the membrane (0.00836cm), the diffusion coefficient (𝐷) was calculated 
according to Equation 4.3. 
𝑡𝑙𝑎𝑔 =
ℎ2
6𝐷
 
Equation 4.3 
For the prototype formulations, the concentration of the drug in the donor compartment (𝐶𝑣) 
was 40000µg/g. In the case of simple solvent systems, the concentration of the drug was equal 
to its saturated solubility in the solvent system. Thus, the partition coefficient (𝐾) could be 
obtained from Equation 4.4. 
𝐽 = 𝐴𝐷𝐾𝑚/𝑣
𝐶𝑣
ℎ
 
Equation 4.4 
The permeability coefficient (𝑘𝑝) was calculated according to Equation 4.5.  
𝑘𝑝 =
𝐾𝐷
ℎ
 
Equation 4.5 
The modelling of both non-steady and steady state data using Scientist® Version 3.0 software 
(MicroMath Scientific, USA) was performed using Equation 4.6. 
𝑄𝐴̅̅̅̅ =  
𝐽(̅𝑠)̅̅ ̅̅ ̅
𝑠
=  
𝐴𝐾𝐶𝑣
𝑠√
𝑠
𝐷  sinh (
√𝑠ℎ
2
𝐷 )
 
Equation 4.6 
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𝐾 and 𝐷 parameters obtained from the fitting were used to calculate 𝐽𝑠𝑠 and 𝑘𝑝. 𝐽𝑠𝑠 calculated 
with both methods (Excel and Scientist®) was compared.  
In the finite dose studies, only Scientist® was used to fit diffusion equations to experimental 
data, because of the limitations of the lag time method [36-38]. The modelling was performed 
according to Equation 4.7 (for silicone membrane) 
𝑄𝐴̅̅̅̅ =  
𝐾𝐶𝑣𝑉√
𝐷
𝑠
𝑠2 (𝐴𝐾𝑐𝑜𝑠ℎ√
𝑠ℎ2
𝐷 + 𝑉𝑠𝑖𝑛ℎ
√𝑠ℎ
2
𝐷 )
 
Equation 4.7 
and Equation 4.8 (for the skin) 
𝑄𝐴̅̅̅̅ =  
𝐴𝑃1𝑄0
𝑠 (𝑉√
𝑠
𝑃2
𝑠𝑖𝑛ℎ√
𝑠
𝑃2
+ 𝑃1𝐴𝑐𝑜𝑠ℎ√
𝑠
𝑃2
)
 
Equation 4.8 
The parameters 𝐾 and 𝐷 or 𝑃1 and 𝑃2 were calculated for silicone and pig ear skin studies 
respectively and 𝑘𝑝 was calculated according to Equation 4.5 and Equation 4.9. 
𝑘𝑝 = 𝑃1𝑃2 
Equation 4.9 
The percentage of the applied dose permeated, washed and extracted from the membrane 
was compared for the formulations, in both silicone and pig ear skin finite dose studies. Also 
the retention of NA in the epidermis and the dermis [µg/g] was calculated according to 
Equation 4.10. 
𝑟𝑒𝑡𝑒𝑛𝑡𝑖𝑜𝑛 =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑁𝐴 𝑓𝑜𝑢𝑛𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑘𝑖𝑛
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑘𝑖𝑛
 
Equation 4.10 
For prototype formulations, statistical significance was determined using an independent 
sample 2-tailed t-test performed with IBM SPSS Statistics Version 19 software (SPSS Inc., an 
IBM Company). A probability of p<0.05 was considered statistically significant. All results are 
presented as the mean ± SD (n=5) unless otherwise stated. 
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For simple solvent systems, the percentage of the applied dose permeated, washed and 
extracted from the membrane was compared for the formulations, in both silicone and pig ear 
skin finite dose studies. Statistical significance was determined using one-way ANOVA with 
Tukey post-hoc test performed with IBM SPSS Statistics Version 19 software (SPSS Inc., an IBM 
Company). A probability of p<0.05 was considered statistically significant. All results are 
presented as mean ± SD (n=5) unless otherwise stated. 
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4.3 Results - silicone membrane studies 
4.3.1 Solvent uptake studies  
The results of solvent uptake studies are shown in Table 4.4. 
Table 4.4 Solvent uptake into model membranes, mean ± SD, n=3 
Solvent 
Solubility parameter 
[cal
1/2
/cm
3/2
] 
Molecular weight [g/mol] 
Solvent uptake into 
silicone membrane [%] 
MO 7.44 >500 1.74 ± 0.14 
IPM 8.22 270.45 58.18 ± 8.87 
DPPG 8.66 356.54 15.74 ± 0.48 
PGML 9.44 258.40 1.13 ± 0.98 
PGMC 9.85 230.31 1.57 ± 0.10 
PG 14.07 76.09 0.19 ± 0.38 
Water 22.97 18.02 0.83 ± 0.37 
 
The highest solvent uptake into the silicone membrane was obtained for IPM, which is one of 
the most lipophilic of the chosen solvents (with the exception of MO) with a solubility 
parameter (δ) value closest to the solubility parameter postulated for the silicone membrane, 
i.e. 7.5 cal1/2/cm3/2 [39]. 
4.3.2 Nicotinamide partitioning  
The investigation of the influence of solvents on NA partitioning into the silicone membrane 
was performed to provide insight into the drug affinity for the membrane. The partition 
coefficient of NA was calculated according to Equation 4.2. The results are shown in Table 4.5. 
Table 4.5 Nicotinamide partitioning into silicone membrane, mean ± SD, n=3 
Solvent 
Concentration of 
NA in the solvent 
before uptake 
[mg/g] 
Concentration of 
NA in the 
membrane 
[mg/g] 
Concentration of 
NA in the solvent 
after uptake 
[mg/g] 
Partition 
coefficient 
Increase in the 
mass of the 
membrane [%] 
IPM 3.10 0.19 ± 0.01 3.05 ± 0.01 0.0626 ± 0.0040 52.92 ± 1.67 
DPPG 4.30 0.27 ± 0.01 4.26 ± 0.02 0.0626 ± 0.0020 14.76 ± 0.87 
PGML 40.56 0.28 ± 0.02 41.50 ± 2.00 0.0067 ± 0.0008 1.36 ± 0.32 
PGMC 56.34 0.23 ± 0.03 49.70 ± 15.53 0.0049 ± 0.0015 1.82 ± 0.06 
PG 300.37 0.21 ± 0.01 290.99 ± 9.65 0.0009 ± 0.0003 0.02 ± 0.03 
 
The highest partition coefficient (p<0.05, one-way ANOVA) was obtained for IPM and DPPG. 
The lowest partition coefficient (p<0.05, one-way ANOVA), was obtained for PG. 
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4.3.3 Nicotinamide permeation from prototype formulations 
4.3.3.1 Infinite dose permeation studies across silicone membrane 
The infinite dose permeation profiles of prototype DENI and NIAD formulations obtained in the 
silicone permeation study are shown in Figure 4.1. 
a) 
 
b) 
 
Figure 4.1 Infinite dose permeation profiles of prototype DENI and NIAD formulations across silicone 
membrane: a) cumulative amount of nicotinamide, b) percentage of nicotinamide permeated (data 
shown as mean ± SD, n=5) 
The prototype NA formulations are different in terms of cumulative amounts (𝑄𝐴) of NA 
permeated across silicone membrane in the infinite dose studies. A statistically significant 
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difference (t-test, p<0.05) in 𝑄𝐴 was found after 6, 8 and 10 hours, with higher values for the 
DENI formulation. 
Statistically significant differences (t-test) were observed for 𝐽𝑠𝑠 (p<0.005), 𝐾 (p<0.05) and 𝑘𝑝 
(p<0.005) calculated with the lag time method and for all compared permeation parameters 
obtained by Scientist® modelling: 𝐽𝑠𝑠, 𝑘𝑝 (p<0.05) and 𝐾, 𝐷 (p<0.0005). The permeation 
parameters are shown in Table 4.6. 
Table 4.6 Permeation parameters obtained in silicone infinite dose studies for DENI and NIAD 
formulations (data shown as mean ± SD (n=5), *p<0.05, **p<0.005, ***p<0.0005) 
Parameter [unit] DENI NIAD 
QA* (after 10h of experiment) [μg/cm
2
] 37.15 ± 5.76 27.65 ± 4.13 
La
g 
ti
m
e 
Jss** [μg/cm
2
/h] 3.99 ± 0.61 2.65 ± 0.43 
D [cm
2
/h] 2.33×10-5 ± 0.00 2.33×10-5 ± 0.00 
K*  0.036 ± 0.006 0.024 ±0.004 
kp** [cm/h] 9.97×10
-5
 ± 1.53×10-5 6.64×10-5 ±1.08×10-5 
Sc
ie
n
ti
st
 
Jss* [μg/cm
2
/h] 3.93 ± 0.60 2.88 ± 0.43 
D*** [cm
2
/h] 2.36×10-5 ± 0.04×10-5 2.37×10-3 ± 0.11×10-3 
K***  0.036 ± 0.007 2.55×10-4 ± 0.04×10-4 
kp* [cm/h] 9.84×10
-5
 ±
 
1.50×10-5 7.2×10-5 ± 1.08×10-5 
 tlag [h] 2.74×10
-10
 ±
 
4.69×10-11 2.76×10-8 ± 1.33×10-9 
 
There was no significant difference (t-test, p<0.05) between flux and permeability coefficient 
calculated from steady state data (lag time method) and from non-steady and steady state 
data (Scientist®). Thus, modelling of the permeation data with Scientist® software may be 
helpful in determination of the permeation parameters. 
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Figure 4.2 Steady state flux for infinite dose NA permeation across silicone membrane from prototype 
DENI and NIAD formulations calculated with two different methods (mean ± SD, n=5, *p<0.05, 
**p<0.005) 
4.3.3.2 Finite dose permeation studies across silicone membrane 
The finite dose permeation profiles of prototype DENI and NIAD formulations obtained in the 
finite dose silicone permeation studies are shown in Figure 4.3. 
No significant differences (t-test, p>0.05) were found for the permeation parameters (𝑄𝐴, 𝐷, 𝐾 
and 𝑘𝑝). Also no differences (t-test, p>0.05) in the mass balance of NA between the membrane 
and the cell compartments were found for the two formulations. The summary of the results is 
shown in Table 4.7. Presence of several excipients in the tested formulations might have 
complicated the experimental conditions causing a high standard deviation. 
Table 4.7 Permeation parameters obtained in silicone finite dose studies for DENI and NIAD 
formulations (data shown as mean ± SD, n=5) 
Parameter [unit] DENI NIAD 
QA [μg/cm
2
] after 24h 264.08±46.18 227.93±9.26 
% of NA permeated 59.07±15.97 55.24±6.30 
% washed from the membrane 43.12±19.09 39.31±7.81 
% extracted from the membrane 0.00±0.00 0.00±0.00 
Total recovery [%] 102.19±4.63 94.55±2.23 
D [cm
2
/h] 4.20x10
-5
±1.84*10
-5
 7.50x10
-5
±7.11*10
-5
 
K 131.12 ± 138.01 90.16 ± 135.41 
kp 
0.43 ± 0.20 0.39 ± 0.30 
tlag 4.86×10
-10
 ±
 
2.15×10-11 8.73×10-9 ± 8.28×10-9 
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a) 
 
b) 
 
Figure 4.3 Finite dose permeation profiles of prototype DENI and NIAD formulations across silicone 
membrane: a) cumulative amount of nicotinamide, b) percentage of nicotinamide permeated (data 
shown as mean ± SD, n=5) 
 
4.3.4 Nicotinamide permeation from simple solvent systems - infinite dose 
silicone studies 
In vitro infinite dose Franz-cell permeation studies with silicone as a model membrane were 
conducted to evaluate the single solvents and simple solvent systems in terms of influence on 
NA diffusion across the membrane. The solubility of NA in the chosen solvent systems and the 
solubility parameter difference between the vehicle (solvent) and the membrane (δv - δm) is 
shown below to allow for comparison between the systems tested. 
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The permeation of NA from the following single solvent systems was studied: 
Table 4.8 Single solvents used in the infinite dose silicone studies  
Solvent Solubility 48h ± SD [mg/mL] δv - δm [cal
1/2
/cm
3/2
] 
IPM 0.68 ± 0.04 0.72 
DPPG 1.63 ± 0.01 1.16 
PGML 22.15 ± 0.35 1.94 
PGMC 38.17 ± 1.25 2.35 
PG 243.37 ± 8.76 6.57 
Water 552.70 ± 11.49 15.47 
 
The cumulative amount of NA permeated per unit area (𝑄𝐴) [µg/cm
2] from each solvent 
system was plotted against time [h]. The permeation profiles obtained for the single solvent 
systems are shown in Figure 4.4. 
 
Figure 4.4 Infinite dose permeation profiles of NA applied in single solvents to the silicone membrane 
at 32 ± 0.5°C (mean ± SD, n=5) 
The 𝑄𝐴 of NA permeated after 6 h from single solvents is shown in Figure 4.5. 
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Figure 4.5 Cumulative amount of NA permeated after 6 h from single solvents in the infinite dose 
permeation studies across silicone membrane at 32 ± 0.5°C (mean ± SD, n=5) 
Because synergistic effects on permeation were observed for combinations of PG with fatty 
acids and their esters by previous authors [40-47], the 50:50 mixtures of the chosen single 
solvents were further investigated in the infinite dose silicone permeation studies.  
The following binary solvent systems were investigated: 
Table 4.9 Binary solvent systems used in the infinite dose silicone studies 
Solvent system Ratio of solvents used 
Solubility 48h ± SD 
[mg/mL] 
δv - δm 
[cal
1/2
/cm
3/2
] 
IPM:DPPG (ID) 50:50 1.12 ± 0.02 0.94 
IPM:PGML (IL) 50:50 8.29 ± 0.09 1.33 
DPPG:PGML (DL) 50:50 9.93 ± 0.23 1.53 
IPM:PGMC (IC) 50:50 12.70 ± 0.37 1.55 
DPPG:PGMC (DC) 50:50 15.74 ± 0.24 1.75 
PGML:PGMC (LC) 50:50 31.35 ± 1.38 2.14 
PG:PGML (PL) 50:50 128.54 ± 4.24 4.25 
PG:PGMC (PC) 50:50 143.75 ± 3.12 4.46 
PG:H2O (PH) 50:50 471.96 ± 6.67 11.02 
 
The permeation profiles obtained for the binary solvent systems are shown in Figure 4.6. 
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Figure 4.6 Infinite dose permeation profiles of NA applied in binary solvent systems to the silicone 
membrane at 32 ± 0.5°C (mean ± SD, n=5) 
The 𝑄𝐴 of NA permeated after 6 h from each of the binary solvent systems tested is shown in 
Figure 4.5. 
 
Figure 4.7 Cumulative amount of NA permeated after 6 h from binary solvent systems in the infinite 
dose permeation studies across silicone membrane at 32 ± 0.5°C (mean ± SD, n=5) 
Steady state data (in general, the time points from 2 to 6 hours) were taken into account to 
calculate 𝐽𝑠𝑠 using the lag time method. Steady state data and 𝐽𝑠𝑠 obtained from these data 
were used to determine 𝑘𝑝. Also, 𝐽𝑠𝑠 and 𝑘𝑝 were calculated from the results obtained with 
Scientist® software, by fitting both non-steady and steady state data to the relevant equations 
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(see section 4.2.7). 𝐽𝑠𝑠 and 𝑘𝑝 values obtained with both methods ware not significantly 
different (t-test, p>0.05). On the contrary, there was a strong correlation between 𝐽𝑠𝑠 and 𝑘𝑝 
values (r2≈1 both for 𝐽𝑠𝑠 and 𝑘𝑝) once again confirming the utility of Scientist® software 
modelling for the permeation data. The correlation plots are shown in Figure 4.8. 
a) 
 
b) 
 
Figure 4.8 Correlation between lag time method and Scientist® calculations: a) steady state flux, b) 
permeability coefficient (mean ± SD, n=5) 
The 𝐽𝑠𝑠 and 𝑘𝑝 values obtained from the NA silicone permeation studies for simple solvent 
systems are shown in Figure 4.9 and Figure 4.10.  
 
Figure 4.9 Steady state flux for infinite dose NA permeation across silicone membrane from simple 
solvent systems at 32 ± 0.5°C (mean ± SD, n=5) 
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a) 
 
b) 
 
Figure 4.10 Permeability coefficients for infinite dose permeation across silicone membrane from 
simple solvent systems at 32 ± 0.5°C (mean ± SD, n=5); a) formulations with low permeability 
coefficients, b) formulations with high permeability coefficients 
From the data shown above, it can be seen that NA permeation across silicone membrane 
depends strongly on the solvent in which it is applied. From the solvent systems tested, the 
highest 𝐽𝑠𝑠 and 𝑘𝑝 were obtained for IPM (one-way ANOVA, p<0.05). The lowest 𝐽𝑠𝑠 and 𝑘𝑝 
values were found for water, PG and their 50:50 mixture (PH). These three systems were not 
significantly different from each other in terms of 𝐽𝑠𝑠 and 𝑘𝑝 (one-way ANOVA, p>0.05). For 
the solvent systems with the highest 𝐽𝑠𝑠 across silicone membrane, the flux decreased in the 
following order: IPM > IC ≈ ID > IL > DPPG. These systems have close δ values to the δ of 
silicone membrane (7.5 cal1/2/cm3/2) [39]. The differences (δv - δm) between the solubility 
parameter of the solvent system (δv) and the solubility parameter of the membrane (δm) were 
calculated and are shown in Table 4.8 and Table 4.9. Also high 𝐽𝑠𝑠 and 𝑘𝑝 values were observed 
for the solvents with low solubility of the drug in the solvent system and high solvent uptake 
into the membrane. 
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4.3.5 Solvent and nicotinamide permeation - finite dose silicone studies  
Finite dose permeation studies across silicone membrane were performed. NA and solvent 
permeation profiles are shown in Figure 4.11 and Figure 4.12, respectively.  
a) 
 
b) 
 
Figure 4.11 Finite dose silicone permeation profiles for nicotinamide: a) cumulative amonut of 
nicotinamide permeated, b) cumulative percentage of nicotinamide permeated at 32 ± 0.5°C (mean ± 
SD, n=5) 
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a) 
 
b) 
 
Figure 4.12 Finite dose silicone permeation profiles for solvents: a) cumulative amount of solvent 
permeated, b) cumulative percentage of solvent permeated at 32 ± 0.5°C (mean ± SD, n=5) 
The highest cumulative amount of NA (p<0.05, one-way ANOVA) permeated from PGML and 
PGMC, which is in line with the highest cumulative amount of these solvents permeated 
(p<0.05, one-way ANOVA) when compared with IPM and DPPG. The lowest cumulative 
amount of NA (p<0.05, one-way ANOVA) was obtained for IPM, DPPG and PG. In the case of 
IPM and DPPG, this is because of the low solubility of NA in these solvents and thus, low dose 
of NA applied. For PG, the cumulative amount of the solvent is not different (p>0.05, one-way 
ANOVA) from the cumulative amount of PGML and PGMC that permeated after 6 hours. 
However, the percentage of PG permeated is significantly lower (p<0.05, one-way ANOVA) 
0
5
10
15
20
25
30
0 2 4 6 8
C
u
m
u
la
ti
ve
 a
m
o
u
n
t 
o
f 
so
lv
e
n
t 
p
e
rm
e
at
e
d
 [
µ
m
o
l/
cm
2 ]
 
Time [h] 
IPM
DPPG
PGML
PGMC
PG
0
10
20
30
40
50
60
70
80
0 2 4 6 8
C
u
m
u
la
ti
ve
 p
e
rc
e
n
ta
ge
 o
f 
so
lv
e
n
t 
p
e
rm
e
at
e
d
 [
%
] 
Time [h] 
IPM
DPPG
PGML
PGMC
PG
In vitro studies in silicone membrane and pig skin 
111 
 
than the values obtained for PGML and PGMC. This may indicate that the relatively low 
amount of NA permeated from PG may be because of the low permeation of this solvent. 
The percentages of applied dose of NA and solvents permeated, washed and extracted from 
the membrane after 6h are shown in Figure 4.13. 
The highest (p<0.05, one-way ANOVA) percentage of NA permeated from IPM and DPPG, even 
though the lowest (p<0.05, one-way ANOVA) percentage of these solvents (not different from 
PG) permeated over the course of the study. However, high percentages of IPM and DPPG 
(77.61 ± 5.33 and 54.70 ± 6.13, respectively) were extracted from the silicone membrane, 
indicating that the presence of the solvents in the membrane is enough to enable NA 
permeation. It is not surprising that most of the applied doses of IPM and DPPG were found in 
the membrane, since these two solvents have a higher affinity for the hydrophobic silicone 
membrane than for the hydrophilic receptor phase. 
 
a)  
 
b)  
 
Figure 4.13 Percentages of applied dose permeated, washed and extracted from the membrane after 
6h for a) nicotinamide and b) solvents, mean ± SD, n=5, *p<0.05 
The highest (p<0.05, one-way ANOVA) percentage of solvent permeation was found for PGML 
and PGMC (67.78±6.18 and 50.51±9.79, respectively). Also, the permeation profiles indicate 
rapid penetration of these solvents, with more than 50% permeated after the first two hours 
of the experiment. These results indicate a depletion of PGML and PGMC from the donor 
phase, which in turn leads to a relatively low percentage of NA permeated and high 
percentage washed from the membrane at the end of the study. 
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The highest (p<0.05, one-way ANOVA) percentage of solvent and NA washed from the 
membrane was obtained for PG. Even though this solvent permeates though the silicone 
membrane to some extent (approximately 10%), only a small percentage of NA (0.30±0.03%) 
permeated from this solvent. This may be because of high solvent hydrophilicity and very low 
affinity for the membrane, resulting in too low solvent uptake into the membrane to enable 
NA permeation. This is in line with the low percentage of solvent extracted from the 
membrane at the end of the study, which was also observed for PGML and PGMC. 
4.4 Results - pig ear skin studies 
4.4.1 Solvent uptake studies - pig ear skin 
The results of solvent uptake studies are shown in Table 4.10 and Figure 4.16. 
Table 4.10 Solvent uptake into the model membranes, mean ± SD, n=3 
Solvent 
Solubility parameter 
[cal
1/2
/cm
3/2
] 
Molecular weight [g/mol] 
Solvent uptake into 
stratum corneum [%] 
IPM 8.22 270.45 18 ± 6 
DPPG 8.66 356.54 28 ± 8 
PGML 9.44 258.40 39 ± 9 
PGMC 9.85 230.31 47 ± 9 
PG 14.07 76.09 81 ± 21 
 
The highest uptake into the SC was obtained for PG and a linear relationship was found 
between the SC solvent uptake and δ values for the chosen solvents (r2=0.96). 
 
Figure 4.14 Solvent uptake and solubility parameter, mean ± SD, n=3  
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4.4.2 Nicotinamide partitioning  
The investigation of the influence of solvents on NA partitioning into the SC was performed to 
provide insight into the drug affinity for this environment. The partition coefficient of NA was 
calculated according to Equation 4.2. The results are shown in Table 4.11. 
Table 4.11 Nicotinamide partitioning into the stratum corneum, mean ± SD, n=3 
Solvent 
Concentration of 
NA in the solvent 
before uptake 
[mg/g] 
Concentration of 
NA in the 
membrane 
[mg/g] 
Concentration of 
NA in the solvent 
after uptake 
[mg/g] 
Partition 
coefficient 
Increase in the 
mass of the 
membrane [%] 
IPM 3.1 7.5 ± 2.7 3.0 ± 0.0 2.5 ± 0.9 11.0 ± 0.4 
DPPG 4.3 5.3 ± 0.6 4.0 ± 0.1 1.3 ± 0.2 14.2 ± 1.1 
PGML 40.6 5.8 ± 1.1 38.2 ± 0.3 0.2 ± 0.0 26.6 ± 10.1 
PGMC 56.3 4.7 ± 0.3 58.2 ± 2.0 0.1 ± 0.0 31.1 ± 21.9 
PG 300.4 14.0 ± 0.7 302.8 ± 7.7 0.05 ± 0.0 58.2 ± 15.6 
 
The highest partition coefficient (p<0.05, one-way ANOVA) was obtained for IPM and DPPG. 
The lowest partition coefficient (p<0.05, one-way ANOVA), was obtained for PG. 
4.4.3 Nicotinamide finite dose permeation studies in pig ear skin - prototype 
formulations 
The permeation profiles of DENI and NIAD formulations obtained in the finite dose pig ear skin 
study are shown in Figure 4.15. 
The DENI and NIAD formulations showed similar permeation characteristics in the pig ear skin 
studies. The differences between 𝑄𝐴 and the amount of NA washed, extracted and permeated 
from each formulation were not statistically significant (t-test, p>0.05). The high standard 
deviation values are most probably because of differences in the skin thickness or integrity and 
are usually encountered when working with animal or human tissue [20, 48]. 
After the 8 h study, approximately 20% of the applied dose permeated through the skin. Most 
of the dose was left on the skin surface (the washing fraction of the mass balance study). Only 
a small percentage of NA was found in extracts from the epidermis and the dermis, indicating 
that DENI and NIAD formulations do not enhance NA retention in the skin.  
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a) 
 
b) 
 
Figure 4.15 Finite dose permeation profiles of prototype DENI and NIAD formulations across pig ear 
skin: a) cumulative amount of nicotinamide, b) percentage of nicotinamide permeated (data shown as 
mean ± SD, n=5) 
The permeation data were fitted into the Scientist® model for finite dose skin permeation 
studies. However, it was impossible to obtain fixed values of 𝑃1 and 𝑃2. Thus, the comparison 
between the formulations in the finite dose pig skin study was performed on the basis of the 
mass balance between the skin and the cell compartments. The summary of the results is 
shown in Table 4.12. 
0
20
40
60
80
100
120
140
0 2 4 6 8 10
Q
A
 o
f 
N
A
 p
e
rm
e
at
e
d
 p
e
r 
u
n
it
 a
re
a 
[µ
g/
cm
2 ]
 
Time [h] 
DENI
NIAD
0
5
10
15
20
25
30
35
0 2 4 6 8 10
C
u
m
u
la
ti
ve
 p
e
rc
e
n
ta
ge
 n
ic
o
ti
n
am
id
e
 
p
e
rm
e
at
e
d
 [
%
] 
Time [h] 
DENI
NIAD
In vitro studies in silicone membrane and pig skin 
115 
 
Table 4.12 Permeation parameters for finite dose studies in pig ear skin for DENI and NIAD 
formulations (data shown as mean ± SD, n=5) 
Parameter [unit] DENI NIAD 
QA [μg/cm
2
] after 8h 89.7 ± 37.4 66.1 ± 36.1 
% of NA permeated 18.4 ± 9.2 17.0 ± 10.2 
% washed from the membrane 39.2 ± 9.9 56.6 ± 15.8 
% extracted from the epidermis 1.9 ± 1.3 3.1 ± 2.0 
% extracted from the dermis 1.2 ± 1.0 2.0 ± 1.2 
Epidermis retention [µg/g] 278.4 ± 135.1 337.7 ± 214.1 
Dermis retention [µg/g] 15.6 ± 12.8 20.6 ± 4.9 
 
4.4.4 Nicotinamide finite dose permeation studies in pig ear skin - simple solvent 
systems 
Finite dose permeation studies across full thickness porcine skin were performed. Simple 
solvent systems saturated with NA, i.e. with the same thermodynamic activity of NA at the 
beginning of the study, were tested. The concentration of NA in each solvent system was 
determined by HPLC. To facilitate analysis, results obtained for single solvents are shown 
separately from binary and multicomponent solvent systems (MSS), containing three or four 
solvents. 
4.4.4.1 Single solvents 
NA permeation from the following single solvents was examined in pig ear skin: 
Table 4.13 Single solvents used in the finite dose pig ear skin studies  
Solvent Concentration of NA [mg/mL] Solubility parameter [cal
1/2
/cm
3/2
] 
IPM 0.68 8.22 
DPPG 1.53 8.66 
PGML 22.81 9.44 
PGMC 38.17 9.85 
PG 246.76 14.07 
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The NA permeation profiles obtained in the finite dose pig ear skin studies of single solvents 
are shown in Figure 4.16. 
a) 
 
b) 
 
Figure 4.16 Finite dose pig ear skin NA permeation profiles for single solvents at 32 ± 0.5°C (mean ± 
SD, n=5); a) cumulative amount of nicotinamide, b) percentage of nicotinamide permeated 
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The cumulative amount (𝑄𝐴) of NA and the % of appied dose permeated after 8 h from each of 
the solvents tested are shown in Figure 4.17. 
a)  
 
b)  
 
Figure 4.17 Cumulative amount of NA (a) and % of the applied dose (b) permeated after 8 h from 
single solvents in the finite dose permeation studies in pig ear skin at 32 ± 0.5°C (data shown as mean 
± SD, n=5, *p<0.05) 
For IPM the majority of the dose permeated over the course of the study when compared with 
the other solvents (one-way ANOVA, p<0.05). However, the smallest 𝑄𝐴 of NA, which was 
significantly different from PG (one-way ANOVA, p>0.05), was obtained for IPM. IPM has high 
penetration enhancing potential for NA, but low solubility of NA in this solvent resulted in a 
small total amount delivered across the skin. A similar effect can be observed for DPPG which 
was significantly different from PG in terms of 𝑄𝐴 (one-way ANOVA, p<0.05). On the other 
hand, the lowest % of NA permeated is observed for PG and is significantly different from IPM 
and DPPG (one-way ANOVA, p<0.05). This is because of the high NA solubility in this solvent, 
i.e. a high amount of NA is needed to reach saturation in PG. Thus, a high dose of the drug is 
applied to the skin in the saturated PG solution and only a small part of this dose permeates 
during the experiment. In the middle of this range of solvents are PGML and PGMC, for which 
it was possible to deliver a relatively small total amount of NA across the membrane, reflected 
in approximately 10% of applied dose. Thus, two groups of solvents significantly different from 
each other (one-way ANOVA, p<0.05) can be distinguished on the basis of the percentage of 
NA permeated after the 8 h experiment. DPPG and IPM belong to the group with 
comparatively higher percentages permeated whereas PG, PGML and PGMC result in low 
percentages of NA found in the receptor solution at the end of the study. 
The influence of the selected solvents on NA permeation can be illustrated with the 
permeability coefficient (𝑘𝑝), which compensates for the difference in solubility of NA in the 
solvents. IPM has the highest 𝑘𝑝 for NA across the skin (one-way ANOVA, p<0.05). The second 
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highest 𝑘𝑝 was obtained for DPPG and was significantly different from all the other solvents 
(one-way ANOVA, p<0.05). PG, PGML and PGMC resulted in the lowest 𝑘𝑝 values not 
significantly different from each other (one-way ANOVA, p>0.05). The 𝑘𝑝 obtained for single 
solvents is shown in Figure 4.18. 
 
Figure 4.18 Permeability coefficients for the finite dose NA permeation studies in pig ear skin for 
single solvents at 32 ± 0.5°C (data shown as mean ± SD, n=5, *p<0.05, significantly different from 
other solvents) 
In the development of a topical NA formulation for atopic dermatitis treatment NA retention in 
the deep layers of the skin rather than its permeation through the membrane is preferable. At 
the same time, it is desirable that as little as possible of the applied dose remains on the skin 
surface at the end of the application process. Thus, data on the percentage of NA permeated, 
washed from the skin and retained in skin layers were obtained and are shown in Figure 4.19.  
  
Figure 4.19 Percentages of NA permeated, washed from the skin and extracted from the epidermis 
and dermis in the finite dose permeation studies in pig ear skin for single solvents at 32 ± 0.5°C (data 
shown as mean ± SD, n=5, *p<0.05, significantly different from other solvents) 
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In the case of PG, approximately 90% of the applied dose remains on the skin surface and this 
value is significantly higher from all other solvents tested (one-way ANOVA, p<0.05). The 
smallest percentage of NA left on the skin surface at the end of the permeation studies was 
found for IPM and DPPG when compared with the other solvents (one-way ANOVA, p<0.05). 
These two solvents were not different from each other in terms of the percentage of NA 
remaining on the skin surface at the end of the study (one-way ANOVA, p>0.05). PGML and 
PGMC are in the middle of this range of solvents (approximately 80% of the dose was washed 
from the skin surface at the end of the study) and are not significantly different from each 
other (one-way ANOVA, p>0.05). These results are consistent with the permeation data, i.e. a 
small percentage of NA permeated resulted in a high percentage recovered from the skin 
surface.  
When the overall amount of NA retained in the epidermis was calculated [µg/g], the lowest 
values were found for IPM and DPPG (one-way ANOVA, p<0.05). These two solvents were not 
statistically different from each other in terms of NA retention in the epidermis (one-way 
ANOVA, p>0.05). PG and PGMC were the solvents with the highest epidermal retention 
potential for NA (one-way ANOVA, p<0.05). A significantly higher (t-test, p<0.05) retention of 
NA was found for the epidermis than for the dermis for all the solvents, which is because of 
the higher mass of the dermis and its greater thickness. Delivery in IPM and DPPG resulted in 
smaller dermal retention values of NA, when compared with PG (one-way ANOVA, p<0.05). 
PGML and PGMC showed moderate NA retention potential and were not statistically different 
from any of the solvents tested (one-way ANOVA, p>0.05). These results are illustrated in 
Figure 4.20. 
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a)  
 
b)  
 
Figure 4.20 NA retention in epidermis (a) and dermis (b) in the finite dose permeation studies in pig 
ear skin for single solvents at 32 ± 0.5°C (mean ± SD, n=5, *p<0.05) 
 
4.4.4.2 Binary solvent systems 
Various authors have examined a number of drugs and have shown that the percutaneous 
absorption is affected synergistically when using solvent combinations [49-52]. Also, the 
importance of balanced drug solubility in the vehicle for optimal delivery has been emphasized 
[53, 54]. Very high solubility of NA in PG may be one of the reasons for the high percentage of 
the dose remaining on the skin surface at the end of the permeation study. A large amount of 
the drug remaining on the skin surface and not penetrating into the skin is not desirable from 
an economic and therapeutic point of view. The concentration of NA used in topical 
formulations usually ranges from 2 to 5% [55-64]. Thus, the solvent ratio in the binary systems 
was chosen so that the NA concentration in the vehicle varied around these values and did not 
exceed 10% (i.e. 100 mg/mL). To achieve this, diminishing the ratio of PG incorporated into the 
solvent systems was necessary because of the very good solubility of NA in this solvent. Thus, 
single solvents were combined into the binary solvent systems listed in Table 4.14. The 
concentration of NA in the saturated solutions applied to the skin was determined by the HPLC 
method described previously and is also shown in Table 4.14.  
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Table 4.14 Binary solvent systems used in the finite dose pig ear skin studies 
Solvent system Ratio of solvents used 
Concentration of NA 
[mg/mL] 
Solubility parameter 
[cal
1/2
/cm
3/2
] 
IPM:PGML (IL) 50:50 8.07 
8.83 
 
DPPG:PGML (DL) 50:50 9.17 9.05 
IPM:PGMC (IC) 50:50 12.70 9.03 
DPPG:PGMC (DC) 50:50 15.09 9.25 
PG:PGML (PL) 10:90 36.14 9.90 
PG:PGMC (PC) 10:90 64.73 10.27 
 
The NA permeation profiles obtained in the finite dose pig ear skin studies of binary solvent 
systems are shown in Figure 4.21.  
The cumulative amount of NA which permeated after 8 h from each of the solvent systems is 
shown in Figure 4.22. The 𝑘𝑝 values obtained for solvent systems are also illustrated.  
Binary systems incorporating 10% of PG in combination with PGML or PMGC (PL and PC) result 
in the highest 𝑄𝐴 of NA when compared with the other systems tested (one-way ANOVA, 
p<0.05). On the other hand, IC and IL are significantly different (one-way ANOVA, p<0.05) from 
the other solvent systems in terms of percentage of NA permeated, resulting in a higher 
percentage of NA delivered across the skin (see Figure 4.23). When 𝑘𝑝 values were compared, 
the only significant (one-way ANOVA, p<0.05) differences were found between IL and binary 
solvent systems incorporating DPPG. A synergistic effect of the solvent mixtures on NA 
permeation was not observed. The 𝑘𝑝 values obtained for the binary systems were lower or 
not significantly different from the values for IPM or DPPG (one-way ANOVA, p<0.05). 
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a) 
 
b) 
 
Figure 4.21 Finite dose pig ear skin NA permeation profiles for binary solvent systems at 32 ± 0.5°C 
(mean ± SD, n=5); a) cumulative amount of nicotinamide, b) percentage of nicotinamide permeated 
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a) 
 
b)  
 
Figure 4.22 a) Cumulative amounts of NA, b) permeability coefficients obtained for binary solvent 
systems in the finite dose permeation studies in pig ear skin at 32 ± 0.5°C (data shown as mean ± SD, 
n=5, *p<0.05) 
The results of the mass balance studies are shown in Figure 4.23. The highest % of NA was 
washed from the skin surface for the PC system (one-way ANOVA, p<0.05). The lowest % of NA 
left on the skin surface at the end of the permeation studies was found for IL and IC when 
compared with the other solvents (one-way ANOVA, p<0.05) and it was not significantly 
different from IPM and DPPG which resulted in the lowest % residue from the single solvents 
(one-way ANOVA, p>0.05). All the binary solvent systems resulted in significantly lower % 
residues of NA when compared with PG (one-way ANOVA, p<0.05).  
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Figure 4.23 Percentages of NA permeated, washed from the skin and extracted from the epidermis 
and dermis in the finite dose permeation studies in pig ear skin for binary solvent systems at 32 ± 
0.5°C (data shown as mean ± SD, n=5, *p<0.05) 
The highest retention of NA in the epidermis and the dermis (one-way ANOVA, p<0.05) was 
observed for binary solvent systems which incorporated 10% of PG with PGML or PGMC (PL 
and PC). However, PL and IC were not significantly different from each other in terms of NA 
retention in the dermis (one-way ANOVA, p>0.05). The results are shown in Figure 4.24.  
a) 
 
b) 
 
Figure 4.24 NA retention in epidermis (a) and dermis (b) in the finite dose permeation studies in pig 
ear skin for binary solvent systems at 32 ± 0.5°C (mean ± SD, n=5, p<0.05) 
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NA retention in the skin layers following the application of PL and PC was higher than for the 
single solvents, however statistical significance was reached only for PC when dermis retention 
was taken into account (one-way ANOVA, p<0.05). Similarly, for other binary solvent systems 
no statistically significant increase in epidermis and dermis retention of NA was observed in 
comparison with single solvent systems (one-way ANOVA, p>0.05). These results indicate that 
the synergistic effect of binary solvent systems on NA retention in the skin layers is in most 
cases not significant. 
It is worth noting that high epidermis and dermis retention of NA obtained for solvent systems 
incorporating 10% PG coincides with the similarity of the δ value of these solvent systems 
(9.90 and 10.27 cal1/2/cm3/2 for PL and PC respectively) to the δ of the skin (approximately 10 
cal1/2/cm3/2). This may indicate that optimal adjustment of the δ value of the vehicle may lead 
to improved retention of NA in the skin following topical application. 
4.4.4.3 Ternary and quaternary solvent systems 
Since binary solvent systems with 10% PG showed promising effects in terms of NA skin 
retention and there is a possibility of a greater synergy when more than two solvents are used; 
the following ternary and quaternary solvent systems were investigated: 
Table 4.15 Ternary and quaternary solvent systems 
Solvent system 
Ratio of solvents 
used 
Concentration of NA 
[mg/mL] 
Solubility parameter 
[cal
1/2
/cm
3/2
] 
IPM:PGML:PG (ILP) 45:45:10 26.35 9.35 
IPM:PGMC:PG (ICP) 45:45:10 37.98 9.54 
DPPG:PGML:PG (DLP) 45:45:10 28.41 9.55 
IPM:PGML:PGMC:PG (ILCP) 30:30:30:10 39.58 9.66 
DPPG:PGMC:PG (DCP) 45:45:10 36.09 9.74 
DPPG:PGML:PGMC:PG (DLCP) 30:30:30:10 42.21 9.79 
 
The solvents were selected so that each multicomponent solvent system comprised of: 
 PG, which is a hydrophilic solvent with good solubilising properties of NA and a δ value 
close to the δ of the drug, 
 one (for ternary solvent systems) or two (for quaternary solvent systems) solvents with 
δ values closest to skin, i.e. PGML and/or PGMC, 
 one of the solvents in which NA is poorly soluble and which has a δ value lower than 
skin, i.e. IPM or DPPG. 
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The proportion of PG in all the multicomponent solvent systems (MSS) was fixed at 10%, 
because of the high solubility of NA in this solvent and thus a high amount of NA that would be 
needed to reach saturation of PG. The other solvents were incorporated into the systems in 
equal proportions. 
The NA permeation profiles obtained in the finite dose pig ear skin studies of multicomponent 
solvent systems are shown in Figure 4.25. 
a) 
 
b) 
 
Figure 4.25 Finite dose pig ear skin NA permeation profiles for multicomponent solvent systems at 32 
± 0.5°C (mean ± SD, n=5); a) cumulative amounts of nicotinamide, b) percentages of nicotinamide 
permeated 
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The 𝑄𝐴 permeated after the 8h experiment from the MSS and the 𝑘𝑝 values are shown in 
Figure 4.26. The highest 𝑄𝐴 was obtained for the ILCP solvent system and it was significantly 
higher than for all the single, binary and multicomponent solvent systems tested (one-way 
ANOVA, p<0.05). Also, the highest % of the applied dose permeated after 8h from the MSS was 
obtained for ILCP and it was significantly different from DCP, DLP and DLCP (one-way ANOVA, 
p<0.05) (see Figure 4.27). The 𝑘𝑝 values obtained for the MSS were comparable. The only 
statistically significant (one-way ANOVA, p<0.05) differences were between ILCP vs. DCP and 
DLP vs. DCP. The 𝑘𝑝 values obtained for the MSS were not significantly (one-way ANOVA, 
p>0.05) higher from the values obtained for IPM or DPPG alone, indicating that the synergistic 
effect of multicomponent formulations on NA permeation is not significant. 
a)  
 
b)  
 
Figure 4.26 a) Cumulative amounts of NA, b) permeability coefficients obtained for multicomponent 
solvent systems in the finite dose permeation studies in pig ear skin at 32 ± 0.5°C (mean ± SD, n=5, 
*p<0.05) 
The percentage of NA washed at the end of the study from the skin surface was similar for all 
the multicomponent solvent systems (MSS). The highest percentage of NA remaining on the 
skin surface at the end of the study was found for DCP and it was significantly different from 
ILP and ILCP (one-way ANOVA, p<0.05). The lowest % of NA was found for ILP, however it was 
significantly different only from DCP (one-way ANOVA, p<0.05). The percentage of NA washed 
from the skin surface obtained for ILP, ILCP, DLP and ICP was not significantly different from 
IPM and DPPG, which showed the lowest percentage of NA remaining at the end of the study 
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(one-way ANOVA, p>0.05). All the MSS resulted in a significantly lower % residue of NA when 
compared with PG (one-way ANOVA, p<0.05).  
 
Figure 4.27 Percentages of NA washed from the skin in the finite dose permeation studies in pig ear 
skin for ternary and quaternary solvent systems at 32 ± 0.5°C (mean ± SD, n=5, *p<0.05) 
The results of NA retention in the epidermis and the dermis are shown in Figure 4.28. From the 
MSS tested, the highest retention of NA in the epidermis was obtained for DCP when 
compared with the other MSS (one-way ANOVA, p<0.05) both in terms of percentage of NA 
extracted and in terms of the amount of NA present in this skin layer after DCP application. 
Combining DPPG, PGMC and PG (45:45:10) resulted in a significant increase in NA retention in 
the epidermis when compared both with single solvents and binary solvent systems (one-way 
ANOVA, p<0.05), indicating a possible synergistic effect of these three solvents used in 
combination. This is possibly because of the optimal δ value of DCP, which is close to the δ 
value of the skin (9.74 and 10 cal1/2/cm3/2, respectively). 
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a) 
 
b)  
 
Figure 4.28 NA retention in: a) epidermis, b) dermis in the finite dose pig ear skin permeation studies 
for ternary and quaternary solvent systems at 32 ± 0.5°C (mean ± SD, n=5, *p<0.05) 
Quaternary solvent systems showed the best dermal retention of NA. The results were 
significantly different (one-way ANOVA, p<0.05) in the case of ILCP vs. ILP and DCP. However, 
no statistically significant differences (one-way ANOVA, p>0.05) in the fraction of NA applied 
(see Table 4.15) which was retained in the dermis was found between the multicomponent 
solvent systems tested. Quaternary solvent systems resulted in a higher retention of NA in the 
dermis when compared with almost all binary systems and single solvents (one-way ANOVA, 
p<0.05). Only one binary solvent system, i.e. PC, showed similar (one-way ANOVA, p>0.05) 
potential for NA retention in the dermis when compared with DLCP. The δ values are 9.66, 
9.79 and 10.27 cal1/2/cm3/2, for ILCP, DLCP and PC respectively. However, the concentration of 
NA in PC (approximately 60mg/mL) is higher than in the quaternary solvent systems 
(approximately 40mg/mL) (see Table 4.14 and Table 4.15, respectively). Thus, a comparatively 
higher overall amount of NA is applied to the skin in PC. This may also be the reason for high 
amount of NA found in the dermis at the end of the study after the application of this binary 
solvent system. 
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4.4.5 Solvent and nicotinamide permeation - finite dose pig ear skin studies  
Finite dose permeation studies across full thickness pig ear skin were performed. NA and 
solvent permeation profiles are shown in Figure 4.29.  
Similarly to the silicone membrane data, the lowest cumulative amount of NA (p<0.05, one-
way ANOVA) permeated from IPM and DPPG, which is in line with the low solubility of NA in 
these solvents and thus, the low dose applied to the donor compartment. High lipophilicity of 
IPM and DPPG renders them poor solvents for the drug and is also responsible for the lack of 
permeation of these solvents across full thickness pig ear skin. This is because of the presence 
of a hydrophilic layer of dermis which hinders the permeation of lipophilic substances. In the in 
vivo situation, an abundant blood supply in the dermis acts as a sink and allows for the 
permeation of lipophilic chemicals into the systemic circulation. However, the dermis is not 
perfused in vitro and thus, it is difficult to mimic the in vivo permeation of lipophilic solvents. 
The highest cumulative amount of NA which permeated (p<0.05, one-way ANOVA) was 
obtained for PG, which is in line with the data reported in section 4.4.4. Also, this was the only 
vehicle from the chosen solvents that permeated across full thickness pig ear skin. This is not 
surprising, since PG is the most hydrophilic of the solvents tested and thus, it is able to 
penetrate through the hydrophilic layer of dermis. 
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a) 
 
b) 
 
Figure 4.29 Finite dose pig ear skin permeation profiles for nicotinamide a) cumulative amount of 
nicotinamide, b) percentage of nicotinamide permeated at 32 ± 0.5°C (mean ± SD, n=5)  
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a) 
 
b) 
 
Figure 4.30 Finite dose pig ear skin permeation profiles for solvents a) cumulative amount of solvent, 
b) percentage of solvent permeated at 32 ± 0.5°C (mean ± SD, n=5)  
The percentages of applied doses of NA and solvents permeated, washed and extracted from 
the pig ear skin after 8h are shown in Figure 4.31. 
The highest (p<0.05, one-way ANOVA) percentage of NA permeated from IPM, followed by 
DPPG, PGML, PGMC and PG, which is in line with the results obtained in the studies, where 
only NA permeation was monitored. This order may be because of differences in NA solubility 
in these solvents with the lowest solubility for IPM and the highest for PG. Even though highest 
cumulative amount of NA permeated from PG, it is still a relatively a small percentage of the 
dose that was applied to the donor compartment of a Franz cell.  
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The results of solvent analysis suggests that even though no permeation was observed for IPM, 
DPPG, PGML and PGMC, the presence of these solvents in the skin (approximately 2-5% of the 
dose applied) was enough to enable drug transport across the membrane. The stratum 
corneum is considered the main barrier for permeation [65], thus the presence of solvents in 
this skin layer is important for NA penetration, because the process occurs only for the drug in 
solution. Once the drug reaches the hydrophilic environment of the dermis, it may be 
dissolved in water present in this layer and thus, transported into the receptor fluid. 
Nevertheless, the high percentage of NA extracted from the skin in the case of IPM and DPPG 
(40.11±11.58 and 37.29±3.59, respectively) indicates that some of the drug is entrapped in the 
skin and does not reach the receptor fluid, probably because of the retention of these solvents 
in the skin. 
a)  
 
b)  
 
Figure 4.31 Percentage of applied dose permeated, washed and extracted from the pig ear skin after 
8h for a) nicotinamide and b) solvents, mean ± SD, n=5, *p<0.05 
The highest percentage of NA washed from the skin (p<0.05, one-way ANOVA) was obtained 
for PGMC and PG, followed by PGML. This is in line with the high percentages of these solvents 
that were washed from the skin at the end of the study. For IPM and DPPG, the washing 
fraction contained approximately 20% of the solvents applied. Nevertheless, this value was 
higher than the percentages of the solvents extracted from the skin. There was a low 
percentage of total recovery obtained for these two solvents (25.90±1.82 and 20.11±0.64, for 
IPM and DPPG respectively) which could be elucidated in the future. Evaporation studies, such 
as dynamic vapour sorption or thermogravimetric analysis, may be performed in the future to 
give more insight into this phenomenon. 
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4.5 Discussion 
4.5.1 Solvent uptake studies 
Uptake studies provide information on the affinity of the solvent for the membrane. Several 
authors have correlated solvent sorption into silicone membrane with the results of 
permeation studies, pointing out to the importance of the vehicle interaction with the 
membrane in the permeation process [3, 8, 10, 12, 66]. Thus, solvent uptake studies into pig 
ear stratum corneum and silicone membrane were performed to assess the extent of the 
interaction between the model membranes and the chosen solvents and their potential to 
increase NA delivery across this membrane.  
Solvents with δ values close to the δ of silicone membrane (7.5 cal1/2/cm3/2) [39] showed 
higher uptake into this membrane (approximately 58% and approximately 16%, for IPM and 
DPPG respectively). The exception was MO, which was not incorporated into the silicone 
membrane despite its lipophilicity and δ value of 7.44 cal1/2/cm3/2. The reason for this may be 
the high molecular weight (MW) of MO components. In a study by Cross et al. [67], the highest 
sorption of solvents into the silicone membrane was observed for solvents with  δ values 
ranging from 7 to 9.5 cal1/2/cm3/2, which is in line with the findings from this study (δ values of 
8.22 and 8.66 cal1/2/cm3/2, for IPM and DPPG respectively). More hydrophilic solvents with 
higher δ values were not incorporated into the lipophilic membrane (uptake less than 1%). 
Previous studies also showed that for very large molecules, solvent uptake into the silicone 
membrane may be also dependent on their molecular size and shape [14, 67]. The same study 
by Cross et al [67] did not find a correlation between solvent sorption into the silicone 
membrane and the δ value. Thus, the authors postulated that MW is an important factor for 
membrane sorption predictions, which is in line with the data for MO - a mixture of long chain 
alkanes. Also, Dias et al. [14] observed a similar relationship to the one found here for a range 
of different solvents.  
The results of solvent uptake studies indicate that there is a major difference between SC and 
silicone in terms of the ability of these two membranes to absorb solvents with different 
properties. Even though SC is perceived as a lipophilic membrane, the uptake of the chosen 
solvents into the SC increased with their hydrophilicity. On the other hand, a reverse situation 
was observed for silicone membrane. It may be postulated, that the molecular size plays an 
even greater role in the solvent uptake process into the SC when compared with silicone 
membrane. This may be because of less tightly packed structured of the polymer when 
compared with the compact structure of the stratum corneum. The molecular size of IPM and 
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DPPG (MW 270.44 and 356.54 g/mol, respectively) pose more difficulties for absorption into 
the SC, whereas molecules with smaller size (for example the MW of PG is 76.09g/mol) are 
more easily taken up by the membrane. Thus, in the case of the SC, solvent MW, its molecular 
size and solubility parameter may influence the solvent uptake.  
In general, high solvent sorption into the membrane will cause changes in its physicochemical 
properties and influence the diffusion and partitioning of nicotinamide. This in turn, will 
influence the permeation of the drug. This phenomenon is discussed below. 
4.5.2 Nicotinamide partitioning 
It was observed that NA dissolved in lipophilic solvents (IPM and DPPG) has higher 
membrane/solvent partition coefficient values than NA dissolved in more hydrophilic solvents 
(One way ANOVA, p<0.05) both for silicone membrane and pig ear stratum corneum (see 
section 4.3.2 and 4.4.2, respectively).  
For the silicone membrane, the results may be explained by the low solubility of NA in IPM and 
DPPG and the high uptake of these solvents into the membrane. A high membrane/solvent 
partition coefficient indicates higher affinity of the drug for the membrane than for these 
highly lipophilic solvents. The low partition coefficient obtained for PG indicates higher affinity 
of the drug for this hydrophilic solvent than for the silicone membrane or SC. It is worth noting 
that for all solvents tested the amount of NA found in the silicone membrane was comparable, 
despite large concentration differences between the NA solutions in these solvents. This may 
be because of the differences in the membrane uptake of these solvents, i.e. solvents with 
high NA solubility showed low affinity for the membrane and solvents with low NA solubility 
were readily taken up into the silicone. 
For SC, the phenomenon can be solely explained by solubility differences between the 
solvents, as their uptake into the membrane did not correlate with the amount of NA found in 
the SC at the end of experiment. This means that, even though a relatively high membrane 
concentration of NA was achieved for PG, its high solubility in this solvent and thus high 
concentration in the solvent used in the experiment, did not allow for the achievement of a 
high partition coefficient value. 
4.5.3 Nicotinamide permeation from prototype formulations 
Two different nicotinamide formulations were tested: NIAD – a simple aqueous gel containing 
mainly water and modified acrylic polymer as a gelling agent; and DENI – a two phase system – 
water in oil emulsion in which IPM and MO are the lipid phase and water is the hydrophilic 
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phase, emulsified with sorbitan laurate surfactant (hydrophilic-lypophilic balance (HLB) of 8.6). 
In DENI, glycerol acts as the formulation humectant. Moreover, both of the prototype 
formulations contain pH regulators (trietanoloamine, citric acid) and phenoxyethanol as a 
preservative. Taking into account the differences in the prototype formulations composition, it 
was expected that they would impact nicotinamide permeation differently. 
In vitro testing of topical formulations is recommended before in vivo studies are performed 
[68, 69]. Also, the controlled conditions of in vitro permeation studies give a better insight into 
the influence of the vehicle on the percutaneous absorption of the drug when compared with 
the more complex in vivo situation. Thus, the performance of the prototype formulations in 
terms of percutaneous absorption of NA was evaluated in vitro prior to the in vivo studies 
described in the next chapter. Because of incorporation of NA into two different vehicles, a 
difference in the thermodynamic activity of the drug in these two formulations and an 
influence of vehicle components on the in vitro NA permeation were expected. 
In the infinite dose study across silicone membrane, the DENI formulation achieved 
significantly (t-test, p<0.05) higher values of flux and permeability coefficient. This may result 
from the presence of IPM in this formulation, which is known for its penetration enhancing 
properties [14, 67]. The presence of surfactant could be another cause of higher nicotinamide 
skin penetration from DENI. Also, IPM and MO may play a role in diminishing NA solubility in 
the vehicle and increasing thermodynamic activity of the drug [1]. The solubility of NA both in 
IPM and MO is low, when compared with water, which is the main ingredient in the NIAD 
formulation. Thus, incorporation of these solvents into DENI results in higher thermodynamic 
activity of NA when compared with NIAD. 
In several studies, transport across silicone membrane was correlated with the solvent uptake 
into the membrane [3, 8, 10, 12, 66, 67]. IPM has high affinity for the lipophilic membrane. On 
the contrary, water, which is the main solvent in the NIAD formulation, is not sorbed into the 
silicone membrane. Thus, a higher affinity of IPM for the silicone membrane increases its 
potential for NA delivery. In a study by Twist and Zatz [3], enhanced flux of parabens was 
attributed to higher solubility of the model permeants in the membrane when applied in 
solvents readily taken up by the silicone. Because water is not sorbed into the silicone 
membrane and NA has a very high affinity for this hydrophilic solvent, NA does not partition 
readily into the membrane from NIAD. On the other hand, membrane uptake of IPM present in 
DENI should increase the partitioning of the drug into this membrane. Additional studies on NA 
partitioning into the silicone membrane from the chosen solvents show that the NA 
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membrane/solvent partition coefficient is significantly (One way ANOVA, p<0.05) higher for 
IPM than for hydrophilic solvents. This approach may explain the significantly (t-test, p<0.05) 
higher partition coefficient obtained for the DENI formulation in the infinite dose silicone 
membrane permeation study.  
Viscosity is one of the factors influencing diffusion. The more viscous the formulation the 
slower is the diffusion process [70]. It was established in previous studies that formulation 
modifiers can not only increase drug flux through the membrane, but also influence the 
release rates of the drug from the formulation [71]. In vitro studies showed that the increase in 
the viscosity of a formulation decreased the rate of retinoic acid release into the receptor 
phase [71]. During the application of prototype NA formulations it was observed that NIAD 
was less viscous than DENI, which may be because of the lack of lipophilic components in the 
vehicle. Thus, a lower diffusion coefficient obtained for NA from DENI may be caused by the 
presence of the lipophilic compounds in the formulation. Tests of formulation viscosity, along 
with release testing, may confirm this. 
A significantly higher 𝑄𝐴 (t-test, p<0.00001) was found after 8h in the finite dose silicone study 
when compared with the infinite dose experiment. The values of 120±21 and 118±5 µg/cm2 in 
the finite dose study and 29±4 and 23±3 µg/cm2 in the infinite dose study were obtained, for 
DENI and NIAD respectively. The discrepancies between occluded and non-occluded conditions 
were also observed for rooperol tetra-acetate permeation across silicone membrane [72]. The 
delivery of the drug differed significantly (at the 95% confidence level) from a hydrophilic gel 
and a water-in-oil formulation under occluded conditions. However, no significant (at 95% 
confidence level) difference was observed for the formulations under non-occluded 
conditions. The gel contained primarily water (approximately 75%) and propylene glycol (PG) 
(25%), while the water-in-oil formulation comprised of 25% water, 25% of PG and 50% of 
lipophilic components (including 12% of MO). Rooperol tetra-acetate is highly lipophilic, thus 
the authors suggested that higher flux values obtained from the gel under occluded conditions 
are because of the favoured release of the drug from hydrophilic bases. In contrast, in the NA 
infinite dose study across silicone membrane the highly hydrophilic NA permeates better from 
DENI, which contains lipophilic components. Apart from the uptake of IPM into the membrane 
and the increased thermodynamic activity caused by MO and IPM, the expected favoured 
release from the lipophilic formulation may be another reason for better NA delivery from 
DENI.  
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In a study by Pefile et al. [72], the difference between the results obtained under occluded and 
non-occluded conditions was attributed to water evaporation from the vehicle, and thus an 
increase in its lipophilicity and changes in the thermodynamic activity of the drug in the 
vehicle. Similarly, Tanaka et al. [7] obtained different results for hydrocortisone butyrate 
propionate flux across silicone membrane under occluded and non-occluded conditions. The 
authors also related these differences to the thermodynamic activity changes of the drug in 
the vehicle occurring under ‘open’ conditions caused by water and ethanol evaporation from 
the vehicles. Water is the main solvent used in both prototype NA formulations tested in this 
study and NA is highly soluble in this solvent. Thus, water evaporation could increase the 
thermodynamic activity of NA [1], explaining the higher 𝑄𝐴 found for the finite dose studies 
when compared with the infinite dose studies across the silicone membrane. 
In the finite dose silicone and pig ear studies, no significant differences (t-test, p>0.05) in the 
permeation and drug retention in the model membranes between NIAD and DENI were 
observed. As mentioned above, these results are most probably because of changes occurring 
during the finite dose studies. These experiments are performed under dynamic conditions, 
where the formulation can be modified by various factors such as solvent evaporation and 
depletion [73, 74]. However, because of the differences in the vehicle components, 
compensation effects are possible. At the end of the finite dose studies a thin dry residue was 
observed where NIAD was applied, in contrast to the greasy and moist formulation residue for 
DENI. Since NIAD contains mainly water, the effect of increased thermodynamic activity of the 
drug because of the evaporation of the solvent from the donor compartment may be more 
pronounced for this formulation. Thus, water evaporation from NIAD may compensate for the 
penetration enhancement caused by the presence of IPM and MO in the DENI formulation. 
Solvent evaporation studies, such as dynamic vapour sorption or thermogravimetric analysis, 
may give more insight into the evaporation of water from the prototype formulations and may 
provide more insight into the thermodynamic activity changes occurring during the finite dose 
studies. However, it must be kept in mind that the complexity of the prototype formulations 
may hinder such analysis. Thus, studies on simpler solvent systems may be more helpful in 
elucidating the mechanisms underlying the permeation process of NA from the prototype 
formulations. 
It is worth noting that in the finite dose silicone study more than half of the dose penetrated 
over the 24h time period. This indicates that NA diffuses through the membrane readily 
despite its hydrophilicity. Also a relatively high percentage (approximately 20%) of the applied 
dose was found in the receptor solution after 8h of NA permeation through pig ear skin. The 
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molecular diffusion coefficient is inversely related to the MW of the diffusant [75] and smaller 
molecules were shown to penetrate the skin more readily [76]. Thus, the small dimensions of 
NA, reflected in its MW (122,13g/mol) and molecular volume (108.13Å3) [77], may be the 
reason for relatively high drug permeation across the silicone membrane and the pig ear skin. 
Nevertheless, NA hydrophilicity causes a lack of NA retention in the lipophilic silicone 
membrane. Similarly, NA was not retained in the epidermis and the dermis. Thus, the results 
obtained for DENI and NIAD formulations may indicate that solvents used in the prototype 
formulations do not cause NA retention in the model membranes. 
4.5.4 Nicotinamide permeation from simple solvent systems 
The interactions between the vehicle, the drug and the skin need to be understood for the 
rational development of the topical formulation. Theoretical calculations and in vitro studies 
are helpful in elucidating these relations. An appropriate choice of solvents for the optimal NA 
delivery was attempted based on the theoretical solubility parameters and in vitro studies. The 
chosen solvents encompass a wide range of solubility parameters: from the most lipophilic MO 
to the most hydrophilic water (δ of 7.74 and 22.97 cal1/2/cm3/2, respectively). Values obtained 
for the skin and the model drug lie in the middle of this range. However, the literature δ value 
for the skin (approximately 10 cal1/2/cm3/2) indicates its lipophilicity, while NA is a hydrophilic 
compound (δ=13.85). When a solvent with an appropriate δ value is chosen, it may increase 
NA solubility in the membrane, by shifting the δ value of the skin towards the solubility 
parameter of the drug [78]. Increased solubility in the skin means increased affinity of the drug 
for the membrane and thus, increased percutaneous transport of the drug [79-81]. This 
hypothesis was further investigated in the in vitro permeation studies. 
Infinite dose studies across silicone membrane were performed for simple solvent systems. 
The highest 𝑘𝑝 was obtained for IPM and the lowest for water, PG and their 50:50 mixture 
(one-way ANOVA, p<0.05). The 𝐽𝑠𝑠 ranged from 11±1 to 188±31 μg/cm
2/h, for PG and IPM 
respectively. High 𝐽𝑠𝑠 values were obtained for IPM, DPPG and mixtures of IPM with DPPG, 
PGML and PGMC. These systems have close δ values to that of silicone membrane (7.5 
cal1/2/cm3/2) [39]. This was also reflected in the high IPM and DPPG sorption into the silicone 
membrane obtained in the solvent uptake studies. At the same time, a high NA flux was 
related to the low solubility of the drug in the solvent system. This effect was observed by 
previous authors for the permeation of another derivative of nicotinic acid (nicorandil) across 
an artificial membrane [42]. These results are also in line with other literature where it is noted 
that good solubility of a drug in a vehicle indicates its high affinity for this vehicle and thus its 
lower permeation [82]. NA is hydrophilic, thus its solubility in lipophilic solvents, such as IPM 
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and DPPG, is low. At the same time, these are the solvents that have a high potential to 
penetrate the lipophilic silicone membrane. The solvent uptake into the silicone membrane 
was correlated with drug permeation by previous authors [3, 8, 10, 12, 66] and data presented 
above confirm this approach. A high membrane interaction of solvents with low δ values was 
observed by Dias et al. [14] and resulted in a high flux of a hydrophilic drug (caffeine) from 
these solvents. A linear relationship was found between the solvent uptake and caffeine flux. A 
high uptake of aliphatic alcohols into silicone membrane resulted in an increased solubility and 
diffusivity of parabens in the membrane when compared with water and PG [3]. Thus, the 
increased permeation of NA across the silicone membrane observed for solvents with a high 
membrane uptake may be because of the increased diffusion and solubility of NA in this 
membrane. Dias et al. [13] found that for caffeine, IPM was one of the solvents which were 
postulated to penetrate the skin lipids and to alter the drug solubility in the membrane 
(influencing its partitioning). This increase in partitioning may be the reason for the highest 𝑘𝑝 
of NA observed for IPM when compared with the other solvent systems (one-way ANOVA, 
p<0.05). Studies on the partitioning behaviour of NA between the silicone membrane and the 
chosen solvents described above support this concept, as indeed the highest partition 
coefficient was obtained for IPM. 
Finite dose studies more closely mimic the real in vivo application conditions and allow for the 
quantification of the drug in the skin layers. Thus, further studies were performed using finite 
doses of formulations with full thickness pig ear skin as a model membrane. The focus was on 
establishing solvent systems with the highest NA retention in the skin layers and the lowest 
percentage of NA washed from the skin surface at the end of the 8h permeation study. Also, 
the permeability coefficients, the applied concentration of NA and the solubility parameters of 
the solvent systems tested are shown in Table 4.16. 
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Table 4.16 The results of finite dose pig ear permeation studies from simple solvent systems (mean ± 
SD, n=5) 
Solvent 
kp ± SD [cm/h] 
(x10-3) 
Epidermis retention ± SD 
[ug/g] 
Dermis retention ± SD 
[ug/g] 
% Washed ± SD 
CNA  
[mg/mL] 
δ 
cal1/2/cm3/2 
IPM 2.7 ± 0.3 4 ± 1 3 ± 1 7 ± 3 0.68 8.22 
DPPG 1.1 ± 0.1 10 ± 6 4 ± 0 9 ± 3 1.53 8.66 
IL 1.1 ± 0.3 65 ± 21 21 ± 6 14 ± 9 8.07 8.83 
IC 1.0 ± 0.2 120 ± 42 35 ± 6 15 ± 6 12.70 9.03 
DL 0.2 ± 0.1 379 ± 121 11 ± 4 42 ± 5 9.17 9.05 
DC 0.4 ± 0.1 483 ± 99 24 ± 11 40 ± 7 15.09 9.25 
ILP 0.9 ± 0.2 667 ± 150 101 ± 9 16 ± 6 26.35 9.35 
PGML 0.1 ± 0.0 450 ± 88 23 ± 3 74 ± 5 22.81 9.44 
DLP 1.2 ± 1.1 954 ± 362 126 ± 10 21 ± 6 28.41 9.55 
ILCP 1.2 ± 0.1 998 ± 514 159 ± 32 18 ± 6 39.58 9.66 
DCP 4.2 ± 0.1 2061 ± 457 106 ± 14 36 ± 4 36.09 9.74 
DLCP 0.7 ± 0.1 921 ± 138 141 ± 15 27 ± 5 42.21 9.79 
PGMC 0.1 ± 0.1 883 ± 60 46 ± 14 75 ± 6 38.17 9.85 
PL 0.8 ± 0.1 1199 ± 260 79 ± 15 44 ± 5 36.14 9.90 
ICP 0.8 ± 0.1 1284 ± 408 133 ± 12 23 ± 8 37.98 10.27 
PC 0.3 ± 0.1 1449 ± 204 105 ± 17 62 ± 10 64.73 11.96 
PG 0.04 ± 0.03 1165 ± 561 58 ± 67 92 ± 8 246.76 14.07 
 
The relationship between the solubility parameter (δ) and the permeability coefficient (𝑘𝑝) 
obtained for the tested solvent systems is shown in Figure 4.32. 
 
Figure 4.32 Relationship between the solubility parameter and the permeability coefficient in the 
finite dose pig ear studies for simple solvent systems (mean ± SD) 
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The importance of the δ value in skin permeation was emphasised by previous authors. Liron 
and Cohen [78] observed maximum skin 𝑘𝑝 values for alkanoic acids with the δ value close to 
10 cal1/2/cm3/2. Also, higher 𝑘𝑝 values in human skin in vitro were obtained for substances with 
the δ value close to 10 cal1/2/cm3/2 for a series of narcotic analgesics [83]. In the NA pig ear skin 
permeation studies, the highest (one-way ANOVA, p<0.05) 𝑘𝑝 was observed for IPM when 
compared with all solvent systems tested. Although high 𝑘𝑝 values were also observed for 
binary solvent systems incorporating IPM and PGML or PGMC, synergistic effects between the 
solvents were not observed. Also, no synergistic effect was found for ternary and quaternary 
solvent systems, i.e. 𝑘𝑝 values obtained for these solvent mixtures were lower than for IPM 
(one-way ANOVA, p<0.05). These results indicate that, from the chosen solvents, IPM is the 
best solvent in terms of increasing the skin permeability of NA, despite the fact that its δ value 
is far from the δ value of the drug (8.22 and 13.85 cal1/2/cm3/2, for IPM and NA respectively). A 
strong interaction of IPM with the skin observed by previous authors in DSC and X-ray 
diffraction studies [84] together with the close δ value of this solvent to that of skin may be 
the reason for this. Similar DSC and diffraction studies performed for the other solvents tested 
may elucidate their influence on the skin. 
The retention of NA in the skin is crucial for its efficacy in the treatment of dry skin conditions 
such as atopic dermatitis (AD). An optimal adjustment of the δ value of the vehicle to that of 
the drug and the skin should lead to the optimised retention of the drug in the tissue. The skin 
retention data for the single solvents show that PG, as a solvent with the solubility parameter 
(14.07 cal1/2/cm3/2) closest to the δ value of NA (13.85 cal1/2/cm3/2), is capable of increasing 
drug retention both in the epidermis and the dermis. Nevertheless, the high NA solubility in PG 
renders this solvent not cost-effective, because a high amount of NA in the formulation is 
required to reach saturation (i.e. maximal thermodynamic activity) of the drug in PG [1]. 
Hence, a high percentage of NA remains on the skin surface at the end of 8h permeation. Also, 
rapid permeation of PG and thus solvent depletion may be the reason for the high percentage 
of NA washed from the skin surface [11, 52, 85]. Also, it has to be noted that, the drug retained 
in the skin would be ultimately removed by the blood supply. On the other hand, the use of 
solvents with relatively low δ values, such as IPM and DPPG (8.21 and 8.66 cal1/2/cm3/2 
respectively), results in a low dose of NA applied (because of low solubility) and the lowest 
concentration of the drug in the skin layers (one-way ANOVA, p<0.05). PGML and PGMC are 
the solvents with δ values closest to the δ value of skin (9.44, 9.85 and 10 cal1/2/cm3/2 
respectively). At the same time, NA solubility in these solvents is high enough to obtain 
comparatively good drug concentration in the skin layers, but the amounts are not significantly 
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different when compared with PG, IPM and DPPG (One-way ANOVA, p>0.05). These results are 
in line with previous findings [4, 86] and theoretical predictions [1], where a balance between 
the drug concentration in the vehicle and the partition coefficient between the vehicle and the 
skin is needed for optimal delivery. Thus, PGML and PGMC use in NA delivery is a rational 
compromise between high doses that can be achieved with PG and the high permeability 
obtained with IPM and DPPG.  
Topical products for AD treatment are usually used up to three times a day [87]. Thus, the 
formulation is applied approximately every 8h. A build-up of NA which did not permeate 
during that time may occur in the case of a high percentage of the dose left on the skin 
surface. For example, approximately 75% of NA was present on the skin surface at the end of 
the study for PGML and PGMC. Increased skin retention and decreased flux of NA was 
reported when the molecule was formulated in combination with salicylic acid [31]. The 
authors suggested that this may be because of changes in the partition behaviour of the two 
drugs present in a transdermal film. Similar changes in partitioning may be postulated when 
combinations of solvents are used. Thus, the next step was to investigate if better epidermal 
concentrations with a lower percentage of NA left on the skin surface at the end of application 
period may be achieved by using binary and multicomponent solvent systems. The amount of 
NA retained in the dermis and the epidermis together with the percentages of NA washed 
from the skin surface obtained for all the simple solvent systems are summarised in Table 4.16. 
Because of the high solubility of NA in PG, the concentration of this solvent in the solvent 
mixtures was set at 10%. This allowed for a lower concentration of NA in the saturated 
solution. Thus, the drug was used more effectively, because a lower amount of NA was needed 
to achieve maximal thermodynamic activity in the vehicle. A 10% addition of PG into single 
solvents (PGML and PGMC) resulted in an increased retention of the drug in both analysed skin 
layers when compared with the single solvents, however in most cases statistical significance 
was not reached (one-way ANOVA, p>0.05). The addition of DPPG to the binary solvent 
systems resulted in a significant increase in epidermal NA retention only for the DCP system 
when compared with binary systems (one-way ANOVA, p<0.05). In the case of binary and 
ternary solvent systems tested in the current study, PG may play an important role in 
increasing NA affinity for the skin and addition of the other solvents (PGML, PGMC and DPPG) 
optimises this effect. This may be because of the optimal adjustment of the δ value of the 
vehicle to the δ value of the epidermis and the drug. As can be seen in Table 4.16, the δ value 
of solvents with the highest epidermal retention of NA ranged from 9.74 to 14.07 cal1/2/cm3/2 
However, there was no significant (one-way ANOVA, p>0.05) effect on epidermal retention for 
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the multicomponent solvent systems other than DCP when compared with binary solvent 
systems and single solvents. Thus, synergistic effects cannot be postulated for the other 
multicomponent solvent systems.  
The use of quaternary solvent systems resulted in the best dermal retention of NA when 
compared with binary systems and single solvents (one-way ANOVA, p<0.05). These results 
indicate that there may be a synergistic effect of combining the solvents with different δ 
values (and thus different affinities for the skin) on NA retention in the dermis. High dermal 
retention of NA was obtained for the solvent systems with the δ value ranging from 9.35 to 
11.96 cal1/2/cm3/2 What is more, a significantly lower % of NA was left on the skin surface 
following the application of all binary and multicomponent solvent systems when compared 
with PG (one-way ANOVA, p<0.05), indicating that combining the solvents may result in more 
cost-effective formulations. The relationship between the δ value and the retention of NA in 
the skin is shown in the figures below. 
 
Figure 4.33 Relationship between the solubility parameter and NA retention in the epidermis in the 
finite dose pig ear studies for simple solvent systems (mean ± SD) 
 
Figure 4.34 Relationship between the solubility parameter and NA retention in the dermis in the finite 
dose pig ear studies for simple solvent systems (mean ± SD) 
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4.5.5 Solvent permeation studies - simple solvent systems 
The affinity of the solvent for the skin layers may be reflected in the uptake, permeation and 
retention of the solvent in the skin or model membrane. This in turn may be related to the 
drug permeation and its residence in the membrane. Thus, there is a need for monitoring not 
only the drug but also the solvent fate for better understanding of the processes that govern 
drug permeation and penetration enhancement [2].  
In the finite dose silicone permeation studies, a relationship between rapid solvent permeation 
and decreased drug penetration caused by solvent depletion from the donor compartment 
could be seen for the PGML and PGMC vehicles. While approximately half of PGMC and two 
thirds of PGML permeated, reaching a plateau, the fraction of NA found in the receptor 
solution after the 6 hours study was approximately 30% of the original dose. A similar situation 
was observed by other authors when solvent depletion (via rapid evaporation) from the 
vehicle caused a decrease in the flux of a model drug [88, 89]. High solvent retention in the 
membrane, observed for IPM and DPPG, was related to the high percentage of NA which 
permeated from these vehicles. This indicates that the presence of these solvents in the 
membrane enabled the drug penetration from the donor compartment into the receptor 
phase. For PG, a high percentage of the solvent was washed from the membrane surface and 
also a high percentage of NA remained in the donor compartment at the end of the study, 
suggesting that low permeation of this hydrophilic solvent and low membrane retention 
hinders drug permeation across silicone membrane. Lower silicone permeation of PG when 
compared with another lipophilic solvent (octyl salicylate) was observed previously [36], 
indicating that lipophilic solvents penetrate silicone membrane more easily.  
In the finite dose full thickness pig ear skin permeation studies, the highest percentage of NA 
permeated from IPM, followed by DPPG, PGML, PGMC and PG, which is in line with the results 
obtained in the studies, where only NA permeation was monitored. This trend may be because 
of differences in NA solubility in these solvents with the lowest solubility for IPM and the 
highest for PG. Even though a high cumulative amount of NA permeated from PG, it is still only 
a small percentage of the dose that was applied to the donor compartment of a Franz cell. 
Similarly to the silicone data, the high percentage of NA washed from the skin surface was 
related to the high percentages of PGML and PGMC that remained in the donor compartment 
indicating that solvent permeation is necessary for the drug to be transported into and 
through the skin. On the other hand, the results of solvent analysis may suggest that even 
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though no permeation was observed for IPM, DPPG, PGML and PGMC, the presence of these 
solvents in the skin (approximately 2-5% of the dose applied) was enough to assist the drug 
transport across the membrane. The stratum corneum is considered to be the main barrier for 
permeation [65], thus the presence of solvents in this skin layer is important for NA 
penetration because the process occurs only for the drug in solution. Once the drug reaches 
the hydrophilic environment of the dermis, it may be dissolved in the aqueous environment of 
this layer and thus, transported into the receptor fluid. Nevertheless, the high percentage of 
NA extracted from the skin in the case of IPM and DPPG (40±12 and 37±4, respectively) 
indicates that some of the drug is entrapped in the skin and does not reach the receptor fluid, 
probably because of the retention of these solvents in the skin. 
The lack of permeation observed for lipophilic solvents in the full thickness pig ear studies is 
most probably because of the hydrophilic nature of the dermis, which effectively represents a 
barrier for the transport of these solvents. Studies performed on heat-separated skin may be 
helpful in addressing this issue. Nevertheless, the small amount of solvents present in the skin 
enabled NA permeation to some extent.  
To conclude, the above mentioned results indicate, that a balance between solubility of the 
drug in the solvent and solvent affinity to the skin is desirable for an optimal topical delivery. 
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5 Evaluation of prototype nicotinamide formulations in vivo 
The composition of the vehicle is crucial for the development of an effective and safe 
nicotinamide (NA) formulation which may be used in atopic dermatitis (AD) treatment. The 
most common ingredients of the vehicles used in the treatment of dry skin conditions contain 
water, humectants, occlusive materials and emollients formulated into an ointment or cream 
with the aid of adjuvants [1]. Thus, four principal excipients from these groups were included 
in the prototype NA formulations: water, glycerol (GLY) as a humectant, liquid paraffin 
(mineral oil, MO) as an occlusive agent and isopropyl myristate (IPM) as an emollient and 
penetration enhancer. A formulation containing these excipients (DoublebaseTM gel, Dermal 
Laboratories Ltd, UK) is available on the UK market [2].  
DoublebaseTM gel is indicated in dry skin conditions such as AD [2, 3]. DoublebaseTM gel was 
shown to be superior to two other marketed formulations (Ultrabase® cream and Diprobase® 
cream) in terms of decreasing transepidermal water loss (TEWL) and increasing skin hydration 
in healthy volunteers after a single application [4]. Also corneometry readings were 
significantly (p<0.0001) higher for the DoublebaseTM gel when compared with non-treated skin 
and with the two formulations after repeated application in a two-day test [4]. Moreover, after 
a seven-day application of the DoublebaseTM gel, skin hydration improved significantly (p<0.05) 
in women with self-perceived dry skin on their lower legs when compared with non-treated 
skin and skin treated with Aqueous Cream BP [5]. Taking into account the efficacy of the 
DoublebaseTM gel in alleviating dry skin conditions and improving skin hydration, the excipients 
present in this formulation were used in the development of the NA formulation for AD 
treatment. 
As mentioned before, the influence of NA on the skin state was to be tested separately from 
the other excipients present in the formulations, which may also influence the skin. Thus, two 
prototype formulations containing 4% NA were prepared by Dermal Laboratories Ltd., UK: 
DENI contained all of the above mentioned components, while NIAD was formulated into a gel 
containing primarily water. 
The prototype NA formulations were tested in vitro in the previous chapter. The results of 
finite dose experiments indicate that there is no statistically significant difference (t-test, 
p<0.05) between the two formulations in terms of NA permeation across silicone membrane 
and porcine skin. However, not only the drug, but also the formulation components may 
influence the state of the skin and the final formulation performance in vivo [6-12]. 
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The skin state may be assessed in vivo with a wide array of non-invasive and minimally invasive 
techniques. Tape stripping is one of the techniques which allows for the investigation of 
morphological and physiological properties of the tissue [13, 14]. It also enables the 
assessment of percutaneous penetration and skin retention of the drug quantified on the 
tapes [15-17]. The amount of the stratum corneum (SC) removed with consecutive tapes can 
be an indicator of cell cohesion [18, 19]. Since the SC consists mainly of protein (approximately 
75%) [20], the protein content measurement is used to quantify the amount of the SC stripped 
from the skin surface [21-23].  
Another technique is transepidermal water loss (TEWL) measurement, which gives information 
on the skin barrier function to prevent water loss [24]. Combining tape stripping with TEWL 
measurements can give information on the skin resistance to damage [25, 26] and the depth of 
the SC that is reached with the stripping procedure [27]. Also improvement or deterioration of 
the skin barrier function caused by topical products can be reflected in TEWL values [11, 28-
30].  
The investigation of corneocyte size and maturity gives information on the skin cell 
proliferation and maturation process [31]. Topically applied products may influence these 
processes. For example, changes in corneocyte surface area and cornified envelope 
maturation caused by Aqueous Cream BP topical application in healthy subjects were studied 
using this technique [28].  
Changes in the SC protease activity (PA) are associated with skin barrier dysfunction [32-37]. 
The measurements of protease activity can give important information on the influence of the 
formulation on skin state, especially on the desquamation and inflammatory processes [28, 
35]. 
The purpose of this study was to assess changes in the skin condition associated with the 
application of prototype topical formulations, studied in the previous chapter, and their 
placebos. The changes in measured parameters should indicate improvement or deterioration 
in the skin barrier function and health brought about by application of topical formulations. 
The amount of protein stripped from the skin surface, the corneocyte surface area, the 
corneocyte maturity, activities of selected SC proteases and the TEWL were measured. 
Changes in these parameters caused by the application of the formulations to the mid ventral 
forearm of healthy volunteers were characterised. Also the influence of the formulation 
composition on NA retention in the skin in vivo was investigated. The observation of these 
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effects, together with the assessment of skin delivery of the model compound, may enable the 
design of improved topical products. 
5.1 Materials 
Prototype formulations (DENI and NIAD) and their placebos (DE and AD respectively) were 
supplied by Dermal Laboratories Ltd., UK. The composition of DENI and NIAD formulations is 
shown below. In the placebo formulations NA was replaced with purified water. 
Table 5.1 Composition of DENI formulation 
Material % w/w 
Nicotinamide EP 4.0 
Isopropyl Myristate EP  
Paraffin Liquid EP  
Glycerol EP  
Modified acrylic polymer (Pemulen
TM
 HSE TR1)  
Sorbitan Laurate EP  
Triethanolamine BP 2000  
Phenoxyethanol EP  
Water Purified EP  
 
Table 5.2 Composition of NIAD formulation 
Material % w/w 
Nicotinamide EP 4.0 
Modified acrylic polymer (Pemulen
TM
 HSE TR1)  
Sorbitan Laurate EP  
Citric Acid Anhydrous EP  
Phenoxyethanol EP  
Triethanolamine BP 2000  
Water Purified EP  
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Table 5.3 Materials used in the in vivo studies 
Material Supplier 
Laboratory water purifier (OPTION 3, 75 litre volume) USF Elga, UK 
PBS tablets (DulbeccoA, pH 7.3±0.2 at 25°C) Oxoid, UK 
Nicotinamide (NA) Dermal Laboratories Ltd., UK 
HPLC grade solvents: Acetonitrile (AcCN), Water Fisher Scientific, UK 
HPLC vials with flat bottom inserts and caps with rubber seal Fisher Scientific, UK 
Plastic syringes (1, 2 and 5mL) and needles Fisher Scientific, UK 
Microscope cover glasses Fisher Scientific, UK 
Surgical scalpels, scissors and tweezers Fisher Scientific, UK 
Acetone Fisher Scientific, UK 
Dessicator Fisher Scientific, UK 
Magnesium perchlorate desiccant Acros Organics, UK 
Sodium dodecyl sulphate (SLS) Sigma Aldrich, UK 
Ethylenediaminetetraacetic acid Sigma Aldrich, UK 
Acetic acid Sigma Aldrich, UK 
Nile red Sigma Aldrich, UK 
Trizma® hydrochloride buffer solution (Tris pH 8.0) Sigma Aldrich, UK 
Triton-100 Sigma Aldrich, UK 
PAP Pen for immunostaining 5 mm tip width Sigma Aldrich, UK 
DL-dithiothreitol (DDT) Fluka Analytical, UK 
Dimethyl sulfoxide (DMSO) (>69 % D: 1.67) VWR International, UK 
AnalaR Normapur Perchloric acid 70% VWR International, UK 
Polysine
TM
 Microscope Slides VWR International, Belgium 
D-Squame tape (2.2cm diameter, 3.8cm
2
 area) CuDerm Corporation, USA 
Standard D-Squame disc racks  and pressure device CuDerm Corporation, USA 
Aminomethyl coumarin (AMC) 
 
DSM Nutritional Products Ltd, 
Switzerland 
Fluorogenic substrate for tryptase: Tos-Gly-Pro-Lys-AMC I-1370 
 
DSM Nutritional Products Ltd, 
Switzerland 
Fluorogenic substrate for kallikrein 5: Boc-Phe-Ser-Arg-AMC I-1400 
DSM Nutritional Products Ltd, 
Switzerland 
Fluorogenic substrate for kallikrein 7: MeOSuc-Arg-Pro-Tyr-AMC Pefafluor 
180-23 
DSM Nutritional Products Ltd, 
Switzerland 
Fluorogenic substrate for plasmin: MeOSuc-Ala-Phe-Lys-AMC I-1275 
DSM Nutritional Products Ltd, 
Switzerland 
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Primary monoclonal antibody, anti-human involucrin (clone SY5) Cambridge Scientific, UK 
Rabbit polyclonal antibody to mouse fluorescent IgG-H&L (whole molecule) 
fluorescein isothiocyanate (FITC) antibody 
Abcam, UK 
Eppendorf Research® pipettes Eppendorf AG, Germany 
Closed chamber Aquaflux® AF103 Biox Systems, UK 
Squame Scan A850 infrared densitometer Heiland Electronic,Germany 
Fluorescence microscope, microphot-FZA with rhodamine dichroic filter Nikon, UK 
Analytical balances (accuracy 0.0001g and 0.0001mg) Sartorius GMBH, Germany 
Nikon D5100 Digital Single Lens Reflex camera Nikon, UK 
ImageJ® software NIH-Image, USA 
Orbital incubator S150 Stuart Scientific, UK 
Centrifuge 5415R Eppendorf, UK 
HPLC Column Primesep A 250x4.6mm, Particle 5µm, 100Å SIELC Technologies, USA 
HPLC Column Symmetry C18, 5um, 4.6x150mm Waters, USA 
SecurityGuard Cartridge with C18 (ODS, Octadecyl) 4mmLx3mm filter Phenomenex, USA 
5.2 Methods 
5.2.1 Ethical approval 
The study entitled ‘The influence of topical formulation composition on test compound 
transport into the skin and on skin condition’ (Ref. No A01/2011) was approved by the National 
Research Ethics Committee London - Camberwell St Giles (REC Ref. No. 11/LO/1275). 
5.2.2 Volunteer recruitment 
Because of inter- and intra-individual variability, a high number of volunteers are needed to 
reach statistical significance in in vivo studies [38]. Most commonly 12 to 20 subjects have 
been included to study formulation effects on skin [39-50]. Thus, 20 healthy adult volunteers 
were recruited for this study. Subjects with any previous or on-going skin disease, any skin 
abnormalities (tattoos, birth marks, scars etc.) at the test sites, known sensitivity to any of the 
formulation ingredients or taking or using medication purchased over the counter in 
pharmacies or prescribed by a healthcare practitioner which may have an effect on the skin 
were excluded from the study. Written informed consent was obtained from all participants 
prior to taking part, after they were given at least 24 hours to read the Participant Information 
Leaflet and had ample opportunity to discuss any questions they had. Before the study, 
participants were asked to complete a questionnaire stating their age, gender, ethnic 
background and skin state. 8 male and 12 female volunteers aged 23-55 years (average 29±9 
years), all Caucasian, participated in the study. 
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5.2.3 Application of test formulations 
Bi-lateral formulation application sites located on the left and right volar forearms measured 
approximately 25cm2. They were demarcated using a laminated template (Figure 5.1). There 
were 2 application sites for each arm (total of 4 per volunteer) and 1 untreated (control) site 
allocated randomly on one of the forearms (Figure 5.2). 
 
Figure 5.1 Laminated template aligned on the forearm 
Individual applications comprised 50µL (i.e. 2µL/cm2) of the test formulations dispensed by 
volunteers from 1mL syringes and then gently massaged into the designated treatment site. 
Topical products in atopic dermatitis treatment are usually indicated for up to three times a 
day application [51]. Thus, the formulations were applied by the subjects three times a day to 
the specified skin sites for a treatment period of 21 days (a period which takes into account 
the stratum corneum turnover time). Information on participants’ compliance with the 
application regime was recorded in Participant’s individual Diaries and collected by the 
investigator at the end of the study (average compliance was 90±12). 
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Figure 5.2 Application sites 
Volunteers were asked to refrain from applying any topical products to the skin areas under 
investigation during the 24 hours prior to the study and during the treatment regimen until the 
day of measurements. There were no other restrictions regarding normal day-to-day life of 
participants, including clothing, washing, bathing, showering, sports participation etc. After 21 
days of application, a one-day wash-out period was allowed, when no formulation was 
applied, and the measurements (tape stripping and TEWL) were performed on the 23rd day of 
the study. The measurements were performed in the laboratory, in ambient conditions at a 
temperature of 25.8±1.7°C and a relative humidity of 44.6±3.6%. Before the measurements, 
volunteers acclimatised in these conditions for at least 15 minutes. 
5.2.4 Tape stripping 
After completing the formulation application regimen, the skin was stripped consecutively 20 
times at each of the 4 treated sites and 1 control site with D-Squame® discs (CuDerm 
Corporation, USA). In total 5 skin areas on the volar forearms were sampled. The D-Squame® 
tape was placed on the skin at a constant pressure of 225g/cm2 applied with a D-Squame 
pressure device (CuDerm Corporation, USA) for 5 seconds and then the tape was removed. 
5.2.5 Protein content determination 
Protein content [µg/cm2 of tape] was quantified as an indirect way of measuring the amount 
of the SC removed with each tape. After the tape stripping procedure the tapes were placed 
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on the standard D-Squame® racks (CuDerm Corporation, USA) and the absorption readings 
were taken with an infrared densitometer (SquameScan 850A, Heiland Electronic,Germany). 
The amount of protein was calculated according to the equation validated by Voegeli et al. 
[52]: 
𝐶protein = 1.366𝐴 − 1.557 
Equation 5.1 
where: 
𝐶protein- concentration of the protein on the tape [µg/cm
2] 
𝐴 - absorption [%]. 
5.2.6 Transepidermal water loss measurements 
TEWL was measured at each of the five designated skin areas before tape stripping (baseline) 
and after each 5 tapes with a closed chamber Aquaflux® AF103 (Biox Systems, London, UK). 
ΔTEWL, i.e. the difference between the TEWL measurement of the stripped area and the 
baseline measurement, was calculated.  
The tape stripping and TEWL measurement procedure is shown in Figure 5.3.  
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Figure 5.3 Tape stripping and TEWL measurement procedure 
 
5.2.7 Corneocyte size and maturity measurements 
Tapes number 1, 5, 9, 13 and 17 were used for corneocyte size and maturity measurements. 
Corneocyte maturity and corneocyte surface area were measured by immunofluorescence and 
Nile red staining method described below. The method was previously developed and 
described by Hirao et al. [53]. 
Each tape was transferred into a separate glass vial and approximately 1mL of the dissociation 
buffer comprising of 2% sodium dodecyl sulphate (sodium lauryl sulphate, SLS), 20mM DL-
dithiothreitol, 5mM ethylenediaminetetraacetic acid and 0.1M Tris-hydrochloride buffer pH 
8.0 was added to each vial. The tapes were extracted at approximately 100°C for 5-10min. 
Extracts were then transferred into Eppendorf tubes and centrifuged at 6000rpm for 10min. 
The supernatant was removed and the extraction procedure was repeated three times. The 
cellular precipitate was suspended in 100µL of the dissociation buffer.  
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2-5µL of the cell suspension was applied to a microscope slide (WVR International, Belgium) 
and left to dry at room temperature. The applied suspension was encircled with a liquid 
blocker PAP Pen (Sigma Aldrich, UK) to avoid loss of cells and solutions from the slide. 15µL of 
the primary monoclonal antibody anti human involucrin (clone SY5, Cambridge Scientific, UK) 
1:100 in sterile purified water was then applied and the slides were left overnight in the 
desiccator at 4°C. Next, 15µL of the Anti-Mouse IgG (whole molecule)−FITC secondary antibody 
H&L produced in rabbit (Abcam, UK) 1:50 in PBS was applied and the slides were left for 1h in a 
dark room at room temperature. After rinsing the slides with PBS, 20µg/mL solution of Nile red 
in 75% glycerol (prepared from 500µg/mL stock solution in acetone) was applied to the slides 
for 10min at room temperature in the dark room. The slides were rinsed with PBS, covered 
with cover slips and observed under a fluorescence microscope (Nikon, UK). Images of Nile 
red-stained (red pixels) and immuno-stained (green pixels) cells were taken with a Nikon 
D5100 camera (Nikon, UK), magnified 10x, 2.3 pixels per µm, resolution 4928x3264 pixels. 
ImageJ® software (Version 1.44p, NIH-Image, USA) was used to measure the RedGreenBlue 
pixel ratio (to analyse cell maturity) and number of pixels (to investigate corneocyte surface 
area from Nile red stained pictures) as described before [54]. Cell maturity was also analysed 
by calculating the ratio between red and green cells counted on the green fluorescence image. 
A similar method of cell maturity assessment was described by Hirao et al. [53]. 
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Figure 5.4 Cell size and maturity measurement procedure 
 
5.2.8 Protease activity measurements 
Protease activity (PA) was measured by the HPLC assay of the fluorescent product 
(aminomethyl coumarin, AMC) of enzymatic reactions involving peptide substrates. The 
method was previously described by Voegeli et al. [55]. Tapes not utilised for corneocyte size 
and maturity measurements were used for PA determination. 
Each tape was placed in a separate Eppendorf tube and extracted with 750µL of the buffer (pH 
8.0) containing 0.1M Tris-HCl and 0.5% TritonX-100 (15 min., 25°C, 1000rpm) in the orbital 
incubator S150 (Stuart Scientific, UK). 400µL of extracts from three tapes were pooled (2-4, 6-
8, 10-12, 14-16, 18-20). 250µL of pooled extracts was transferred into 4 Eppendorfs. 1.25µL of 
5mM fluorogenic substrates dissolved in DMSO (final substrate concentration 25µM) was 
added, each to a different Eppendorf. The solutions were mixed (2h, 37°C, 1000rpm, orbital 
incubator). After 2h incubation, 250µL of 1% acetic acid was added to the reaction mixture. 
The reaction mixture was transferred into a HPLC vial and analysed by HPLC for the AMC 
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content. The HPLC method for AMC quantification was validated prior to the studies 
(coefficient of variance<10-15%, r2>0.999) and is described in Table 5.4. 
Table 5.4 Parameters of the HPLC method for AMC quantification 
Column 
Symmetry Shield RP18, 5µm, 4.6x150mm  
(Waters, Milford, MA, USA) 
Guard column 
SecurityGuard Cartridge System with C18 (ODS, Octadecyl) 
4mmLx3mm filter (Phenomenex, USA) 
HPLC System 
HP Series 1050 quaternary pump, HP Series 1050 autosampler, HP 
series 1100 degasser, Waters 470 Fluorescence Detector 
Software 
PRIME software 
Ver.4.2.0., HPLC Technology Co. Ltd, UK 
Mobile phase 1 Acetonitrile:Water:Trifluoroacetic acid (30:70:0.1, v/v/v) - KLK5 
Mobile phase 2 Acetonitrile:Water:TFA (25:75:0.1, v/v/v) - TRY, PLA 
Mobile phase 3 Acetonitrile:Water:TFA (20:80:0.1, v/v/v) - KLK7 
Injection volume 20μL 
Flow rate 1 mL/min 
Temperature control 40ºC 
Fluorescence detection wavelength 442nm for emission, 354nm for excitation 
Retention time of AMC ~3min 
Analysis time ~10min 
Calibration curve range 
1-10ng/mL (standard concentrations: 1; 2,5; 5; 7,5; 10ng/mL of AMC 
prepared from a 1000ng/mL stock solution by dilution with the 
reaction buffer) 
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Figure 5.5 Protease activity measurement 
 
5.2.9 Nicotinamide content 
NA skin retention was determined for the sites treated with DENI and NIAD formulations. NA 
content in the tapes was determined with the HPLC method described in section 3.2.5. 
Extracts from PA measurements (before pooling) were taken. The extraction method was 
validated prior to the study (as described in the appendices). 
 
5.2.10 Statistical analysis 
Statistical significance was determined using IBM SPSS Statistics version 19 software (SPSS Inc., 
an IBM Company). Normality was assessed using the Kolmogorov-Smirnov statistical test with 
Sig.>0.05 indicating normality. A one-way ANOVA with Tukey post-hoc test (p<0.05) was 
performed to compare differences in total protein content, mean TEWL, ΔTEWL, cell size and 
cell maturity in the tapes taken from 4 test sites and 1 control site. A probability of p<0.05 was 
considered statistically significant. A Kruskal-Wallis test with a Mann-Whitney U post-hoc test 
and Bonferroni correction was performed for KLK5, TRY, PLA and KLK7 activity comparisons 
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because of the lack of normal distribution of these data. A probability of p<0.005 was 
considered statistically significant. A correlation between cell maturity determined with 
ImageJ® software and the cell counting method was assessed with Spearman’s rho correlation 
test. A probability of p<0.05 was considered statistically significant. All results are presented as 
the mean ± standard error of mean (SEM) (n=20) unless otherwise stated. 
5.3 Results 
5.3.1 Protein content 
The amount of protein taken with each of the tapes was quantified according to the method 
described in section 5.2.5. In general, less protein was stripped with increasing tape number 
which is in line with previous findings [21, 22, 54, 55]. The average amount of protein stripped 
from the investigated sites with each tape is shown in Figure 5.6. 
 
Figure 5.6 Amount of protein stripped with each tape (data shown as mean ± SEM, n=20) 
The total amount of protein [µg/cm2] stripped from each measured site was calculated and is 
shown in Figure 5.7. 
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Figure 5.7 Total protein taken from the measurement sites (data shown as mean ± SEM, n=20), the 
measurement sites significantly different from each other are marked with an asterisk (*p<0.05). 
A statistically significant (one-way ANOVA, p<0.05) difference in total protein content was 
found between DENI vs. NIAD and DE vs. NIAD formulations. A lower amount of protein was 
found in tapes stripped from the application sites of formulations containing lipophilic 
excipients (DENI, DE). 
5.3.2 Transepidermal water loss 
TEWL [g/m2/h] was measured five times at each of the areas of interest (before the tape 
stripping and after each five tapes). As previously reported [21, 54], TEWL increased with the 
removal of the SC layers. This is illustrated in Figure 5.8. The effect was more pronounced for 
the sites treated with placebo formulations and the control site, however statistical 
significance was not reached (one-way ANOVA, p>0.05). 
 
Figure 5.8 TEWL obtained for each formulation at baseline (0) and after taking every five tapes (5, 10, 
15, 20) (data shown as mean ± SEM, n=20) 
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ΔTEWL between the TEWL measurement of the stripped area and the baseline measurement 
was calculated and is illustrated in Figure 5.9. Higher differences from the baseline TEWL were 
found for the control and AD application sites, especially after 15 and 20 tapes were taken. 
However, statistical significance was not reached (one-way ANOVA, p>0.05). 
 
Figure 5.9 ΔTEWL between the TEWL after the tape stripping procedure and the baseline TEWL (data 
shown as mean ± SEM, n=20) 
The average TEWL values obtained for each measurement site were calculated. A statistically 
significant difference (one-way ANOVA, p<0.05) for mean TEWL was found between the NIAD 
formulation and its placebo (AD), with higher values obtained for the latter (see Figure 5.10). 
 
Figure 5.10 Average TEWL obtained for each formulation (data shown as mean ± SEM, n=20, *p<0.05) 
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5.3.3 Corneocyte size 
Corneocyte size was measured for tape number 1, 5, 9, 13 and 17. In most cases, there was a 
decrease of the cell surface area with the tape number, observed also by Mohammed et al. 
[54]. The results for each site of interest are shown in Figure 5.11. 
 
Figure 5.11 Corneocyte size (data shown as mean ± SEM, n=20) 
The average cell surface area was calculated for each measurement site. Statistically significant 
(one-way ANOVA, p<0.05) differences were found between average cell surface area obtained 
from NIAD vs. DE and NIAD vs. control sites with larger cells for NIAD in both cases (see Figure 
5.12). 
 
Figure 5.12 Average corneocyte size (data shown as mean ± SEM, n=20, *p<0.05) 
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5.3.4 Corneocyte maturity 
Corneocyte maturity was measured for tape number 1, 5, 9, 13 and 17 in two ways:  
 by ImageJ® software calculation of the red/green pixels ratio, 
 by visual determination of mature (red) and immature (green) cells and calculation of 
the red/green cell number ratio.  
The results for each site of interest are shown in Figure 5.13. In general, the maturity of 
corneocytes decreased with the depth of stratum corneum (reflected in the increasing tape 
number), which is in line with previous findings [53, 54]. A statistically significant difference 
(one-way ANOVA, p<0.05) in cell maturity was found when the NIAD formulation was 
compared vs. placebo (AD) according to the cell counting method for tape 9. More mature 
cells were observed for the NIAD formulation. There was a moderate correlation between 
both methods used to calculate the corneocyte maturity assessed with Spearman’s rho 2-
tailed test (r=0.38, p=0.000). 
a) 
 
b) 
 
Figure 5.13 Corneocyte maturity a) ImageJ® method, b) visual determination and cell counting method 
(data shown as mean ± SEM, n=20, *p<0.05) 
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5.3.5 Protease activity 
The activity of four proteases: kalikrein 5 (KLK5), tryptase (TRY), plasmin (PLA) and kalikrein 7 
(KLK7) was measured at each of the sites for five pools of three tapes. 
a) 
 
b) 
 
c) 
 
d) 
 
Figure 5.14 Protease activity a) KLK5, b) TRY, c) PLA, d) KLK7 (mean ± SEM, n=20) 
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The summary of results for each protease is shown in Figure 5.14. 
Total PA was calculated (i.e. the sum of the activity in the five pools of tapes taken from one 
measurement site) and is shown in Figure 5.15. Statistically significant (Kruskal-Wallis, 
p<0.005) differences were found between DENI vs. NIAD and DE vs. NIAD formulations for the 
total TRY and KLK7 enzyme activities. Lower activities of both enzymes were found for NIAD 
formulation.  
 
Figure 5.15 Total protease activity (data shown as mean ± SEM, n=20, *p<0.005) 
 
5.3.6 Nicotinamide content 
NA was analysed in the extracts from the tapes taken from the skin areas where DENI and 
NIAD formulations were applied. The extracts of three tapes were pooled together giving five 
pools for each treatment site per volunteer. 
High inter-individual variability was observed for NA content in the tapes with results ranging 
from 0.010 to 0.741 and from 0.006 to 0.675 µg of NA/µg protein, obtained for DENI and NIAD 
respectively. Thus, the DENI/NIAD ratio of NA found in the tapes was calculated for each 
volunteer. The average DENI/NIAD ratio for NA content in the pools of tapes is shown in Figure 
5.16. The DENI/NIAD ratio for total NA content obtained in this study was 1.27±0.76 (mean ± 
SEM, n=20) indicating similarity of DENI and NIAD in terms of NA retention in the outermost 
layers of the SC. 
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Figure 5.16 DENI/NIAD ratio for total nicotinamide content from pooling of tapes (data shown as 
mean ± SEM, n=20) 
 
5.4 Discussion 
The prototype NA formulations were developed by Dermal, Ltd., UK and were tested in vivo. 
To separate the vehicle effect from the influence of NA on the skin condition, 4% NA was 
incorporated into two different vehicles. One of the formulations contained mainly water 
(NIAD), while the other was composed of other excipients, which are commonly used in topical 
formulations indicated in the treatment of dry skin conditions (DENI). Also placebo 
formulations, AD and DE respectively, where NA was substituted with purified water, were 
prepared to give a greater insight into the vehicle influence on the state of the skin. The 
prototype formulations and their placebos were tested in vivo in a healthy volunteer study. 
The amount of protein quantified in the tapes is an indicator of skin cohesion [18, 19]. For 
example, protein content was used to assess the decrease in skin cohesion caused by 
treatment with a washing emulsion and water [56]. The more cohesive the skin the more 
difficult it is to strip it with an adhesive tape. Thus, the lower (one-way ANOVA, p<0.05) 
amount of protein found in tapes stripped from the application sites of lipid containing 
formulations (compared with NIAD) suggests that DENI and its placebo improve skin cohesion. 
This may be because of the lipophilic components present in these test formulations. Caussin 
et al. [57] found that lipophilic and hydrophilic moisturisers have different effects on the SC. 
Lipophilic moisturisers increased skin hydration as opposed to the hydrophilic preparations. In 
another study, it was shown that lipophilic excipients form separate domains in the SC, which 
may be the reason for their positive effects on skin [58]. Nevertheless, the lower amount of 
protein found for tapes taken from DENI and DE treated sites may be also attributed to 
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changes in the adhesion to the tapes caused by the presence of the lipophilic vehicle. The 
influence of vehicle on the amount of the SC removed with adhesive tapes was observed by 
Tsai et al [59] with significantly (one-Way ANOVA, p<0.05) higher values obtained for an 
alcoholic solution when compared with semisolid formulations. Similar results were obtained 
by Lademann et al. [60] for ethanol-based and oily formulations, with deeper layers of the skin 
reached after the tape stripping of the skin treated with the first formulation. There was no 
statistically significant (one-way ANOVA, p>0.05) difference in terms of protein content 
between DENI and its placebo (DE), suggesting that NA present in the first formulation does 
not influence the amount of protein stripped with the tapes. 
Significantly lower average TEWL values (one-way ANOVA, p<0.05) were obtained for NIAD 
when compared with its placebo (AD). This may indicate that NA present in the NIAD 
formulation has a positive effect on skin integrity, rendering it more robust against water loss 
and disruption by tape stripping. These results are in line with data obtained by Tanno et al. 
[61]. In a study on volunteers with dry skin, significantly lower TEWL values were observed 
after 4 weeks treatment with a NA solution compared with its placebo. NA was found to 
increase ceramide and free fatty acid levels and TEWL correlated with the level of ceramides. 
Also, Crowther et al. [40] attributed lower TEWL values to the increase in skin thickness caused 
by a NA containing moisturiser. On the other hand, Buraczewska et al. [7] found that a polymer 
hydrogel increased TEWL after a 7 week treatment (when compared with non-treated skin). 
What is more, the skin treated with this preparation was more prone to damage caused by 
SLS. In this study, no significant (one-way ANOVA, p>0.05) difference between mean TEWL was 
found between non-treated and AD-treated skin. However, possible skin barrier deterioration 
caused by AD, which is a simple hydrogel formulation, cannot be excluded. TEWL values at 
baseline and after stripping of 5 and 10 tapes were higher (although not significantly, one-way 
ANOVA, p>0.05) for AD when compared with the control site. This effect may be reversed by 
NA present in the NIAD formulation. This is reflected in significantly (one-way ANOVA, p<0.05) 
lower mean TEWL values obtained for NIAD when compared with AD. 
Glycerol (GLY) is a humectant commonly used in topical moisturisers. It was shown to 
accelerate skin barrier recovery [42]. Administered topically, orally and intra-perineurally, GLY 
improved skin properties of aquaporin-3-deficient mice [62]. However, a significant decrease 
(p=0.0252) in TEWL was found only after 4-weeks treatment with a GLY-containing formulation 
when compared with placebo in the atopic patient group. Further treatment showed that the 
two formulations were not different in terms of improving skin integrity and severity of the 
disease (SCORAD) [63]. Also, no improvement in barrier function after GLY-based moisturiser 
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treatment was observed by other authors [9, 11, 64]. The combination of GLY and NA was 
more effective in improving the skin barrier function [40]. Atrux-Tallau et al. [65] found that 
low (up to 2%) and high (3-10%) doses of glycerol applied after acute chemical skin irritation 
with sodium lauryl sulphate caused an increase or persistence of high TEWL in damaged skin. 
Because of its polarity, GLY integrates into the hydrophilic regions of orthorombically packed 
lipids and increases the distance between the lipid lamellae [66]. This interaction with the SC 
may be the reason for the penetration enhancing effects of GLY observed for nicotinic acid 
[67]. However, it may also be responsible for an increased water loss through the skin because 
of the opening of its structure. Thus, presence of GLY may be the reason for the lack of 
significant (one-way ANOVA, p>0.05) positive effect of NA on TEWL in DENI formulation when 
compared with other formulations.  
Larger corneocytes were found for NIAD treated skin when compared with DE and control sites 
(one-way ANOVA, p<0.05). Holzle and Plewig [31] established that smaller and irregular 
corneocytes are related to damaged or diseased skin. Also the corneocyte surface area was 
correlated with the cell maturity [54]. Thus, the results obtained in this study may indicate that 
NA present in the NIAD formulation slows down the corneocyte turnover time allowing for 
larger cell formation. However, this potential effect on turnover was not reflected in 
corneocyte maturity measurements. There was almost no statistically significant difference 
(one-way ANOVA, p>0.05) in this parameter between the sites treated with NA containing 
formulations and their placebos or control sites. 
GLY penetrates the SC and interacts with the hydrophilic regions of the SC lipids [66]. The 
short- and long-term effects of GLY treatment on the corneocyte size were assessed by 
previous authors with a modified tape stripping/fluorescence imaging method [14]. There was 
an increase in the corneocyte size observed 3 hours after GLY treatment, followed by a 
decrease after 7 hours, persisting up to 12 hours after the treatment. The authors suggested 
that this is because of the moisture initially brought to the skin surface from the deeper skin 
layers by GLY and moisture depletion after its evaporation from the skin surface. The study 
found that in general the surface areas of corneocytes increased after a 9-day glycerol 
treatment. However, the results obtained in the current study, indicate that after a 21-day 
treatment GLY, which is present at a relatively high concentration (5%) in DE and DENI 
formulations, may have a cell-shrinking effect because of its dehydrating influence on the 
deeper layers of the skin. This effect is only significant (one-way ANOVA, p<0.05) when no 
protective NA is present in the formulation, i.e. for the DE formulation. However, because of 
the complexity of formulations tested it is difficult to attribute the effect on corneocyte size to 
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GLY alone. An in vivo study with a simple GLY-based formulation performed according to the 
protocol described for prototype NA formulations may provide evidence of GLY’s possible 
negative effects on corneocyte size. 
NIAD treated skin showed lower total activity of TRY and KLK7 proteases (Kruskal-Wallis, 
p<0.005) when compared with the DENI and DE formulations. Desquamation is dependent on 
the relative humidity of the environment and the desquamatory enzymes activity is related to 
the water present in the stratum corneum. In vitro studies demonstrated that application of 
10% GLY increases the activity of stratum corneum chymotrypsin-like enzyme (SCCE) [68]. Also, 
GLY increased the enzymatic digestion of corneodesmosomes in dry skin conditions [69]. Thus, 
It may be postulated that NA (found in NIAD formulation) diminishes TRY and KLK7 activity and 
for the DENI formulation, the decrease in TRY and KLK7 activity caused by NA may be masked 
by the effect of GLY.  
KLK7 was reported to be more active in normal skin when compared with dry skin [70, 71]. At 
the same time, increased activity of key desquamatory enzymes (KLK5 and KLK7) was found for 
chemically (SLS) damaged dry skin [72, 73]. Voegeli at al. [37] correlated increased TEWL and 
decreased epidermal thickness with higher tryptase-like (TRY) protease activity (PA). This is in 
line with the findings from this study, where lower TRY activity for the skin site treated with 
NIAD formulation was associated with lower TEWL values for this site and larger corneocyte 
surface area. This suggests that the decrease in this PA, caused by NA present in the 
formulation, may improve the skin barrier to water loss. 
Similar NA retention in the epidermis obtained for the in vivo study (DENI/NIAD ratio of 
1.27±0.76, mean ± SEM, n=20) is in line with the finite dose in vitro permeation studies 
described in the previous chapter. In the permeation studies, no significant difference (t-test, 
p>0.05) in terms of cumulative amount of NA permeated or retained in the skin after 24 or 8h 
(for silicone and pig skin, respectively) was found. These results may explain the lack of 
differences (DENI/NIAD ratio close to 1) between the formulations tested in vivo. 
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6 Conclusions 
6.1 Pre-formulation studies 
The first stage of this work was to perform preliminary pre-formulation studies. The potential 
candidate solvents for the delivery of NA to the skin were chosen from the compounds 
commonly used in topical and transdermal formulations. Several solvents with a wide range of 
physicochemical properties were tested. Theoretical solubility parameters of the solvents were 
established. Based on solubility parameter (δ) calculation, solvents with δ value close to that of 
the skin (i.e. PGML, PGMC, DPPG and IPM) or nicotinamide (NA) (i.e. PG) were chosen to be 
investigated further in the in vitro studies. NA was stable in these solvents for 48h at 32˚C. 
Also, to simplify the experimental conditions, solvent systems, which were found to be 
miscible were tested in vitro in the uptake and permeation studies. Incorporation of a maximal 
amount of NA into the system, thus achieving a maximal thermodynamic activity, was possible 
after solubility studies were performed.  
However, in the real life situation, neat solvents or their liquid mixtures would be rarely 
applied to the skin as a topical formulation. Additional excipients, such as humectants, gelling 
agents, stabilizers, antioxidants or preservatives, would be added to formulate the final 
product. Thus, prototype formulations (DENI and NIAD) containing several additional 
excipients from these groups were also tested in vitro. Since these more complicated 
formulations are more likely to be applied to diseased skin, than the simple solvent systems, 
their influence on the parameters indicating the skin condition was tested in vivo. Non-invasive 
and semi-invasive techniques such as TEWL measurements and tape stripping were used. 
Knowledge of the basic physiochemical parameters of the formulation components, allowed 
for a critical analysis of the data. The conclusions from both in vitro and in vivo studies are 
described below.  
6.2 In vitro solvent uptake and NA partitioning studies 
Solvent uptake studies into silicone membrane and pig ear stratum corneum were performed. 
The interaction between the silicone membrane and the chosen solvents was highest for the 
solvents with δ values close to the δ value of the membrane (IPM, DPPG). The exception was 
MO, a large molecule which was hardly incorporated into the silicone membrane, despite its δ 
value matching that of the membrane. In the case of stratum corneum (SC), the uptake of the 
chosen solvents into this membrane increased with their hydrophilicity (largest for a relatively 
Conclusions 
184 
 
small molecule - PG), even though the membrane itself is perceived as a lipophilic one. It can 
be concluded that for the SC the molecular size is even more important for the solvent-
membrane interaction than the δ value. 
High sorption of IPM and DPPG into the silicone membrane and low solubility of NA in these 
solvents was reflected in the high partitioning of NA into this membrane. For SC, where the 
uptake of the solvent did not correlate with NA partitioning, it seems that high solubility of NA 
in PG could not be compensated by the uptake of this solvent into the SC and thus a high 
calculated membrane/solvent partition coefficient of NA was not achieved. 
6.3 In vitro nicotinamide permeation studies from prototype 
formulations 
The above-mentioned uptake and partitioning results are reflected in the permeation of NA 
from the prototype formulations. Two prototype NA formulations were developed by Dermal 
Laboratories Ltd. for the treatment of AD. 4% NA was incorporated into two vehicles: one 
containing primarily water (NIAD) and the other comprising also of IPM, MO and GLY (DENI). 
The composition of the vehicles was dictated by the need to separate the influence of NA from 
the other formulation components on the skin condition in vivo. Prior to the in vivo testing, in 
vitro experiments were conducted to assess the performance of the prototype formulations in 
terms of percutaneous absorption of NA. 
In vitro studies performed with silicone membrane as a barrier for NA diffusion showed that 
NA permeated through the lipophilic membrane despite its hydrophilicity. Two prototype 
formulations tested showed different behaviour when applied as infinite and finite doses. In 
the infinite dose studies, significant differences (t-test, p<0.05) in permeation parameters were 
found between DENI and NIAD formulations. This may be because of the presence of lipophilic 
components in the DENI vehicle as opposed to the water-based NIAD formulation. These 
components may influence the viscosity and thus the diffusion of NA from the formulation.  
Evaporation of water, the main solvent used in both formulations, occurred during the finite 
dose experiments. Thus, less solvent was available for the drug to be in solution and the 
thermodynamic activity, i.e. the drive for diffusion, increased. This situation was more 
pronounced for the NIAD formulation, because of its higher water content. Hence, the positive 
effect of lipophilic components present in DENI was compensated by a greater change in 
thermodynamic activity observed for NIAD. This may be the reason for the lack of significant (t-
test, p>0.05) differences between the extent and the rate of NA permeation for both 
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formulations in the silicone and in the pig ear skin finite dose studies. This change in 
thermodynamic activity (for both formulations) may explain the higher cumulative amount of 
NA permeated in the finite dose experiment when compared with the infinite dose study.  
To conclude, in the infinite dose studies, NA permeated from the DENI formulation to a larger 
extent when compared with NIAD. This was possibly because of the presence of lipophilic 
components in the DENI formulation, which were readily taken up by the silicone membrane 
(IPM), and which influenced NA thermodynamic activity and formulation viscosity (IPM, MO) 
and thus favoured NA release from this formulation. However, the prototype formulations 
were not different in terms of NA silicone and pig ear skin permeation in the finite dose 
studies. It may be postulated that some compensatory effects, such as water evaporation from 
the prototype formulations, play an important role in the NA permeation process from these 
formulations.  
Drug retention in the outermost layers of the skin is desirable for topical products. In the finite 
dose studies conducted both with silicone and pig ear skin as model membranes, little or no 
NA was found in the membrane at the end of the study. The results obtained for silicone are 
not surprising, since NA is a hydrophilic compound with a low affinity for lipophilic 
membranes. Considering the vehicle components used to formulate the prototype products, 
IPM has a high affinity for the membrane, but its NA retention potential is hindered by low 
solubility of the drug in this solvent. NA is highly soluble in water but this hydrophilic solvent 
exhibits a low affinity for the silicone membrane. Similarly, low epidermal and dermal 
retention of NA was observed in the pig ear studies. This may be attributed to the lack of a 
solvent in DENI and NIAD vehicles which is able to increase NA affinity for the skin layers.  
6.4 In vitro nicotinamide permeation studies from simple solvent 
systems 
Since the target layer of the skin for AD is the epidermis, the retention of NA in this skin layer 
could be improved by implementing a rational approach to the design of NA topical 
formulations. Also, the complexity of the prototype formulations makes the elucidation of the 
exact mechanism underlying the NA permeation process difficult. Thus, NA permeation from 
simple solvent systems was studied.  
In the infinite dose silicone membrane permeation studies, systems with δ values close to that 
of silicone membrane, high uptake into this membrane and low solubilizing potential for NA 
(i.e. IPM, DPPG and mixtures of IPM with DPPG, PGML and PGMC), achieved the maximal 
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steady state flux. It may be concluded that, because of the above-mentioned properties, these 
solvents increased NA diffusion and solubility in the model membrane. 
NA is hydrophilic, thus its solubility in lipophilic solvents, such as IPM and DPPG, is low. At the 
same time, these are the solvents that have a higher potential to penetrate the lipophilic 
silicone membrane when compared with hydrophilic solvents (such as PG). The highest 𝑘𝑝 
across the silicone membrane in the infinite dose studies was obtained for IPM (t-test, p<0.05). 
This solvent has a δ value close to the δ value of the silicone membrane (7.5 cal1/2/cm3/2) [1]. 
Also, in the finite dose pig ear skin permeation studies the highest 𝑘𝑝 was obtained for IPM 
(one-way ANOVA, p<0.05). No synergistic effects were observed when the selected solvents 
were used in combinations. This suggests that IPM alone interacts strongly with the skin and 
addition of other components to the system does not increase this effect. Thus, adjustment of 
the δ value so that it is closer to the δ value of the drug did not result in an enhanced 
permeation.  
In the finite dose pig ear skin permeation studies, the focus was on establishing the 
formulation with the best potential to retain NA in the skin layers with the lowest loss of 
formulation at the end of application as shown by the percentage of NA present at the skin 
surface at the end of the study. 
From the single solvents tested, PG has a high potential to increase the skin retention of NA, 
however the good solubility of NA in this solvent suggests that a high percentage of the drug is 
left on the skin surface at the end of 8h permeation study. A better epidermal retention with a 
lower percentage of the applied dose left on the skin surface at the end of the application 
period was achieved by using combinations of the chosen solvents. From the solvent systems 
tested, especially binary mixtures with 10% addition of PG were capable of retaining high NA 
doses in the skin. What is more, ternary and quaternary solvent systems resulted also in a high 
epidermal and dermal NA retention. However, the synergistic effect could not be achieved for 
all systems tested. Optimal adjustment of the δ value of the solvent system could be the 
reason for the improved retention of NA when the drug was applied in the multicomponent 
solvent systems. For the epidermis and the dermis, the peak retention was observed at the δ 
value around 9.7 cal1/2/cm3/2, which is in line with the proposed δ value of the skin [2].  
In conclusion, IPM was the solvent with the highest NA penetration enhancing potential across 
silicone membrane and porcine skin. However, solvent systems with a δ value close to 10 
cal1/2/cm3/2 resulted in the best NA retention in the skin. This effect may be attributed to the 
increased solubility of NA in the skin, and thus increased partitioning, when the drug is applied 
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in an appropriate solvent. Thus, adjusting the δ value by using solvent mixtures may be helpful 
in designing an effective NA formulation which would target the drug to the skin. 
6.5 In vitro solvents permeation studies 
As shown above, the similarity of solvent δ value to that of the skin or model membrane, may 
be reflected in the drug permeation and its residence in the membrane. To understand this 
phenomenon, solvent permeation studies were performed together with the permeation of 
NA. 
There were several observations made in the silicone membrane permeation studies. First of 
all, solvent depletion from the donor compartment caused a decrease in the drug permeation. 
Secondly, high solvent retention in the silicone membrane was related to a high percentage of 
NA permeated during the study, indicating that solvent presence is necessary for drug 
transport across the membrane. Low permeation and low retention of the solvent resulted in 
low permeation of the drug. 
Lipophilic solvents (IPM, DPPG, PGML and PGMC) did not permeate across full thickness pig 
ear skin, probably because of the presence of the hydrophilic barrier i.e. the layer of dermis. 
PG was the only solvent that permeated across pig skin and also the highest amount of NA 
(p<0.05, one-way ANOVA) permeated from this solvent when compared with the other 
solvents tested. Nevertheless, some NA permeated from these solvents because of their 
presence in the skin layers, again indicating that this might be an important factor for drug 
permeation. These solvents partition into the skin from the formulation, but not out into the 
receptor fluid. This increases the residence time of this solvent in the skin, enhancing the 
permeation. 
6.6 Influence of prototype formulations on the skin in vivo 
The data obtained in the in vitro studies suggest that determination of the δ value may be 
useful for the prediction of the interactions between the solvent and the model membrane, 
which can be further used to choose the solvents with best penetration enhancing or 
membrane retention properties. Nevertheless, it is not only the drug, but also the vehicle that 
influences the state of the skin. The vehicle composition is especially important in the 
treatment of inflammatory or dry skin disorders. Thus, the performance of the prototype 
formulations in terms of skin health improvement was investigated in vivo. 
A healthy volunteer study was performed with prototype NA formulations (DENI, NIAD) and 
their placebos (DE, AD respectively) applied three times a day for three weeks. The following 
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differences were found between the formulations tested: a lower total protein content (one-
way ANOVA, p<0.05) for DENI and DE (compared with NIAD), a lower mean TEWL values (one-
way ANOVA, p<0.05) for NIAD (compared with AD), a larger mean corneocyte surface area 
(one-way ANOVA, p<0.05) for NIAD (compared with DE and control site), a lower total activity 
of TRY and KLK7 (Kruskal-Wallis, p<0.005) for NIAD (compared with DENI and DE). 
It may be concluded that lipophilic components present in two of these formulations (DENI 
and DE) have a positive impact on skin cohesion. This effect is reflected in the lower (one-way 
ANOVA, p<0.05) amount of protein that was quantified in the tapes stripped from the skin 
treated with DENI and DE formulations (compared with NIAD formulation devoid of these 
lipophilic components).  
On the other hand, NA containing formulations may positively influence skin integrity as 
assessed by TEWL measurements. Lower (One-way ANOVA, p<0.05) TEWL values were found 
for the NIAD formulation when compared with its placebo. Also, larger (one-way ANOVA, 
p<0.05) corneocytes were found in tapes stripped from the NIAD treated site (compared with 
control and DE treated site), indicating an influence of NA present in the formulation on 
corneocyte size. A correlation between the corneocyte surface area and TEWL was established 
by previous authors [3, 4]. However, for mean TEWL values and corneocyte area calculated for 
each volunteer a correlation could not be established in this study, possibly because of the 
relatively small sample size or because of different effects on epidermal turnover for the 
formulations studied here.  
It may be also postulated that NA diminishes TRY and KLK7 activity. These enzymes were 
significantly less active (Kruskal-Wallis, p<0.005) for the NIAD formulation than for the DENI 
formulation and its placebo (DE). It may be speculated, that the absence of any effect of NA on 
cell size, TEWL and PA for the skin site treated with DENI formulation may be because of the 
dehydrating effect of GLY present in this vehicle in a relatively high concentration [5-8]. 
Investigating the effect of GLY alone on skin hydration, corneocyte size and PA in vivo may 
confirm this. Nevertheless, GLY is not the only component in the prototype NA formulations 
and incorporation of other components into the vehicle may also influence the skin. 
The effect of NA on human skin has been previously reported by many authors [9-22]. 
Nevertheless, the results obtained in this study only partially confirm the ability of prototype 
NA formulations to influence positively the state of the skin. Simplifying the experimental 
conditions by the use of simple solvent systems may enable separation of the vehicle influence 
on skin state from the impact made by NA. 
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The only statistically significant difference (one-way ANOVA, p<0.05) between treated and 
control sites, was found for the size of corneocytes when control and NIAD application sites 
were compared. This shows that healthy skin, subject to no pre-treatment with damaging 
agents, is a self-regulating environment, difficult to influence by topically applied formulations. 
An in vivo study on atopic patients may provide stronger evidence of the influence of the 
formulations tested on the skin. 
The data from this in vivo study are presented as a function of the tape number. However, in 
light of a recent publication where the spectroscopic and gravimetric determinations of the SC 
protein in the tapes were correlated [23], the results may also be shown as a function of the SC 
depth reached in the tape stripping procedure. Nevertheless, the complication in data analysis 
caused by different depths obtained for each volunteer cannot be ignored. 
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7 Future work 
Pre-formulation studies were conducted to obtain basic information about the optimal 
formulation components. What followed were the in vitro studies evaluating simple solvent 
systems in terms of uptake and permeation of both nicotinamide (NA) and excipients. Also, in 
vitro and in vivo studies were performed with prototype topical NA formulations intended for 
atopic dermatitis (AD) treatment.  
Next, the simple solvent systems could be formulated into semisolid forms and their 
permeation and influence on skin state could be tested in vivo and in vitro. This would allow 
for their comparison with the prototype formulations containing a minimal amount of 
penetration enhancing solvents. 
The prototype formulations influence on atopic patients’ skin could be evaluated in a clinical 
trial using both AD scoring systems such as SCORAD and objective instrumental skin evaluation 
methods such as TEWL to determine the endpoints. 
Finally, in order to understand the effect of NA on skin health, other biomarkers in skin should 
be considered, for example enzymes involved in processing of filaggrin and production of NMF 
such as bleomycin hydrolase and calpain 1. 
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A Appendices 
A.1 Optimisation and validation of HPLC method for nicotinamide 
assay 
HPLC was chosen as an appropriate analytical method for nicotinamide (NA) assay in the 
samples obtained during this project. The HPLC system parameters, optimal analysis 
conditions and equipment used in analysis are listed below. 
Table A.1 Parameters of the HPLC method for nicotinamide quantification 
Column Primesep A 250x4.6mm, Particle 5µm, 100Å 
Part N
o
 A-46.250.0510, Serial N
o
 PALLCDN9 
Lot N
o
 015-070B (SIELC Technologies, USA) 
Guard column SecurityGuard Cartridge System with C18 (ODS, Octadecyl) 
4mmLx3mm filter (Phenomenex, USA) 
HPLC System I Agilent Technologies 1100 Series HPLC system: 
Degasser G1322A Serial N
o
 JP63203343, 
Quat Pump G1311A Serial N
o
 DE52700795, 
ALS G1313A Serial N
o
 DE23920375, 
Col. Comp. G1316A Serial N
o
 DE53401012, 
DAD 61315B Serial N
o
 DE11113362; 
HPLC system II Agilent Technologies 1200 Series HPLC system: 
Degasser G1322A Serial N
o
 JP73062725, 
Quat Pump G1311A Serial N
o
 DE62965070, 
ALS G1329A Serial N
o
 DE64766771, 
TCC G1316A Serial N
o
 DE63068585, 
VWD 61314B Serial N
o
 DE71361620; 
Software for chromatograms analysis ChemStation for LC Systems software: 
Copyright
© 
Agilent Technologies 1990-2002 or 2001-2008, 
Rev. A.09.03[1417] or B03.02[341] 
Mobile phase Mobile phase A (80): 0.07% Perchloric Acid in Deionised Water 
(1mL of 70% Perchloric Acid in 1L), pH 2 
Mobile phase B (20): Acetonitrile (HPLC grade) 
Injection volume 10μL 
Flow rate 2 mL/min 
Temperature control 40°C 
UV detection wavelength 263nm 
Retention time of nicotinamide ~9.5min 
Analysis time ~15min 
Calibration curve range 2-200μg/mL (6 standards of the concentrations of 2; 10; 20; 50; 
100; 200μg/mL of nicotinamide prepared from a stock solution of 
a concentration of 1000μg/mL by dilution with PBS) 
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A.1.1 Optimisation of the analysis conditions - system suitability testing 
According to the EMEA ICH guidelines, system suitability testing should be included in the 
process of analytical method development and the parameters to be established during this 
procedure depend on the type of analytical method that is validated [1]. The CDER Reviewer 
Guidance; Validation of Chromatographic Methods [2] gives detailed recommendations on this 
subject and this document was followed in the process of method development and 
optimisation. 
The terms used for system suitability parameters calculations are listed below. 
𝑊𝑥 - width of the peak determined at either 5% (W0.05), 10% (W0.1) or 50% (W0.5) of the peak 
height (from the baseline), 
𝑓 - distance between peak maximum and peak front at Wx, 
𝑡0 - elution time of the void volume or a component that is not retained by the column, 
𝑡𝑅 - retention time of the analyte, 
𝑡𝑊 - peak width of straight sides of the peak extrapolated to the baseline measured at 
baseline. 
 
Figure A.1 Representative chromatogram of a standard sample used for the validation of HPLC 
method for nicotinamide assay (standard prepared in PBS at a concentration of 100μg/mL with the 
use of reference standard chemical compound [Nicotinamide EP]) 
The representative chromatogram of a standard sample is shown in Figure A.1 and the terms 
determined from this chromatogram are listed in Table A.2. 
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Table A.2 The terms for system suitability parameter calculations defined from the chromatogram of a 
standard sample 
Term Value [min] 
W0.05 0.36 
W0.1 0.32 
W0.5 0.16 
f0.1 0.16 
t0 1.843 
tR  9.615 
tW 0.72 
A.1.1.1 Capacity factor (k’) 
Capacity factor measures where the peak, which represents the analysed compound is located 
with respect to the elution time of the non-retained components. A method of capacity factor 
calculation is presented below. 
𝑘′ =
𝑡𝑅 − 𝑡0
𝑡0
 
Equation A.1 
Capacity factor was calculated for the representative chromatogram of a standard sample 
which is shown in Figure A.1. The peak is well-resolved from the signal that comes from the 
non-retained components of the sample and the value of 𝑘′ is above 2 (𝑘′ > 2), which is in 
agreement with CDER recommendations. The results are shown in Table A.4. 
A.1.1.2 Precision/injection repeatability (RSD)  
Injection repeatability indicates the performance of the HPLC system used for analysis at the 
time the samples are analysed. It is recommended that injection precision expressed as 
relative standard deviation (RSD) for at least five injections (n ≥ 5) of the same sample should 
be ≤ 1%. For the calculation of this parameter five consecutive injections of the same standard 
sample (standard prepared in PBS at a concentration of 100μg/mL with the use of reference 
standard chemical compound [Nicotinamide EP]) were performed and the RSD of the peaks 
areas and peak retention time was calculated according to the following equations: 
𝑅𝑆𝐷 =
𝑆𝐷
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
100 
Equation A.2 
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𝑅𝑆𝐷 =
𝑆𝐷
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑟𝑒𝑡𝑒𝑛𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒
100 
Equation A.3 
Where: 
𝑅𝑆𝐷 - Relative Standard Deviation 
𝑆𝐷 - Standard Deviation 
The value obtained for analysed samples is in agreement with CEDR recommendations. The 
results are shown in Table A.3 and summarised in Table A.4. 
Table A.3 Injection repeatability for a standard sample of a concentration of 100 μg/mL of 
nicotinamide 
Injection 1 2 3 4 5 Average SD RSD [%] 
Peak area 1129.2 1139.3 1137 1136.4 1138.2 1136.02 3.97 0.35 
Retention time 9.54 9.62 9.62 9.61 9.61 9.60 0.03 0.36 
A.1.1.3 Tailing factor (T) 
The peaks obtained on the HPLC chromatogram should be as sharp as possible because the 
accuracy of quantification decreases with increase in peak tailing. If the peak is tailing it is 
difficult for the integrator to determine the boundaries of the peak and hence the calculation 
of the area under the peak is hindered. Integrator variables were pre-set for optimum 
calculation of the area for the peak of interest. The peak tailing factor was calculated for the 
representative chromatogram of standard sample according to the equation below and 
compared with CDER the recommendations (𝑇 ≤ 2). The tailing factor obtained for 
representative chromatogram falls within the recommended values. 
𝑇 =
𝑊𝑥
2𝑓
 
Equation A.4 
A.1.1.4 Theoretical number of plates (N)  
The theoretical number of plates is a measure of column efficiency, i.e. how many peaks can 
be located per unit run-time of the chromatogram. Parameters which can affect the plate 
number include peak position, particle size of the column packing, mobile phase flow-rate and 
viscosity, the temperature of the column and the molecular weight of the compound analysed. 
Theoretical number of plates calculation utilised in the evaluation of the HPLC system for NA 
analysis is shown in the equation below.  
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𝑁 = 16 (
𝑡𝑅
𝑡𝑊
)
2
 
Equation A.5 
N depends on elution time but it is recommended that the value should be > 2000. The value 
calculated for the representative chromatogram meets this requirement. 
A.1.1.5 Summary of the system suitability testing procedure 
According to CDER recommendations for system suitability testing as a way of assuring the 
quality of chromatographic system performance, the minimum parameters to be tested are k’, 
RSD and T for dissolution or release profile test methods. In the case of the HPLC method of 
NA assay additionally, the N parameter was determined. All the parameters tested meet the 
requirements set by the CDER Reviewer Guidance, Validation of Chromatographic Methods [2]. 
Because no compounds other than NA were analysed in one sample and one HPLC run, the 
resolution parameter was not calculated. The summary of system suitability test parameters is 
shown in Table A.4. 
Table A.4 Summary of system suitability test parameters for HPLC method for nicotinamide assay 
Parameter  Value calculated for the standard 
chromatogram 
CDER recommended value 
Capacity factor (k’) 4.22 k’ > 2 
Injection repeatability (RSD) Peak area: 0.35%, 
Retention time: 0.36%, 
n = 5 
RSD ≤ 1% 
Tailing factor (T) from W0.5 1 T ≤ 2 
Theoretical number of plates (N) 2853 N > 2000 
A.1.2 Validation of the HPLC method for nicotinamide assay 
The validation of the HPLC method for NA quantification was performed on the basis of the 
ICH Note for Guidance on Validation of Analytical Procedures: Text and Methodology 
(CPMP/ICH/381/95) issued by the European Medicines Agency [1]. According to this guideline 
the following validation characteristics should be considered when evaluating the assay of a 
compound of interest: 
 Accuracy, 
 Precision (Repeatability), 
 Specificity, 
 Linearity, 
 Range. 
Appendices 
198 
 
Additional parameters, not perceived by the EMEA as mandatory for the validation of assay of 
a compound of interest include: 
 Detection Limit, 
 Quantitation Limit, 
 Intermediate Precision, 
 Reproducibility, 
 Robustness. 
A.1.2.1 Calibration curves 
During the validation process calibration curves were obtained on each day of validation by 
HPLC analysis of each standard (freshly prepared on the day) performed at least in triplicate. 
The average areas of the peaks obtained for each standard were plotted against the 
concentrations of the standards. A calibration curve equation was determined using the 
method of least squares. Table A.5 contains the representative data used to plot the 
calibration curve, which is shown in Figure A.2. 
Table A.5 Data obtained from HPLC analysis of the standards, used to calculate the calibration curve 
equation (see Figure A.2) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Peak area 
200 2260.1 2264 2275.2 2266.4 7.84 0.35 
100 1139.3 1137 1136.4 1137.6 1.53 0.13 
50 569.7 566.2 567.2 567.7 1.80 0.32 
20 227.1 228.5 225.9 227.2 1.30 0.57 
10 114.7 115.1 114.7 114.8 0.23 0.20 
2 23 22.5 22.7 22.7 0.25 1.11 
0.2 2.1 2.3 2.3 2.2 0.12 5.17 
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Figure A.2 Calibration curve plotted from the data listed in Table A.5 
The following characteristics of the HPLC method for assay of NA were evaluated and 
compared with the ICH Guidance recommendations. 
A.1.2.2 Specificity  
The specificity of the analytical method is the ability to assess without any doubt the 
compound of interest in the sample that is analysed. It means that the presence of other 
chemicals from the sample matrix or introduced during the sample preparation do not affect 
the performance of the analysis. 
To assure specificity of the HPLC method which is being validated two representative 
chromatograms provided in Figure A.3 and Figure A.13 were compared. No interference is 
expected in the analysis from the matrix present in the sample, since the blank sample gives a 
steady baseline reading throughout the analysis time, with no peaks visible at the retention 
time of NA. The discrimination between the blank and standard sample is easy to perform as 
can be seen in the examples shown below. The analyte shows no interference from other 
sample components. 
 
Figure A.3 Chromatogram of a standard sample used for optimisation and validation of HPLC method 
for nicotinamide assay 
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Figure A.4 Chromatogram of a blank sample (no drug added) used for optimisation and validation of 
HPLC method for nicotinamide assay 
A.1.2.3 Accuracy  
Accuracy measures the closeness of the experimental value to the ‘true’ value and should be 
established across the specified range of the analytical method. According to both the EMEA 
and FDA guidelines accuracy should be assessed using a minimum of 3 sample concentration, 
each analysed in triplicate. For the purpose of this validation accuracy has been established for 
all the standards analysed. Each standard was analysed in triplicate on the same day. Data 
from the HPLC chromatograms used for the purpose of accuracy determination are shown in 
Table A.6.  
Table A.6 Peak areas obtained from the chromatograms of nicotinamide standard samples 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Peak area 
200 2260.1 2264 2275.2 2266.4 7.84 0.35 
100 1139.3 1137 1136.4 1137.6 1.53 0.13 
50 569.7 566.2 567.2 567.7 1.80 0.32 
20 227.1 228.5 225.9 227.2 1.30 0.57 
10 114.7 115.1 114.7 114.8 0.23 0.20 
2 23 22.5 22.7 22.7 0.25 1.11 
0.2 2.1 2.3 2.3 2.2 0.12 5.17 
 
The calculated recovery values from the calibration curve obtained on the day of analysis 
(calibration curve 1) and on the next day (calibration curve 2) are listed in Table A.7 and Table 
A.8 and plotted in Figure A.5 and Figure A.6 respectively. 
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Table A.7 On-the-day accuracy of HPLC method for nicotinamide assay 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Calculated concentration [µg/mL] 
200 199.30 199.65 200.64 199.86 0.69 0.35 
100 100.43 100.23 100.17 100.28 0.14 0.13 
50 50.18 49.87 49.96 50.00 0.16 0.32 
20 19.96 20.08 19.85 19.96 0.11 0.58 
10 10.04 10.08 10.04 10.05 0.02 0.20 
2 1.95 1.91 1.92 1.93 0.02 1.15 
0.2 0.11 0.12 0.12 0.12 0.01 8.63 
 
 
Figure A.5 On-the-day accuracy of HPLC method for nicotinamide assay 
 
y = x + 5E-14 
R² = 1 
0
50
100
150
200
250
0 50 100 150 200 250St
an
d
ar
d
 c
o
n
ce
n
tr
at
io
n
 c
al
cu
la
te
d
 
fr
o
n
 t
h
e
 c
al
ib
ra
ti
o
n
 c
u
rv
e
 [
u
g/
m
L]
 
Standard concentration [ug/mL] 
Appendices 
202 
 
Table A.8 Between-days accuracy of HPLC method for nicotinamide assay 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Calculated concentration [µg/mL] 
200 201.86 202.21 203.21 202.42 0.70 0.35 
100 101.73 101.52 101.47 101.57 0.14 0.13 
50 50.84 50.53 50.62 50.66 0.16 0.32 
20 20.23 20.36 20.12 20.24 0.12 0.57 
10 10.19 10.23 10.19 10.20 0.02 0.20 
2 2.00 1.95 1.97 1.97 0.02 1.14 
0.2 0.13 0.15 0.15 0.14 0.01 7.27 
 
 
Figure A.6 Between-days accuracy of HPLC method for nicotinamide assay 
An ideal accuracy curve (an example of which is shown in Figure A.5) should follow the linear 
equation 𝑦 = 𝑎𝑥 + 𝑏 and the slope (a) value should be as close to 1 as possible with the 
intercept value (b) approaching 0. The kinearity of the curve is expressed as the R2 value, which 
should be close to 1. Figure A.5 and Figure A.6 illustrate that the validated HPLC method 
complies very well with these criteria. Accuracy can be expressed as the difference between 
the mean and the accepted true value. It provides information on the systematic error of the 
method. For the whole range of concentrations the difference should not be higher than 10% 
(at the same day) or 15% (between days). 
% 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
𝐶𝑥 − 𝐶𝑠𝑡
𝐶𝑠𝑡
 
Equation A.6 
y = 1.01x + 0.02 
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Where: 
𝐶𝑥 - Concentration calculated from the calibration curve 
𝐶𝑠𝑡 - True concentration of a standard 
The accuracy of the HPLC method subject to validation was calculated with the equation above 
and summarised in Table A.9 and Table A.10. 
 
Table A.9 Summary of on-the-day accuracy of the HPLC method for nicotinamide assay 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
% Accuracy 
200 -0.35 -0.18 0.32 -0.07 0.35 -506.10 
100 0.43 0.23 0.17 0.28 0.14 48.93 
50 0.36 -0.26 -0.08 0.01 0.32 5383.22 
20 -0.22 0.40 -0.75 -0.19 0.57 -297.97 
10 0.40 0.75 0.40 0.52 0.20 39.52 
2 -2.49 -4.70 -3.82 -3.67 1.11 -30.24 
0.2 -46.83 -38.01 -38.01 -40.95 5.09 -12.44 
 
Table A.10 Summary of between-days accuracy of the HPLC method for nicotinamide assay 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
% Accuracy 
200 0.93 1.10 1.60 1.21 0.35 28.90 
100 1.73 1.52 1.47 1.57 0.14 8.70 
50 1.68 1.05 1.23 1.32 0.32 24.40 
20 1.16 1.78 0.62 1.19 0.58 49.00 
10 1.90 2.25 1.90 2.01 0.21 10.24 
2 -0.14 -2.37 -1.48 -1.33 1.12 -84.41 
0.2 -35.00 -26.07 -26.07 -29.04 5.16 -17.76 
 
The majority of the ranges of concentrations complies with the recommended limits. Only the 
readings for the lowest concentrations give higher percentage of recovery, when calculated 
from the calibration curve, which is typical for HPLC methods. This concentration is considered 
as a detection limit for the method. 
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A.1.2.4 Precision  
Precision represents the closeness of the values obtained for a series of measurements of the 
same sample under the same conditions. In other words, it presents the degree of scatter 
between the readings. The more similar the results obtained, the more precise is the method. 
Precision increases with the concentration of the analyte, thus it provides information on the 
random errors. Usually the precision of a method is expressed as variance, standard deviation 
(SD) or relative standard deviation in % (RDS) 
The European and United States guidelines divide the term of precision into three different 
levels: 
 Repeatability - i.e. precision under the same conditions and during the same day of 
analysis, also termed intra-assay precision or same-day precision. 
 Intermediate precision - evaluates variations within the same laboratory: different 
days, different equipment, and different analysts. Determination of this characteristic 
of the method assures that the results obtained with this method will be the same for 
the similar samples after method is developed. 
 Reproducibility - is the precision between laboratories and if intermediate precision is 
established it is not necessary to include this characteristic in the method validation. 
For the purpose of this validation repeatability and intermediate precision were established on 
the basis of EMEA and FDA recommendations. 
Table A.11 Peak areas obtained from chromatograms of three standards analysed in triplicate used to 
determine repeatability of HPLC method expressed as SD and RSD 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Peak area 
200 2260.1 2264 2275.2 2266.4 7.84 0.35 
50 569.7 566.2 567.2 567.7 1.80 0.32 
10 114.7 115.1 114.7 114.8 0.23 0.20 
 
Repeatability was assessed by injection of three standards of high, medium and low 
concentration and each standard was analysed in triplicate. For the whole range of 
concentrations RSD should not be higher than 10%. Table A.11 summarises the results of 
repeatability determination. All the values meet the criteria stated in the guidelines. 
Intermediate precision was assessed for two separate occasions: between two consecutive 
days and between two HPLC chromatographs of the same brand. Three standards of high, 
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medium and low concentrations were analysed in triplicate and the precision of the readings 
from each assay was compared in terms of SD and RSD [%]. Table A.12 and Table A.13 
summarise the results, which are in agreement with recommendations, i.e. RSD should not 
exceed 15%. 
Table A.12 Intermediate precision between days (the same chromatograph, different day) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Peak area 
200 2230.9 2238.6 2242.1 2237.2 5.73 0.26 
50 561.3 563.2 562.2 562.2 0.95 0.17 
10 112.1 111.5 111.9 111.8 0.31 0.27 
 
Table A.13 Intermediate precision between instruments (different HPLC chromatograph) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Peak area 
200 2390.6 2414.3 2413 2406.0 13.32 0.55 
50 600.8 601.4 601.2 601.1 0.31 0.05 
10 117 117.3 117.2 117.2 0.15 0.13 
 
A.1.2.5 Linearity  
Linearity is the ability of the analytical method (in the defined range) to give a response 
proportional to the concentration of the analyte in the samples. It is the range of the 
calibration curve, where the signal exhibits a linear correlation with the concentrations of the 
standards. If the correlation is linear the results could be calculated with the use of statistical 
methods such as the least squares regression. The linear range of HPLC methods with UV 
detection established according to Beer’s Law is dependent on the analyte and the detector. 
All the samples analysed should fall in the linear range, hence the linearity of the method is 
established by the analysis of at least 5 standards of different concentrations, which represent 
the range of 50-150% (sometimes 0-200%) of the expected values of the samples to be 
analysed [3]. To establish linearity of the method three calibration curves obtained during 
validation process were plotted by calculation of a regression lines by the method of least 
squares. Data from the regression lines were used to assess the linearity. The squared 
correlation coefficients (R2), y-intercept (b) and slope (a) of each regression line were 
compared. The slope of calibration curve is the measure of method sensitivity - the higher the 
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value of the slope the higher the sensitivity of the method. RSD of the slope values for 
calibration curves should not be higher than 15%. In practice R2 should not be less than 0.999. 
These data are summarised in Table A.14 and a representative calibration curve is shown in 
Figure A.7. In general, all the calibration curves have low SD and RSD values for determined 
slopes and the R2 value falls within the recommended limit. 
Table A.14 Summary of linearity evaluation of the method 
 Slope Intercept R
2
 
Calibration curve 1 11.34 0.89 1.00 
Calibration curve 2 11.19 0.64 1.00 
Calibration curve 3 11.29 -0.75 1.00 
Average 11.27 0.26 1.00 
SD 0.07 0.89 0.00 
RSD [%] 0.64 337.34 0.00 
 
 
Figure A.7 Representative calibration curve for linearity of the method evaluation 
 
A.1.2.6 Range  
The range of the analytical method is defined as the interval between the upper and lower 
concentration of the sample for which the method is validated. This parameter is derived from 
the linearity of the method. It depends on the purpose of the assay and is established by 
confirming that the analytical method is linear, accurate and precise within the specified 
range.  
The working range of the validated HPLC method for NA assay was established to be 2-
200μg/mL (16.35-1635.32nmol/mL) and the linearity in this range is illustrated in Figure A.7. 
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A.1.2.7 Detection limit  
The detection limit is the lowest amount of a compound of interest in a sample which can be 
detected, but not necessarily quantified. There are several ways for determination of this 
parameter and for the purpose of this validation one was chosen. Based on the visual 
evaluation of the chromatograms and the ability of the integrator to quantify the signal, the 
lowest concentration (0.2μg/mL) was taken as the detection limit for the validated method. A 
relevant chromatogram illustrating the detection limit of the method is presented in Figure 
A.8. 
 
Figure A.8 Representative chromatogram of a standard sample of a concentration of 0.2μg/mL of 
nicotinamide 
 
A.1.2.8 Quantitation limit  
The quantitation limit is the lowest amount of a compound of interest in a sample which can 
be quantified with suitable precision and accuracy. As with the detection limit, there are 
several ways of determination of this characteristic and for the purpose of this validation one 
was chosen. Based on the visual evaluation of the chromatograms and the data obtained 
during the whole validation process a concentration of 2μg/mL was taken as a quantitation 
limit for the validated method. An example of a relevant chromatogram is presented in Figure 
A.9. 
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Figure A.9 Representative chromatogram of a standard sample of a concentration of 2μg/mL of 
nicotinamide 
 
A.1.2.9 Robustness 
The ability of a method to remain unaffected by small variations in analytical parameters is 
very important. Robustness indicates that the method is reliable during its normal use. For this 
work the robustness of the validated HPLC method was assured by good system suitability 
specifications. For the purpose of this validation the robustness of the method was checked 
using two parameters: 
 Sample solution stability (samples in PBS), 
 Change of solvent used to prepare the samples (samples in the mobile phase). 
Sample solution stability was evaluated as an important parameter for the future use of the 
method. Three standards of high, medium and low concentrations were prepared on the first 
day of validation and samples of them were kept in two different environmental conditions (in 
the fridge in 4°C and in the room temperature) and analysed on the day of preparation, after 1, 
2, 4, 7 and 14 days. The concentration of each sample was calculated using a calibration curve 
prepared on the day of analysis. The calculated concentration values obtained after different 
sample treatments are summarised in Table A.15 and Table A.16.  
Table A.15 Results of stability of the standard solutions studies for the samples kept at 4°C 
Day after standard preparation 0 1 5 7 14 
Nominal standard concentration [µg/mL] % of initial standard concentration 
200 99.91 99.05 99.47 101.80 97.26 
50 100.34 99.57 99.97 101.94 98.22 
10 99.33 100.15 100.59 101.51 98.72 
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Table A.16 Results of stability of the standard solutions studies for the samples kept at room 
temperature 
Day after standard preparation 0 1 5 7 14 
Nominal standard concentration [µg/mL] % of initial standard concentration 
200 99.91 99.47 98.23 99.22 65.58 
50 100.34 99.37 96.81 93.90 25.91 
10 99.33 99.36 83.83 64.59 0.00 
 
 
Figure A.10 Stability of standards in PBS - % of the initial sample concentration for 200, 50 and 
10μg/mL standards kept at room temperature (~25°C) and in the fridge (~4°C) 
The results shown above confirm that the samples are stable in the solvent used for their 
preparation for 14 days when kept at 4°C but not stable at room temperature (approximately 
25°C), which implies, that samples should be analysed on the day of their acquisition or kept in 
the fridge for no longer than 14 days. 
The method robustness with respect to the change of solvent used to prepare standard and 
samples was evaluated by analysing three standards of high, medium and low concentrations 
prepared in the mobile phase. Standard concentration values were determined using a 
calibration curve prepared in PBS on the day of analysis. The results are shown in Table A.17 
and  
Table A.18 details the method robustness to the change of solvent used to prepare samples. 
Table A.17 Peak areas obtained from the assay of the standards prepared in the mobile phase used 
for determination of method robustness 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[µg/mL] 
Peak area 
200 2262.2 2260 2270.3 2264.17 5.42 0.24 
50 561.5 561.4 557.8 560.23 2.11 0.38 
10 112.4 111.8 112.1 112.10 0.30 0.27 
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Table A.18 Concentrations calculated for the peak areas shown in Table A.17 from the calibration 
curve obtained on the same day 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[μg/mL] 
Calculated concentration 
[µg/mL] 
200 202.05 201.85 202.77 202.22 0.48 0.24 
50 50.11 50.10 49.78 49.99 0.19 0.38 
10 9.98 9.93 9.96 9.96 0.03 0.27 
 
The stability of the samples prepared in the mobile phase was evaluated in the same manner 
as the stability of the samples in PBS. Figure A.11 summarises the results of the stability 
testing. The results indicate that samples prepared in the mobile phase are stable both at 
room temperature and at 4°C for 14 days after sample preparation.  
 
Figure A.11 Stability of standards in mobile phase - % of the initial sample concentration for 200, 50 
and 10μg/mL standards kept at room temperature (~25°C) and in the fridge (~4°C) 
 
A.1.2.10 Summary of the validation procedure 
According to the recommendations utilised as guidelines for performing the validation of the 
analytical procedure of NA analysis with HPLC, the validated method meets the requirements 
of EU and US legislation and may be utilised for the purpose of the experimental work in this 
thesis. The validation characteristics are listed below. 
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Table A.19 Summary of the validation characteristics for the HPLC method for nicotinamide assay 
Parameter Value Recommendation 
Accuracy [%] on the day < 10% 
*excluding 0.2μg/mL 
standard 
< 10% 
Accuracy [%] between days < 15% 
*excluding 0.2μg/mL 
standard 
< 15% 
Repeatability (RSD) < 10% < 10% 
Intermediate precision (RSD) < 15% < 15% 
Linearity (Average R
2
 value) 0.9999 > 0.999 
Linearity (RSD of slopes values) 1.05% < 15% 
Range 2 - 200μg/mL - 
Detection limit 0.2μg/mL - 
Quantitation limit 2μg/mL - 
Robustness Sample stable for 14 days  at 
4°C; 
Samples robust to the 
change of solvent 
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A.2 Optimisation and validation of GC methods for solvents assay 
GC was chosen as an appropriate analytical method for solvent analysis. The GC system 
parameters, analysis conditions and equipment used aredetailed in Table A.20. 
Table A.20 Parameters of the GC methods for solvent quantification 
Column Agilent 19091J-413; 325°C; 30mx320µmx0.25µm 
GC System Agilent Technologies 7890A GC system with FID detector 
Software for chromatograms analysis OpenLAB software; ChemStation Edition for GC Systems,  
Copyright
© 
Agilent Technologies 2001-2012, 
Injection Volume: 1 μL, Sample Pumps: 6, Injection type: L1 air gap 0.2 µL 
Inlet Heater: 250°C, Septum purge flow 3mL/min, Split 25:1, gas: 
nitrogen 
Flow 1.2 mL/min (for PG 3.5mL/min) 
Owen temperature Initial 100°C, hold 0min; Ramp rate 30°C/min; Final 280°C, hold 2 
min (for PG initial hold 2 min, final 0 min) 
Detector FID, Heater 300°C, hydrogen flow 35 mL/min, air flow 350 
mL/min, makeup flow (nitrogen) 30mL/min 
Retention time IPM ~5.6, DPPG ~7.3, PGML ~5.7, PGMC ~4.9, PG ~3.8 min 
Analysis time 8min 
Standards 0.005-1 μL/mL (6 standards of the concentrations of 0.005; 0.01; 
0.05; 0.1; 0.5; 1 μL/mL of solvents prepared from a stock solution 
of a concentration of 10μL/mL by dilution with methanol) 
Derivatisation (for PG) Internal standard (IS) (1:1 with the sample) 0.6µmol 1,2-
butanediol in methanol (retention time ~4.3 min) 
Derivatising agent (1:1 with the sample/IS mixture) 40 mmol 
phenylboronic acid (forms complexes with diols) in acetone 
A.2.1 Optimisation of the analysis conditions - system suitability testing 
The summary of system suitability testing is shown in Table A.21. The method was optimised 
according to the CDER recommendations [2]. The representative chromatograms of standard 
solvent samples are shown in Figure A.12. 
Table A.21 System suitability testing of GC methods for solvent assay 
Parameter  
Value calculated for the standard chromatogram CDER 
recommended 
value IPM DPPG PGML PGMC PG 
Capacity factor (k’) 1.7 2.5 1.7 3.9 2.8 k’ > 2 
Peak area repeatability (% RSD) n=6 0.8 1.7 2.8 1.4 0.3 RSD ≤ 1% 
Retention time repeatability (% RSD) n=6 0.1 0.0 0.0 0.0 0.0 RSD ≤ 1% 
Tailing factor (T) 1.0 1.0 1.5 1.5 1.7 T ≤ 2 
Theoretical number of plates (N) 200704 54569 10268 38416 41074 N > 2000 
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a) 
 
b) 
 
c) 
 
d) 
 
e) 
 
Figure A.12 Representative chromatograms of standard samples used for system suitability testing of 
GC methods for solvents assay a) IPM, b) DPPG, c) PGML, d) PGMC, e) PG 
Appendices 
214 
 
A.2.2 Validation of the GC methods for solvent assay 
A.2.2.1 Specificity  
The chromatograms of a blank sample of the receptor fluid and the blank skin extraction 
sample are shown in Figure A.13 and Figure A.14. No interfering peaks were found. 
 
Figure A.13 Chromatogram of a blank sample of the receptor fluid 
 
Figure A.14 Chromatogram of the blank skin extraction sample 
 
A.2.2.2 Calibration curves 
The representative calibration curves for the GC analysis of the solvents are shown below. 
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a) 
 
b) 
 
c) 
 
d) 
 
e) 
 
Figure A.15 Representative calibration curves for solvents GC analysis: a) IPM, b) DPPG, c) PGML, d) 
PGMC, e) PG 
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A.2.2.3 Summary of the validation procedure 
The validation parameters obtained for each of the solvents are listed in the tables below. 
According to the recommendations [1, 2, 4], the methods for solvent analysis meet the 
requirements of EU and US legislation and can be used for the purpose of the experimental 
work conducted during the project. 
Table A.22 Validation characteristics of the GC methods for solvent assay 
Parameter IPM DPPG PGML PGMC PG Recommended 
Accuracy [%]  < 10% for the 
range of 0.16-
3.17 µmol/mL 
< 10% for the 
range of 0.17-
3.35 µmol/mL 
< 10% for the 
range of 0.03-
3.39 µmol/mL 
< 10% for the 
range of 0.21-
4.29 µmol/mL 
< 10% for the 
range of 0.67-
13.39 
µmol/mL 
< 10% 
Repeatability 
(RSD) 
< 15% < 10% < 15% < 10% < 10% < 10% 
Intermediate 
precision 
(RSD) 
< 15% < 15% < 15% < 10% < 10% < 15% 
Linearity 
(Average r
2
) 
0.9989 0.9995 0.9991 0.9994 0.9996 > 0.999 
Linearity 
(RSD of 
slope) 
0.00% 0.04% 0.05% 0.01% 0.06% < 15% 
Range 0.03 - 3.17 
µmol/mL 
0.03 - 3.35 
µmol/mL 
0.03 - 3.17 
µmol/mL 
0.04 - 4.29 
µmol/mL 
0.13 - 13.39 
µmol/mL 
- 
Detection 
limit 
0.02 µmol/mL 0.02 µmol/mL 0.02 µmol/mL 0.02 µmol/mL 0.07 µmol/mL - 
Quantitation 
limit 
0.03 µmol/mL 0.03 µmol/mL 0.03 µmol/mL 0.04 µmol/mL 0.13 µmol/mL - 
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A.3 Choice of receptor phase for in vitro permeation studies 
For lipophilic substances, such as the solvents tested, addition of appropriate solubilisers into 
the hydrophilic receptor phase is necessary to perform a permeation study [5]. The 
recommended solubilisers are ethanol (used as 1:1 mixture with water) or non-ionic 
surfactants, such as polyoxyethylene (20) oleyl ether (PE(20)OE) typically added to the 
receptor phase at 6% w/v concentration [6]. According to the OECD guidelines, the solubility of 
tested compounds in the receptor fluid should be adequate, so that sink conditions are 
maintained throughout the study [7]. 
The solubility of chosen solvents in a 1:1 ethanol:water mixture and 6% PE(20)OE in phosphate 
buffered saline (PBS) was tested after 48h equilibration at 32°C and quantified by GC. 6% 
PE(20)OE in PBS was chosen as an appropriate receptor phase for the permeation studies 
because of its superior solubilising properties for the majority of the solvents tested. The 
comparison between the two receptor phases tested is shown in Figure A.16. 
 
Figure A.16 Solubility of chosen solvents in 6% polyoxyethylene (20) oleyl ether and in 1:1 
ethanol:water mixture, 32 ± 1 °C, mean ± SD, n=3 
For all of the solvents tested, the solubility in 6% PE(20)OE was high enough to maintain sink 
conditions throughout the permeation study [8]. Moreover, addition of 50% ethanol into the 
receptor phase may lead to a decrease in barrier properties of the membranes tested [6]. 
Thus, 6% PE(20)OE in PBS was used as a receptor phase in the permeation studies. 
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A.4 Mass balance protocol validation 
A.4.1 Mass balance protocol for finite dose silicone permeation study - prototype 
formulations 
Prior to cell disassembly, the membrane was washed with 1mL of 6% polyoxyethylene (20) 
oleyl ether (PE(20)OE) and rubbed thoroughly with a cotton bud dipped in the washing 
solution. The cotton bud was then added into the washing fraction and extracted for 1h at 
45°C. Thereafter, the cells were disassembled. The membrane was placed in an Eppendorf vial 
and extracted with 1mL of purified water for 1h at 45°C in an orbital incubator (Stuart 
Scientific, UK). Appropriate aliquots of the washing and extraction samples were taken for 
dilution and further HPLC analysis. 
The mass balance procedure was validated prior to the studies. The experiment was 
performed in triplicate. For the membrane washing validation, a known amount of the DENI 
formulation was applied to the donor compartment of the assembled Franz cells. Immediately 
after the application (before the drug partition into the membrane) the membrane was 
washed with 1mL of 6% PE(20)OE and rubbed thoroughly with a cotton bud dipped in the 
washing solution. The cotton bud was then added into the washings and extracted for 1h at 
45°C. The recovery obtained in the washing procedure validation was 104.03±4.62% (n=3). 
For the membrane extraction validation, a known amount of the DENI formulation was applied 
to the donor compartment of the assembled Franz cells (without the receptor fluid) and left 
for 2 hours allowing drug partitioning into the membrane. Thereafter, the cells were 
disassembled. The membrane was placed in an Eppendorf vial and extracted with 1mL of 
purified water for 1h at 45°C. The recovery obtained for the extraction procedure validation 
was 102.09±1.56% (n=3). 
The validation results indicate that the recovery is good for both washing and extraction 
procedures and is in line with the recommended range [7]. Thus, this method of membrane 
washing and extraction can be used in further studies for the assessment of the drug mass 
balance in the receptor phase, the donor compartment and the silicone membrane. 
A.4.2 Mass balance protocol for finite dose pig ear permeation study - prototype 
formulations 
The membrane washing and extraction procedures were performed using a protocol similar to 
the mass balance study described in section 4.2.8.1. The membrane was washed with 1mL of 
6% PE(20)OE and rubbed thoroughly with a cotton bud dipped in the washing solution. The 
cotton bud was added to the washing solution and extracted for 1h at 45°C. Cells were 
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disassembled and the full thickness pig ear skin was separated into epidermis and dermis prior 
to the extraction procedure. This was done to enable assessment of NA retention in different 
skin layers. The epidermis was separated from the dermis using a dry heat separation method 
described by previous authors [9-11]. Skin samples were subject to a hot air treatment at a 
temperature of 50°C for 30 seconds followed by the removal of the epidermis with a surgical 
scalpel. The temperature and the time of the hot air treatment were controlled (DigitronTM-22 
Thermometer, RS Components, UK and Traceable® Extra - Extra Loud Timer, Fisher Scientific, 
UK). The epidermis and the dermis were placed in pre-weighed Eppendorf vials and the mass 
of the membrane was determined. This was followed by epidermis and dermis extraction with 
1mL of purified water for 1h at 45°C. Appropriate aliquots of the washing and extraction 
samples were taken for dilution and further HPLC analysis. 
The mass balance procedure was validated prior to the studies. The experiment was 
performed in triplicate. A blank sample, where no drug was applied to the skin, was included in 
the validation. For the skin washing validation, a known amount of the DENI formulation was 
applied to the donor compartment of the assembled Franz cells. Immediately after the 
application, the membrane was washed 3 times (W1, W2, W3) with 1mL of 6% PE(20)OE and 
rubbed thoroughly with a cotton bud dipped in the washing solution. The cotton bud was then 
extracted in 1 mL of the washing solution for 1h at 45°C. The recovery for the first wash 
obtained in the validation procedure was 116.60±10.91% (n=3). Thus, in later studies skin was 
washed once with 1mL of 6% PE(20)OE. No drug was found in the extracts from the cotton 
bud. Nevertheless, this step of the washing procedure was included in the further studies to 
ensure that no drug remains on the skin surface before extraction. No NA was found in the 
blank samples. 
For the membrane extraction validation, the epidermis and the dermis samples were spiked 
with a known amount of NA. The drug was applied to the separated membranes in an aqueous 
solution. The solution was allowed to dry entirely prior to the extraction. Samples were 
extracted with 1mL of purified water for 1h at 45°C. Appropriate aliquots of the extraction 
samples were taken for dilution and further HPLC analysis. The experiment was performed in 
triplicate for three different amounts of NA applied to the skin. High recovery values were 
obtained for the epidermis extraction and lower values were found for the dermis extraction 
(Table A.23). However, further experiments showed that the total recovery of the mass 
balance procedure is satisfactory.  
Two different formulations were applied to the skin surface: 4% aqueous NA solution and 4% 
DENI formulation (n=3 for both formulations). After 2 hours, the mass balance procedure was 
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performed. The total recovery obtained was 87.59±5.81% and 84.35±10.15%, for the solution 
and DENI formulation respectively. The total recovery is in the recommended range [12]. Thus, 
this method of membrane washing and extraction can be used in further studies for the 
assessment of the drug mass balance in the receptor phase, the donor compartment, the 
epidermis and the dermis. 
Table A.23 Skin extraction validation (mean ± SD, n=3) 
Amount of NA applied [µg] Epidermis recovery [%] ± SD Dermis recovery [%] ± SD 
40 99.18 ± 3.31 83.40 ± 8.70 
100 97.93 ± 1.19 76.24 ± 6.44 
200 96.70 ± 1.02 75.09 ± 7.07 
A.4.3 Mass balance protocol for finite dose silicone permeation study - simple 
solvent systems 
Prior to cell disassembly, the membrane was washed with 1mL of 6% PE(20)OE and rubbed 
thoroughly with a cotton bud dipped in the washing solution. The cotton bud was then added 
into the washing fraction and extracted for 1h at 45°C. Thereafter, the cells were 
disassembled. The membrane was placed in the Eppendorf vial and extracted with 1mL of 
methanol for 1h at 45°C in an orbital incubator (Stuart Scientific, UK). Appropriate aliquots of 
the washing and extraction samples were taken for dilution and further HPLC analysis. 
The mass balance procedure was validated prior to the studies. The experiment was 
performed in triplicate. For the membrane (pig ear skin) washing validation, 10 µL of saturated 
NA solution in PG was applied to the donor compartment of the assembled Franz cells. 
Immediately after the application the membrane was washed with 1mL of 6% PE(20)OE and 
rubbed thoroughly with a cotton bud dipped in the washing solution. The cotton bud was then 
added into the washings and extracted for 1h at 45°C. The recovery obtained in the washing 
procedure validation was 97.29 ± 5.34% (n=3). 
PG was chosen as the solvent in which the solubility of NA is the highest from the solvents 
tested. Thus, high recovery obtained using this solvent should indicate that the mass balance 
protocol was valid for solvents with less drug dissolved. For the membrane (pig ear skin) 
extraction validation, 10 µL of saturated NA solution in PG was applied to the donor 
compartment of the assembled Franz cells (without the receptor fluid) and left for 2 hours to 
allow for drug partitioning into the membrane. Thereafter, the membrane was washed with 
1mL of 6% PE(20)OE and rubbed thoroughly with a cotton bud dipped in the washing solution. 
The cotton bud was then added into the washings and extracted for 1h at 45°C. The cells were 
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disassembled and the membrane was placed in the Eppendorf vial and extracted with 1mL of 
methanol for 1h at 45°C. The recovery obtained in the extraction procedure validation was 
100.53 ± 3.88 % (n=3). 
The validation results indicate that the recovery is good for both washing and extraction 
procedures and is in line with the recommended range [7]. Thus, this method of membrane 
washing and extraction may be used in further studies for the assessment of the drug mass 
balance between the receptor phase, the donor compartment and a model membrane. 
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A.5 Optimisation and validation of HPLC method for AMC assay  
HPLC was chosen as an appropriate analytical method for the aminomethyl coumarin (AMC) 
assay in the samples obtained during studies performed for the purpose of this project. The 
HPLC system parameters, optimal analysis conditions and equipment used in analysis are listed 
in Table A.24. 
Table A.24 Parameters of the HPLC method for AMC quantification 
Column Symmetry Shield RP18, 5µm, 4.6x150mm  
(Waters, Milford, MA, USA) 
Guard column SecurityGuard Cartridge System with C18 (ODS, Octadecyl) 
4mmLx3mm filter (Phenomenex, USA) 
HPLC System HP Series 1050 quaternary pump, HP Series 1050 autosampler, HP 
series 1100 degasser, Waters 470 Fluorescence Detector 
Software for chromatograms analysis PRIME software 
Ver.4.2.0., HPLC Technology Co. Ltd, UK 
Mobile phase 1 Acetonitrile:Water:Trifluoroacetic acid (30:70:0.1, v/v/v) KLK5 
Mobile phase 2 Acetonitrile:Water:Trifluoroacetic acid (25:75:0.1, v/v/v) TRY, PLA 
Mobile phase 3 Acetonitrile:Water:Trifluoroacetic acid (20:80:0.1, v/v/v) KLK7 
Injection volume 20μL 
Flow rate 1 mL/min 
Temperature control 40deg.C 
Fluorescence detection wavelength 442nm for emission 
354nm for excitation 
Retention time of AMC ~3min 
Analysis time ~6min 
Calibration curve range 1-10ng/mL (5 standards of the concentrations of 1; 2,5; 5; 7,5; 
10ng/mL of AMC prepared from a stock solution of a concentration of 
1000ng/mL by dilution with reaction buffer) 
A.5.1 Optimisation of the analysis conditions - system suitability testing 
The representative chromatograms of a standard sample are shown in Figure A.12 and the 
terms determined from this chromatogram are listed in Table A.25. 
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a) 
 
b) 
 
c) 
 
Figure A.17 Representative chromatograms of a standard sample used for the  HPLC method for the 
AMC assay (standard prepared in reaction buffer at a concentration of 1ng/mL with the use of  
reference standard AMC); a) mobile phase 1, b) mobile phase 2, c) mobile phase 3 
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Table A.25 The terms for system suitability parameter calculations defined from the chromatograms 
of a standard sample of AMC 
Term 
Value [min] 
Mobile phase 1 Mobile phase 2 Mobile phase 3 
W0.05 0.46 0.54 0.62 
W0.1 0.38 0.42 0.54 
W0.5 0.15 0.15 0.15 
f0.1 0.23 0.27 0.35 
t0 1.46 1.54 1.54 
tR  3.13 3.67 4.73 
tW 0.27 0.23 0.35 
 
Table A.26 Injection repeatability for a standard sample of a concentration of 1ng/mL of AMC;  
a) mobile phase 1, b) mobile phase 2, c) mobile phase 3 
a) 
Injection 1 2 3 Average SD RSD [%] 
Peak area 10.83 11.05 10.77 10.88 0.14 1.33 
Retention time 3.13 3.13 3.13 3.13 0.00 0.00 
 
b) 
Injection 1 2 3 Average SD RSD [%] 
Peak area 9.65 9.73 10.22 9.87 0.31 3.09 
Retention time 3.67 3.68 3.68 3.67 0.00 0.13 
 
c) 
Injection 1 2 3 Average SD RSD [%] 
Peak area 8.97 8.98 8.92 8.96 0.03 0.36 
Retention time 4.74 4.75 4.74 4.74 0.00 0.10 
 
A.5.1.1 Summary of the system suitability testing procedure 
The summary of system suitability test parameters is shown in Table A.21. 
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Table A.27 Summary of system suitability test parameters for HPLC method for AMC assay 
Parameter  
Value calculated for the standard chromatogram CDER 
recommended 
value Mobile phase 1 Mobile phase 2 Mobile phase 3 
Capacity factor (k’) 1.14 1.38 2.07 k’ > 2 
Injection repeatability (RSD) 
n=3 
    
Peak area 1.33 3.09 0.36 RSD ≤ 1% 
Retention time 0.00 0.13 0.10 RSD ≤ 1% 
Tailing factor (T) from W0.5 1.00 1.00 1.00 T ≤ 2 
Theoretical number of plates 
(N) 
2156 4040 2986 N > 2000 
 
A.5.2 Validation of the HPLC method for AMC assay 
A.5.2.1 Calibration curves 
During the validation process calibration curves were obtained on each day of validation by 
HPLC analysis of each standard performed at least in triplicate. The average areas of the peaks 
obtained for each standard were plotted against the concentrations of the standards and the 
calibration curve equation was calculated with the method of least squares. Table A.28 
contains the representative data used to plot the calibration curves, which is shown in Figure 
A.18. 
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Table A.28 Data obtained from HPLC analysis of the AMC standards, used to calculate the calibration 
curve equations; a) mobile phase 1, b) mobile phase 2, c) mobile phase 3 
a) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
Peak area 
10 110.52 105.70 104.17 106.80 3.32 3.11 
7.5 78.98 78.81 79.35 79.05 0.27 0.35 
5 54.24 54.27 53.94 54.15 0.18 0.34 
2.5 26.38 25.70 25.89 25.99 0.35 1.35 
1 10.83 11.05 10.77 10.88 0.14 1.33 
 
b) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
Peak area 
10 96.52 10 96.52 96.32 0.35 0.37 
7.5 74.38 7.5 74.38 73.79 0.55 0.74 
5 49.86 5 49.86 50.62 0.68 1.34 
2.5 24.19 2.5 24.19 23.87 0.28 1.16 
1 9.65 1 9.65 9.87 0.31 3.09 
 
c) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
Peak area 
10 96.61 10 96.61 94.15 2.29 2.43 
7.5 71.08 7.5 71.08 70.14 0.82 1.16 
5 48.46 5 48.46 48.63 0.70 1.44 
2.5 23.25 2.5 23.25 22.93 0.67 2.94 
1 8.97 1 8.97 8.96 0.03 0.36 
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a) 
 
b) 
 
c) 
 
Figure A.18 Calibration curve for AMC standards plotted from the data listed in Table A.28; a) mobile 
phase 1, b) mobile phase 2, c) mobile phase 
 
A.5.2.2 Specificity  
To assure specificity of the HPLC method to be validated two representative chromatograms 
were compared. No interference is expected in the analysis from the matrix present in the 
sample, since the blank sample gives a steady baseline reading throughout the analysis time, 
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with no peaks visible at the retention time of AMC. Blank sample was prepared in the same 
manner as the samples for protease activity measurements with the exception of no substrate 
addition to the reaction mixture. The discrimination between the blank and standard sample 
was easy to perform. The analyte peak had no interference from other sample components. 
A.5.2.3 Accuracy  
For the purpose of this validation accuracy has been established for all the standards analysed. 
Each standard was analysed in triplicate on the same day. The calculated recovery values from 
the calibration curve obtained on the day of analysis are listed in Table A.29 and plotted in 
Figure A.19, which confirms that the validated HPLC method falls very well into these criteria. 
The accuracy of the HPLC method subject to validation is summarised in Table A.30. For the 
whole range of concentrations accuracy complies with the recommended limits. 
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Table A.29 On-the-day accuracy of HPLC method for AMC; a) mobile phase 1, b) mobile phase 2, c) 
mobile phase 3 
a) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
Calculated concentration [ng/mL] 
10 9.99 9.90 9.93 9.94 0.04 0.43 
7.5 7.55 7.54 7.58 7.56 0.02 0.30 
5 4.92 5.15 5.09 5.05 0.12 2.44 
2.5 2.51 2.48 2.44 2.48 0.04 1.41 
1 0.99 1.03 0.90 0.97 0.07 7.20 
 
b) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
Calculated concentration [ng/mL] 
10 9.91 9.85 9.91 9.89 0.04 0.37 
7.5 7.63 7.55 7.51 7.56 0.06 0.74 
5 5.09 5.23 5.20 5.17 0.07 1.36 
2.5 2.44 2.39 2.39 2.41 0.03 1.18 
1 0.94 0.95 1.00 0.96 0.03 3.28 
 
c) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
Calculated concentration [ng/mL] 
10 10.24 9.94 9.76 9.98 0.24 2.43 
7.5 7.54 7.38 7.40 7.44 0.09 1.16 
5 5.15 5.25 5.10 5.17 0.07 1.44 
2.5 2.48 2.49 2.36 2.45 0.07 2.92 
1 0.97 0.97 0.97 0.97 0.00 0.35 
 
Appendices 
230 
 
a) 
 
b) 
 
c) 
 
Figure A.19 On-the-day accuracy of HPLC method for AMC; a) mobile phase 1, b) mobile phase 2, c) 
mobile phase 3 
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Table A.30 Summary of on-the-day accuracy of the AMC quantification HPLC method; a) mobile phase 1, b) 
mobile phase 2, c) mobile phase 3 
a) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
% Accuracy 
10 -0.12 -0.95 -0.74 -0.61 0.43 -71.33 
7.5 0.71 0.47 1.06 0.75 0.30 39.69 
5 -1.68 3.07 1.83 1.07 2.46 229.65 
2.5 0.33 -0.71 -2.44 -0.94 1.40 -149.25 
1 -0.55 3.18 -10.39 -2.59 7.01 -270.88 
b) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
% Accuracy 
10 -0.87 -1.50 -0.86 -1.08 0.37 -33.86 
7.5 1.68 0.71 0.20 0.86 0.75 87.18 
5 1.86 4.54 3.92 3.44 1.40 40.77 
2.5 -2.33 -4.32 -4.30 -3.65 1.14 -31.25 
1 -5.97 -5.12 -0.13 -3.74 3.15 -84.32 
c) 
Injection 1 2 3 
Average SD RSD [%] 
Standard concentration 
[ng/mL] 
% Accuracy 
10 2.39 -0.61 -2.41 -0.21 2.42 -1152.91 
7.5 0.52 -1.60 -1.32 -0.80 1.15 -143.21 
5 2.94 4.94 2.03 3.30 1.49 44.97 
2.5 -0.76 -0.22 -5.41 -2.13 2.85 -133.87 
1 -2.91 -2.82 -3.45 -3.06 0.34 -11.18 
 
A.5.2.4 Precision  
Repeatability was assessed throughout the concentration range of the calibration curves for all 
three mobile phases and each standard was analysed in triplicate. For the whole range of 
concentrations the RSD should not be higher than 10%. All the calculated values meet the 
criteria stated in the guidelines. 
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The intermediate precision of the readings for samples analysed in triplicate was evaluated in 
terms of SD and RSD [%]. The results are in agreement with recommendations, i.e. RSD did not 
exceed 15% for all three mobile phases. 
A.5.2.5 Linearity  
The data for linearity evaluation are summarised in Table A.31 and a representative calibration 
curve is shown in Figure A.20. In general, all the calibration curves have low SD and RSD values 
of the determined slopes and the R2 value falls within the recommended limit. 
Table A.31 Summary of linearity evaluation of the method 
 Slope Intercept R
2
 
Calibration curve 1 10.27 0.86 0.9998 
Calibration curve 2 10.23 1.02 0.9991 
Calibration curve 3 10.65 -0.01 0.9997 
Average 10.38 0.62 0.9995 
SD 0.23 0.56 0.0004 
RSD [%] 2.23 89.49 0.0379 
 
 
Figure A.20 Representative calibration curve for evaluation of the linearity of the method  
 
A.5.2.6 Range 
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A.5.2.7 Quantitation limit  
Based on the visual evaluation of the chromatograms and the data obtained during the whole 
validation process a concentration of 1ng/mL was taken as the quantitation limit for the 
validated method. Relevant chromatograms are presented in Figure A.12. 
A.5.2.8 Robustness 
For the purpose of this validation the robustness of the method was checked for the influence 
of two parameters: 
 Standard solution stability (standards kept at room temperature), 
 Sample solution stability (samples from protease activity measurements kept at 4°C). 
The standard solution stability was evaluated as an important parameter for the future use of 
the method. Two standards of high and low concentrations were prepared on the first day of 
validation. They were kept at room temperature and analysed on the day of preparation, after 
1, 2, 4, 7 and 14 days. The concentration of each sample was calculated with use of the 
calibration curve plotted on the day of analysis. The results are presented in Table A.32 and 
Figure A.21. 
Table A.32 Results of stability of the standard solutions studies for the samples kept in the room 
temperature 
Day after standard preparation 0 1 4 7 14 
Nominal standard concentration [ng/mL] % of nominal standard concentration 
5 101.07 103.33 101.70 102.72 103.06 
1 97.41 95.78 102.30 91.85 100.44 
 
 
Figure A.21 Stability of AMC standards - % of the initial standard concentration for 10, 5 and 1ng/mL 
standards kept at room temperature (~25°C) 
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The results shown above confirm that the standards are stable in the solvent used for their 
preparation for 14 days when kept at room temperature (approximately 25°C). 
Sample solution stability was evaluated for samples from KLK5 protease activity measurements 
kept at 4°C analysed on several days after preparation. The results shown in Table A.33 
indicate that the samples are stable for a period of 6 days. 
Table A.33 Results of stability of the sample solutions studies for the samples kept at a temperature of 
4°C 
Day after sample preparation 0 3 6 13 
Sample from KLK5 protease activity measurements % of initial standard concentration 
1 100.00 91.46 94.56 87.39 
2 100.00 92.17 94.64 86.35 
3 100.00 93.04 100.07 93.67 
 
A.5.2.9 Summary of the validation procedure 
According to the recommended guidelines for performing the validation of the analytical 
procedure of AMC analysis with HPLC, the validated method meets the requirements of EU 
and US legislation and may be utilised for the purpose of the experimental work, which will be 
conducted during the project. The validation characteristics are listed in Table A.34. 
Table A.34 Summary of the validation characteristics for the HPLC method for AMC assay 
Parameter Value Recommendation 
Accuracy [%] on the day < 10% < 10% 
Repeatability (RSD) < 10% < 10% 
Intermediate precision (RSD) < 15% < 15% 
Linearity (Average R
2
 value) 0.9995 > 0.999 
Linearity (RSD of slopes values) 2.23% < 15% 
Range 1 - 10ng/mL - 
Quantitation limit 1ng/mL - 
Robustness 
Standards stable for 14 days 
at room temperature and 
samples stable for 6 days at 
4°C  
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A.6 Ethical approval documentation  
Participant Information Leaflet 
Ref. No A01/2011 
Title: The influence of topical formulation composition on test compound transport into the 
skin and on skin condition 
You are being invited to take part in a research study. This research has been reviewed by the 
National Research Ethics Committee. Before you decide it is important for you to understand 
why the research is being done and what it will involve.  Please take time to read the following 
information carefully. Talk to others about the study if you wish.  
Part 1 tells you the purpose of this study and what will happen to you if you take part.   
Part 2 gives you more detailed information about the conduct of the study.  
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
Part one 
What is the purpose of the Study? 
This research is to investigate the influence of formulation composition on test compound 
permeation through the skin. The study will provide insight into our understanding of the ways 
in which formulation excipients act within the skin to aid permeation. The research will also 
explore ways of assessing associated changes in skin condition, brought about by application of 
these formulations, which may be of future interest when designing improved topically 
administered products developed for a variety of cosmetic and possibly medicinal uses. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep and asked to sign a consent form. You are still free to withdraw at 
any time and without giving a reason. 
If I agree to take part what will I have to do? 
Before testing can begin all participants must have completed Informed Consent Form, Form I 
and Form II. You will be asked to write your name, address and email address in Form I. You 
will be asked to record your gender, ethnic group, age range and skin condition in Form II. 
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You will have 4 application sites measuring approximately 25cm2 demarcated using a 
laminated template and a surgical marker on the left and right volar (underneath) surface of 
your forearms. Normally there will be 2 sites for each arm. 
You will be given four test formulations and asked to apply 50µL of each of them separately to 
the four application sites 3 times each day for a treatment period of 21 days (total of 63 
applications). 1mL syringes (without needles) will be provided for you to measure the amount 
of formulation to apply. You will have to be very careful to make sure you apply each 
formulation to the correct site, and use a different finger to gently massage each formulation 
into the skin to avoid cross contamination. 
You will be asked to complete a Participant Diary, where you will record the dates and times of 
the applications. The Participant Diary is attached to this Participant Information Leaflet. The 
completed Diary will be collected by the investigator on the last day of the study 
(measurements day). 
If you agree to participate you will be asked to refrain from applying any topical products to 
your arms 24 hours prior to the study and throughout the study. There will be no other 
restrictions regarding your normal day to day activities, including the clothing you wear, 
washing, bathing, showering, sports participation etc. 
Measurements day 
After treating the application sites with the test formulations for the 21 day period, a standard, 
semi-invasive technique called skin tape stripping will be used to repeatedly sample layers of 
the outer dead skin which can then be assayed in the laboratory to determine a) the quantities 
of test compound and particular excipients permeated, and b) a variety of biochemical 
markers and/or physical characteristics indicative of skin condition. The latter include 
measuring: protease activity (an enzyme system involved in skin cell turnover); protein content 
(which provides a very sensitive way of estimating the amount of skin cells removed which is 
too small to weigh); and skin cell maturity and size (which provide further indication of the 
quality of the skin). In addition, by non-invasively measuring transepidermal water loss (TEWL) 
at the sites before formulation treatment and at various intervals during stripping, it will be 
possible to obtain more information relating to the integrity and barrier properties of the skin. 
In vivo tape stripping 
This is a routine and minimally invasive procedure that involves the investigator repeatedly 
and gently pressing pieces of adhesive tape on the skin sites and then gently removing them. 
The adhesive tapes remove successive layers of cells from the outermost dead layer of the skin 
(the stratum corneum). Using this procedure the skin at each application site and an untreated 
Appendices 
237 
 
control site (5 sites altogether) will be repeatedly stripped by the investigator up to a 
maximum of 20 times. 
TEWL measurements 
This is a routine and non-invasive procedure that involves the investigator repeatedly and 
gently placing a probe on the test sites for approximately 15 seconds.  This will measure water 
evaporation from the skin and provide a measure of skin permeability. 
These TEWL measurements will be performed at the five test sites after the 21 day treatment 
regimen and will be repeated, during the tape stripping procedure, after every fourth 
stripping. 
What are the potential benefits and disadvantages of taking part in this investigation?  
There are no specific benefits or particular disadvantages to individuals taking part in this 
work. However, the results of the study may lead to future improvements in products 
designed for cosmetic and/or medicinal use. 
All of the techniques used in this study have been used routinely in previous studies. The tape 
stripping technique can feel slightly uncomfortable and subjects will have the opportunity to 
restrict the number taken to less than 20 if they so wish, although this has not been necessary 
in previous work of this sort undertaken in our group. Only ingredients found in commonly 
used products that can be purchased over the counter by the general public will be used in the 
test formulations.  Individuals with known sensitivity to any of the ingredients will be excluded 
from taking part.Participants will not be exposed to significant risk. In the unlikely case of 
negligent or non-negligent harm occurring to a participant during the course of the study, the 
participant will be covered by the School of Pharmacy’s insurance policy. 
In the unlikely event of any adverse events occurring at treatment sites, full details will be 
recorded and appropriate medical advice/treatment arranged. Participants will be able to 
withdraw from the study at any time by giving an oral or written notice to the investigator.  
What if there is a problem?  
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. If you have a concern about any aspect of this study, you 
should ask to speak with the investigator who will do their best to answer your questions 
(Anna Duszyńska Tel. 02077535800 ext. 4870). If you remain unhappy and wish to complain 
formally, you can do this through the Head of the Department of Pharmaceutics at the School 
of Pharmacy (Professor Kevin Taylor).  
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Will my taking part in the study be confidential? 
Yes. All the information about your participation in this study will be kept confidential.  Further 
details about this aspect are included in Part 2. 
Exclusion criteria  
Anyone with any previous or ongoing skin disease will be excluded from the study. Anyone 
who has known sensitivity to any of the formulation ingredients will be excluded, as will 
anyone who is taking or using medication purchased over the counter in pharmacies or 
prescribed by a healthcare practitioner which may have an effect on the skin. This especially 
applies to medicines that are listed by the World Health Organisation (WHO) as affecting skin 
differentiation and proliferation which include Steroids (topical or systemic), Benzoyl peroxide, 
Coal tar, Dithranol, Fluorouracil, Podophyllum resin, Salicylic acid and Urea. Individuals with 
any skin abnormalities (tattoos, birth marks, scars  etc) at the test sites will also be excluded 
from taking part. 
Contact Details: 
You are free to ask any further questions to Anna Duszyńska (investigator) before or after you 
decide to take part (Tel. 02077535800 ext. 4870; e-mail: a.duszynska@live.pharmacy.ac.uk). 
This completes Part 1 of the Information Sheet 
If the information in Part 1 has interested you and you are considering participation, please 
continue to read the additional information in Part 2 before making any decision. 
Part two 
Will my taking part in the study be kept confidential?  
Any personal information about participants (e.g. as disclosed on their signed consent forms) 
will be kept confidential but may be disclosed to appropriately authorised individuals including 
the regulatory authorities and quality assurance/audit personnel. 
Data will be recorded, saved, analysed and reported under participants’ unique study 
identification numbers so that the data remain anonymous. 
Publications 
Presentations/publications resulting from his work will not disclose any personal data. 
Confidentiality policy for research 
The personal information gained in this study will remain confidential and will not be passed 
on to other individuals outside of the research team. 
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What will happen to the results of the research study? 
Data obtained from this study will be studied in order to further our understanding of the 
research area. The results will also be published in scientific journals. If you would like a 
summary of the final results, please contact Anna Duszyńska (contact details on Part one of 
this Participant Information Leaflet).  
Appendices 
240 
 
Consent Form 
Ref. No A01/2011 
Title of project: The influence of topical formulation composition on test compound 
transport into the skin and on skin condition 
Participant’s Identification number ............................................................................................  
Please tick 
1. I confirm that I have read and understand the information sheet for the above 
study (Participant Information Leaflet, version number 1.0). I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
3. I agree of my own free will to take part in the above study. I agree to comply 
with the study requirements. 
4. I confirm that the information I give to the study personnel will be correct to 
the best of my knowledge. 
5. I understand that sections of any of my study records may be looked at by 
responsible individuals from the School of Pharmacy, the sponsoring company 
or from regulatory authorities where it is relevant to my taking part in 
research. I give permission for these individuals to have access to my records. 
6. I agree to waive ownership of all data collected including the right to withdraw 
data from the study, and I give permission for the data to be transferred to 
countries outside the EU. 
 
 
……………………………………… ……………………………… …………………….. 
Participant name   Signature   Date 
 
 
……………………………………… ……………………………… …………………….. 
Chief investigator name   Signature   Date 
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Participant’s Diary 
Ref. No A01/2011 
Participant’s Identification number ............................................................................................ 
Day of study Date 
Application  
(tick the box if you applied the formulations) 
Morning Afternoon Evening 
0  Don’t apply anything! 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
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16     
17     
18     
19     
20     
21     
22  Wash-out period: Don’t apply anything 
23  
Measurements day! 
We’re meeting in the lab 322 
The School of Pharmacy, University of London, 29-39 
Brunswick Square, WC1N 1AX London 
Any questions?  
Contact Anna Duszynska at +447593270619 or a.duszynska@live.pharmacy.ac.uk 
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How to apply? 
 Take the laminated template and rubber bands provided 
 Align the template on your left forearm and secure with rubber bands according to the 
instructions on the template (wrist side towards your wrist, elbow side towards your 
elbow) 
 Take one of the syringes provided 
 Withdraw 0.05mL of Formulation1 from its container (0.05mL is marked as half of the 
first unit on the 1mL syringe) 
 Apply the formulation to the appropriate site as marked in the picture 
 Gently massage the formulation into the area of your skin demarcated by the template 
 Take another syringe and apply Formulation2 in the same manner as described above 
to the appropriate site on your left forearm 
 Take off the template from your left forearm and align it on your right forearm as 
before 
 Apply Formulation3 and Formulation4 to the designated sites in the same manner as 
described above 
 After application wait for about 2 minutes before rolling your sleeves down or putting 
on long sleeved clothes to allow the formulation to absorb 
Apply: 
 4 formulations 
 3 times a day 
 for 3 weeks (21 days) 
Please always take special care to apply each formulation to the correct site 
Use a different finger to gently massage each formulation into the skin to avoid cross 
contamination and remember to wash your hands before and after application of formulations 
Don’t apply anything on your forearms 24 hours before the first application 
Don’t apply any other products on your forearms while you are applying the test formulations 
Don’t apply anything on your forearms on the 22nd and 23rd day of the study (this is the wash 
out period necessary for the measurements to be performed) 
Don’t exchange formulations with other volunteers 
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Meet me in the lab 322 on the day 23rd for the measurements (please allow about 2 hours 
time for the meeting) 
 
Figure A.22 Application sites 
 
Formulation 
1 
Formulation 
2 
Formulation 
4 
Formulation 
3 
Left arm Right arm 
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A.7 Corneocyte size measurement with ImageJ® procedure 
The following steps were taken to calculate the average area of cells: 
1. Calculate the pixel/µm conversion by analysing an image of stage micrometer 
(1000µm): 
a. Open ImageJ® software and open an image of the stage micrometer and draw 
a line of a known length (for example 100µm) (File → Open → choose image), 
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b. Measure the length of the line in pixels, 
 
c. Note the value, 
d. Set the scale (Analyse → Set Scale), 
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e. Enter the value of pixels counted previously and the distance in µm. 
 
2. Analyse cell size (area) 
a. Open red fluorescence image of the microscopic slide (File → Open → choose 
file to open), 
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b. Invert the colours of the image (Edit → Invert), 
 
c. Change the image type to 8-bit (Image → Type → 8-bit), 
 
 
Appendices 
249 
 
d. Adjust threshold (Image → Adjust → Threshold), 
 
e. Apply threshold by clicking ‘Apply’ in the ‘Threshold’ box that appeared, 
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f. Process the image by applying watershed (Process → Binary → Watershed) 
 
g. Analyse particles (Analyse → Analyse particles) 
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h. Set the size of particles you want to analyse in the ‘Analyse Particles’ box; for 
this study particles of the area between 300 and 2000µm2 were taken into 
account, 
 
i. Click OK. Make note of the value for ‘Mean’ size that appear in the ‘Summary’ 
box. 
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A.8 Corneocyte maturity measurement procedures 
The following steps were taken to estimate the maturity of cells with ImageJ®: 
1. Open red fluorescence image of microscopic slide (File → Open → choose image), 
2. Measure RGB pixels (Plugins → Analyse → Measure RGB), 
 
3. Take note of the ‘Mean’ value for red pixels 
 
4. Open green fluorescence image of microscopic slide (File → Open → choose image), 
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5. As previously measure RGB pixels (Plugins → Analyse → Measure RGB) and take note 
of the ‘Mean’ value for green pixels 
 
6. Calculate the red/green ratio for the noted values 
The following steps were taken to estimate the maturity of cells with manual cell counting 
1. Open green fluorescence image of microscopic slide with Microsoft Paint, 
2. Mark a rectangular area (19.99x10.00cm) in a place representative for the whole 
picture with square drawing tool, 
3. Mark with red circle, count bright red cells in the designated area, note the value, 
4. Mark with green circle drawing tool, count pale green cells in the area, note the value, 
5. Calculate red/green cell ratio. 
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A.9 Pig ear preparation methods 
Pig ears obtained from local abattoir were kept at -20°C before preparation of the membrane. 
Full thickness skin was prepared based on the methods of pig ear skin preparation summarised 
in Table A.35 [9, 10, 13-21]. The ears were cleaned under cold running tap water. The full 
thickness skin was removed from the underlying cartilage with a scalpel. Circles of a similar 
size, big enough to cover the opening of a Franz cell receptor were cut with surgical scissors. 
Hair was trimmed with surgical scissors. The isolated skin samples were stored on the 
aluminium foil in the freezer at -20°C until required for permeation studies. 
 
Table A.35 Summary of the literature methods for pig ear skin preparation  
Reference Bounoure et al., 
2008 
Caon et al., 2010  Davison et al., 
2009  
Dick and Scott, 1992  Kanikkannan et 
al., 2001  
Source of 
the skin 
Pig ears; 
slaughterhouse 
Pig ears from 
young animals; 
local 
slaughterhouse 
Pig ears from 
single animal; 
local abattoir 
Outer region of pig ears 
(Cheshire White Pigs), 
local abbatoir 
Dorsal surface of 
the ears from 5-6 
months old pigs; 
prior to scalding; 
local 
slaughterhouse 
Cleaning 
procedure 
- Tap water Sterile water, 
patted dry 
Cold running water Water and blotted 
dry with Kim wipes 
Type of skin 
preparation 
FT for the 
permeation studies; 
SE for FT-IR studies 
FT - Epidermis ST 
Praparation 
method 
FT skin removed 
leaving the fat 
behind; 
Epidermis peeled off 
after 12h soaking in 
2M potassium 
bromide at 37°C and 
dried for 3 days in 
desiccator 
Hair and 
subcutaneous fat 
removed 
Shaved with 
electric clippers 
Shaved with callipers, 
whole skin membrane 
removed from the 
underlying cartilage, 
epidermis isolated by 
soaking the whole skin 
in water at 60°C for 70s, 
followed by blunt 
dissection of the 
epidermal membrane 
and floating of the 
membrane onto 
aluminium foil 
Hair on the dorsal 
surface removed 
with surgical 
scissors; 
Dermatomed to 
0.5mm 
Thickness FT <1.30mm FT 1.00±0.05mm - - (Epidermal membrane) ST 0.5mm 
Storage 
conditions 
- -80°C, max 2 
months; thawed 
at room temp. 
before 
permeation 
experiments 
2-4°C until the 
following day 
Up to 7 days at -20°C  - 
Utilisation 
of the skin 
samples 
Evaluation of 
iontophoresis and 
penetration 
enhancers on 
metopimazine 
transdermal 
absorption with 
permeation and FT-
IR methods 
Evaluation of the 
transdermal 
permeation of 
different paraben 
combinations 
Control of 
microbial 
contamination of 
Franz diffusion 
cell receptor 
phase 
Comparison of the 
permeability of pig ear 
skin with human 
abdominal skin 
Percutaneous 
permeation of JP-
8+100 jet fuel 
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Summary of the literature methods for pig ear skin preparation (continued) 
Reference Padula et al., 2008  Schmook et al, 2001  Senygit et al., 
2009  
Singh et al., 2002  Vallet at al., 2007  
Source of 
the skin 
Pig ears collected 
immediately after 
the death of the 
animal; local 
slaughterhouse 
Skin of domestic pigs 
(Landrasse 
Edelschwein,  
females, aged 5 
months) ;local 
breeder; was 
dissected after 
euthanasia 
with Ketavet:T-61 
Inner part of pig 
ears excised after 
sacrifice, local 
slaughterhouse 
Outer region of 
pig ears, local 
slaughterhouse 
Fresh pig ears obtained 
from local abattoir 
immediately after 
animals were killed 
Cleaning 
procedure 
- - - Cold running 
water 
Cold running water 
Type of skin 
preparation 
FT ST - ST for permeation 
studies; 
SC for binding 
studies 
FT and ST for 
permeation 
comparison studies 
Praparation 
method 
Skin excised from 
outer region of the 
ears with a surgical 
blade; hair trimmed 
with scissors; 
subcutaneous fat 
removed 
Dermatomed to 
0.6mm with 
Aesculap 
dermatome 
- Shaved with 
clippers; 
dermatomed to 
0.5mm; 
SC isolated by 
incubation for 4h 
at 37°C in 0.5% 
tripsin in PBS 
FT skin removed from 
the underlying 
cartilage; 
ST dermatomed with 
electric dermatome 
(Zimmer® Inc., Dover, 
Ohio, USA) 
Thickness - ST 0.6mm - ST 0.5mm FT 1.90±0.41mm 
ST 0.61±0.14mm 
Storage 
conditions 
-20°C until used; 
wrapped in 
aluminium foil 
- Up to 3 days at 2-
5°C 
ST skin up to 5 
days at 4°C in 
Eagle’s minimum 
essential medium 
to preserve 
viability; 
SC in desiccator 
4°C when transported 
from the abattoir; 
- 20°C, max one year 
Utilisation 
of the skin 
samples 
HPLC method 
validation for 
determination of 
retinoids in pig skin 
layers 
Comparison of 
human skin or 
epidermis models 
with 
human and animal 
skin in in-vitro 
percutaneous 
absorption of model 
drugs: salicylic acid, 
hydrocortisone, 
clotrimasole, 
terbinafine  
Skin 
accumulation of 
topical 
corticosteroids 
In vitro 
permeability and 
binding of 
hydrocarbons in 
pig ear and 
human abdominal 
skin 
In vitro percutaneous 
penetration of 
organophosphorus 
compounds using full-
thickness and split-
thickness pig and 
human skin 
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A.10 Nicotinamide extraction method from the tapes  
NA content in the tapes was determined using the HPLC method described in section A.1. The 
extraction method was validated prior to the study. Blank samples were prepared by tape 
stripping of the non-treated skin according to the method described in Chapter 5. The tape 
was placed in a separate Eppendorf tube and extracted with 750µL of buffer at pH 8.0 
containing 0.1M Tris-HCl and 0.5% TritonX-100, 15 min., 25°C, 1000rpm vortex (Orbital 
incubator). The experiment was performed in triplicate. No interfering peak was found in blank 
samples.  
Validation samples were obtained by spiking the tapes with a known amount of NA and 
performing the extraction procedure as above. The recovery values for three different 
amounts of NA were above 90% and are summarised in Table A.36. 
Table A.36 Validation of nicotinamide quantification in the tape strips (% recovery) 
Tape spiking 
[µg/mL] 
% of nicotinamide recovery from the 
tapestrips 
Average SD % RSD 
1 2 3 
0 (blank) 0 0 0 0 0 0 
1 96.22 99.85 96.22 97.43 2.09 2.15 
2 97.09 101.18 99.81 99.36 2.08 2.09 
4 95.72 95.72 96.62 96.02 0.52 0.55 
 
The stability of the extraction samples was investigated. Samples are stable over the period of 
14 days at 4°C and at room temperature (recovery above 90%). The results are summarised in 
Table A.37 and Table A.38. 
Table A.37 Room temperature stability of nicotinamide samples extracted from tapes 
Day after sample preparation 0 5 12 14 
Sample concentration [µg/mL] % of initial sample concentration 
1 100.00 103.93 95.68 103.04 
2 100.00 95.00 95.04 99.97 
4 100.00 98.59 91.17 100.99 
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Table A.38 Stability of nicotinamide extraction samples kept at 4°C 
Day after sample preparation 0 5 12 14 
Sample concentration [µg/mL] % of initial sample concentration 
1 100.00 109.25 94.79 108.37 
2 100.00 96.36 96.38 100.86 
4 100.00 98.83 99.22 100.76 
 
A.11 Validation of time needed to achieve saturation in the solubility 
studies 
Preliminary saturated solubility studies in single solvents were performed to assess the time 
necessary to achieve saturation. The summary of the results is shown below. 
Table A.39 Summary of the solubility studies of nicotinamide in chosen single solvents (results shown 
as mean ± SD, n=3) 
Solvent 
Solubility [mg/mL] 
24h 48h 72h 
MO* - - 0.0057 ± 0.001 
IPM 0.68 ± 0.02 0.67 ± 0.008 0.68 ± 0.005 
DPPG 1.57±0.01 1.62±0.008 1.69±0.01 
PGML 21.97±0.22 22.15±0.35 22.73±3.42 
PGMC 38.70±0.74 38.17±1.25 39.31±0.76 
EtOH 134.86 ± 2.93 149.82 ± 0.64 138.63 ± 8.65 
GLY 198.09 ± 24.89 232.17 ± 10.97 238.66 ± 9.02 
PG 229.74±13.09 243.37±8.76 263.97±11.68 
H2O 555.58 ± 2.81 552.96 ± 8.63 561.23 ± 5.51 
*The solubility of NA in MO is very low and thus the results after 72 hours are assumed to be the closest 
approximation of the drug solubility in this solvent. 
No significant differences were found between the results obtained at each time point. 
However some literature data indicate that the equilibration time for saturated solutions 
should be at least 48h. Thus, this equilibration time was chosen for further experiments [22, 
23]. 
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